{"6e77816b285f471f4c0ba9b969622e35cad2030f": [["Immune stimulating properties of a novel polysaccharide from the medicinal plant Tinospora cordifoliaIntroductionThe possibility of bioterrorism, outbreak of severe acute respiratory syndrome (SARS) and Bird Flu virus, continuing spread of HIV/AIDS and emergence of resistant pathogenic strains against current medications compel investigators to look for new protective measures against these threats.", [["acute respiratory syndrome", "DISEASE", 165, 191], ["SARS", "DISEASE", 193, 197], ["HIV/AIDS", "DISEASE", 240, 248], ["Tinospora cordifoliaIntroduction", "ORGANISM", 81, 113], ["Bird Flu virus", "ORGANISM", 203, 217], ["HIV", "ORGANISM", 240, 243], ["Tinospora cordifoliaIntroduction", "SPECIES", 81, 113], ["Bird Flu virus", "SPECIES", 203, 217], ["HIV", "SPECIES", 240, 243], ["Tinospora cordifoliaIntroduction", "SPECIES", 81, 113], ["Bird Flu virus", "SPECIES", 203, 217], ["HIV", "SPECIES", 240, 243], ["a novel polysaccharide", "PROBLEM", 33, 55], ["bioterrorism", "PROBLEM", 132, 144], ["severe acute respiratory syndrome", "PROBLEM", 158, 191], ["SARS", "PROBLEM", 193, 197], ["Bird Flu virus", "PROBLEM", 203, 217], ["HIV/AIDS", "PROBLEM", 240, 248], ["resistant pathogenic strains", "PROBLEM", 266, 294], ["current medications", "TREATMENT", 303, 322], ["new protective measures", "TREATMENT", 356, 379], ["Tinospora cordifoliaIntroduction", "OBSERVATION", 81, 113], ["possibility of", "UNCERTAINTY", 117, 131], ["bioterrorism", "OBSERVATION", 132, 144], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["respiratory syndrome", "OBSERVATION", 171, 191]]], ["Immune activation is an effective as well as protective approach against emerging infectious diseases [1] .", [["infectious diseases", "DISEASE", 82, 101], ["Immune activation", "PROBLEM", 0, 17], ["protective approach", "TREATMENT", 45, 64], ["emerging infectious diseases", "PROBLEM", 73, 101]]], ["Although immune system possesses a wide array of microbial detection and host defense mechanisms, pathogen evasion of the immune surveillance and destruction is a frequent occurrence.", [["immune system", "ANATOMY", 9, 22], ["microbial detection", "TEST", 49, 68], ["host defense mechanisms", "PROBLEM", 73, 96], ["the immune surveillance", "TEST", 118, 141], ["destruction", "PROBLEM", 146, 157], ["a frequent occurrence", "PROBLEM", 161, 182]]], ["This escape of immune surveillance is also an important characteristic of several malignancies [2] .IntroductionThe fundamental role of innate immunity in host defense is becoming clearer as analysis of the human genome continues to identify new genes serving innate immune function.", [["malignancies", "ANATOMY", 82, 94], ["malignancies", "DISEASE", 82, 94], ["malignancies", "CANCER", 82, 94], ["human", "ORGANISM", 207, 212], ["human genome", "DNA", 207, 219], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 207, 212], ["immune surveillance", "TREATMENT", 15, 34], ["several malignancies", "PROBLEM", 74, 94], ["the human genome", "PROBLEM", 203, 219], ["several", "OBSERVATION_MODIFIER", 74, 81], ["malignancies", "OBSERVATION", 82, 94]]], ["The innate immune system detects the pathogens or the nonself intruders using specific receptors and responds immediately by activation of the immune competent cells, synthesis of cytokines and chemokines, and release of inflammatory mediators to eliminate or contain the intruders.", [["cells", "ANATOMY", 160, 165], ["cells", "CELL", 160, 165], ["immune competent cells", "CELL_TYPE", 143, 165], ["cytokines", "PROTEIN", 180, 189], ["chemokines", "PROTEIN", 194, 204], ["inflammatory mediators", "PROTEIN", 221, 243], ["the pathogens", "PROBLEM", 33, 46], ["the nonself intruders", "PROBLEM", 50, 71], ["synthesis of cytokines", "TREATMENT", 167, 189], ["chemokines", "TREATMENT", 194, 204], ["inflammatory mediators", "PROBLEM", 221, 243], ["the intruders", "PROBLEM", 268, 281], ["intruders", "OBSERVATION", 272, 281]]], ["Innate immune activation also triggers and paves the way for adaptive immune response by antigen-specific T and B lymphocytes.", [["T", "ANATOMY", 106, 107], ["B lymphocytes", "ANATOMY", 112, 125], ["antigen", "GENE_OR_GENE_PRODUCT", 89, 96], ["T", "CELL", 106, 107], ["B lymphocytes", "CELL", 112, 125], ["antigen-specific T and B lymphocytes", "CELL_TYPE", 89, 125], ["antigen", "TEST", 89, 96], ["lymphocytes", "ANATOMY", 114, 125]]], ["The natural killer (NK) cells play a decisive role in the innate immune defense against virus-infected and malignant cells by virtue of their ability to recognize and destroy abnormal cells [3, 4] .", [["natural killer (NK) cells", "ANATOMY", 4, 29], ["malignant cells", "ANATOMY", 107, 122], ["cells", "ANATOMY", 184, 189], ["natural killer (NK) cells", "CELL", 4, 29], ["malignant cells", "CELL", 107, 122], ["cells", "CELL", 184, 189], ["natural killer (NK) cells", "CELL_TYPE", 4, 29], ["malignant cells", "CELL_TYPE", 107, 122], ["abnormal cells", "CELL_TYPE", 175, 189], ["The natural killer (NK) cells", "TREATMENT", 0, 29], ["virus", "PROBLEM", 88, 93], ["infected and malignant cells", "PROBLEM", 94, 122], ["abnormal cells", "PROBLEM", 175, 189], ["natural killer", "OBSERVATION", 4, 18]]], ["Cytokines play crucial roles in regulating various aspects of immune responses.", [["Cytokines", "PROTEIN", 0, 9], ["Cytokines", "TREATMENT", 0, 9]]], ["Among cytokines, interleukin (IL)-12 plays a central role in coordinating innate and cellmediated adaptive immunity [5] .", [["interleukin (IL)-12", "GENE_OR_GENE_PRODUCT", 17, 36], ["cytokines", "PROTEIN", 6, 15], ["interleukin (IL)-12", "PROTEIN", 17, 36], ["interleukin (IL)", "TREATMENT", 17, 33]]], ["Immune stimulation can provide both prophylactic as well as postexposure protection [6, 7] .", [["Immune stimulation", "TREATMENT", 0, 18], ["both prophylactic", "TREATMENT", 31, 48], ["postexposure protection", "TREATMENT", 60, 83]]], ["Usually, these protective measures are correlated with synthesis of IL-12 and interferon (IFN)-g, the cytokines of Th1 pathway of T cell differentiation associated with the adaptive immune system [8] .", [["T cell", "ANATOMY", 130, 136], ["IL-12", "GENE_OR_GENE_PRODUCT", 68, 73], ["interferon (IFN)-g", "GENE_OR_GENE_PRODUCT", 78, 96], ["Th1", "GENE_OR_GENE_PRODUCT", 115, 118], ["T cell", "CELL", 130, 136], ["IL-12", "PROTEIN", 68, 73], ["interferon (IFN)-g", "PROTEIN", 78, 96], ["cytokines", "PROTEIN", 102, 111], ["these protective measures", "TREATMENT", 9, 34], ["synthesis of IL", "TREATMENT", 55, 70], ["interferon (IFN)", "TREATMENT", 78, 94], ["T cell differentiation", "PROBLEM", 130, 152], ["the adaptive immune system", "TREATMENT", 169, 195], ["cell differentiation", "OBSERVATION", 132, 152]]], ["Several compounds that activate immune system such as microbial lipopolysaccharides (LPS), doublestranded RNA and DNA oligonucleotides containing unmethylated CpG motifs, have been reported earlier [1, 9] .", [["immune system", "ANATOMY", 32, 45], ["LPS", "CHEMICAL", 85, 88], ["CpG", "CHEMICAL", 159, 162], ["microbial lipopolysaccharides", "GENE_OR_GENE_PRODUCT", 54, 83], ["LPS", "SIMPLE_CHEMICAL", 85, 88], ["DNA", "CELLULAR_COMPONENT", 114, 117], ["doublestranded RNA", "RNA", 91, 109], ["unmethylated CpG motifs", "DNA", 146, 169], ["activate immune system", "PROBLEM", 23, 45], ["microbial lipopolysaccharides (LPS", "TREATMENT", 54, 88], ["doublestranded RNA", "TREATMENT", 91, 109], ["DNA oligonucleotides", "TREATMENT", 114, 134], ["unmethylated CpG motifs", "TREATMENT", 146, 169]]], ["Stimulation of multiple receptors is reported to exhibit synergistic effect in cytokine production [10] .", [["multiple receptors", "PROTEIN", 15, 33], ["cytokine", "PROTEIN", 79, 87], ["Stimulation of multiple receptors", "TREATMENT", 0, 33], ["synergistic effect in cytokine production", "PROBLEM", 57, 98]]], ["Complement activation cascade is another integral part of the immune system in which the cellular pathogens like intracellular bacteria are coated with complement components (opsonization) and readily undergo phagocytosis.", [["immune system", "ANATOMY", 62, 75], ["cellular", "ANATOMY", 89, 97], ["intracellular", "ANATOMY", 113, 126], ["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["cellular", "CELL", 89, 97], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 126], ["complement components", "PROTEIN", 152, 173], ["Complement activation cascade", "PROBLEM", 0, 29], ["the cellular pathogens", "PROBLEM", 85, 107], ["intracellular bacteria", "PROBLEM", 113, 135], ["phagocytosis", "PROBLEM", 209, 221], ["cellular", "OBSERVATION_MODIFIER", 89, 97], ["pathogens", "OBSERVATION", 98, 107], ["intracellular bacteria", "OBSERVATION", 113, 135], ["phagocytosis", "OBSERVATION", 209, 221]]], ["Thus, complement activation plays an important role in microbial killing and is essential for transport and clearance of immune complexes.IntroductionPolysaccharides are known immune stimulants of which h-glucans have recently received considerable attention. h-Glucans or other biological response modifiers (BRMs), because of their structural identity with the conserved bpathogenassociated molecular patternQ activate the immune system by binding to specific receptors (pattern recognition receptors) of the innate immune system and stimulate the phagocytic, cytotoxic, and antimicrobial activities by the synthesis and release of cytokines, chemokines and reactive oxygen and nitrogen intermediates [11, 12] .", [["immune system", "ANATOMY", 425, 438], ["Polysaccharides", "CHEMICAL", 150, 165], ["h-Glucans", "CHEMICAL", 260, 269], ["oxygen", "CHEMICAL", 669, 675], ["nitrogen", "CHEMICAL", 680, 688], ["Polysaccharides", "CHEMICAL", 150, 165], ["h-glucans", "CHEMICAL", 203, 212], ["oxygen", "CHEMICAL", 669, 675], ["nitrogen", "CHEMICAL", 680, 688], ["Polysaccharides", "SIMPLE_CHEMICAL", 150, 165], ["h-glucans", "GENE_OR_GENE_PRODUCT", 203, 212], ["h-Glucans", "SIMPLE_CHEMICAL", 260, 269], ["patternQ", "GENE_OR_GENE_PRODUCT", 403, 411], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 473, 502], ["reactive", "SIMPLE_CHEMICAL", 660, 668], ["oxygen", "SIMPLE_CHEMICAL", 669, 675], ["nitrogen intermediates", "SIMPLE_CHEMICAL", 680, 702], ["immune complexes", "PROTEIN", 121, 137], ["bpathogenassociated molecular patternQ", "PROTEIN", 373, 411], ["specific receptors", "PROTEIN", 453, 471], ["pattern recognition receptors", "PROTEIN", 473, 502], ["cytokines", "PROTEIN", 634, 643], ["chemokines", "PROTEIN", 645, 655], ["immune complexes", "PROBLEM", 121, 137], ["IntroductionPolysaccharides", "TREATMENT", 138, 165], ["h-Glucans", "TEST", 260, 269], ["antimicrobial activities", "TREATMENT", 577, 601], ["cytokines", "TREATMENT", 634, 643], ["chemokines", "TREATMENT", 645, 655], ["reactive oxygen and nitrogen intermediates", "TREATMENT", 660, 702], ["reactive oxygen", "OBSERVATION", 660, 675]]], ["Stimulation by particulate h-glucans can also enhance the ability of macrophages to recognize and clear apoptotic cells through upregulation of the polysaccharide receptors [13] .", [["macrophages", "ANATOMY", 69, 80], ["cells", "ANATOMY", 114, 119], ["h-glucans", "CHEMICAL", 27, 36], ["particulate h-glucans", "SIMPLE_CHEMICAL", 15, 36], ["macrophages", "CELL", 69, 80], ["cells", "CELL", 114, 119], ["macrophages", "CELL_TYPE", 69, 80], ["apoptotic cells", "CELL_TYPE", 104, 119], ["polysaccharide receptors", "PROTEIN", 148, 172], ["macrophages", "PROBLEM", 69, 80], ["the polysaccharide receptors", "TREATMENT", 144, 172], ["apoptotic cells", "OBSERVATION", 104, 119]]], ["Specific h-glucan receptors have been reported on various immune cells including monocytes, macrophages, neutrophils, eosinophils, NK cells as well as nonimmune cells including endothelial cells, alveolar cells and fibroblasts [12] . h-Glucans induce proinflammatory and antimicrobial responses such as tumor necrosis factor (TNF)-a and IL-12 synthesis, required for IFN-g production and polarization of T helper cells to Th1 pathway [14] . h-Glucans have also been found to synergize with monoclonal antibodies to suppress and/or eradicate tumors [15, 16] .", [["immune cells", "ANATOMY", 58, 70], ["monocytes", "ANATOMY", 81, 90], ["macrophages", "ANATOMY", 92, 103], ["neutrophils", "ANATOMY", 105, 116], ["eosinophils", "ANATOMY", 118, 129], ["NK cells", "ANATOMY", 131, 139], ["nonimmune cells", "ANATOMY", 151, 166], ["endothelial cells", "ANATOMY", 177, 194], ["alveolar cells", "ANATOMY", 196, 210], ["fibroblasts", "ANATOMY", 215, 226], ["T helper cells", "ANATOMY", 404, 418], ["tumors", "ANATOMY", 541, 547], ["h-Glucans", "CHEMICAL", 234, 243], ["tumor", "DISEASE", 303, 308], ["necrosis", "DISEASE", 309, 317], ["h-Glucans", "CHEMICAL", 441, 450], ["tumors", "DISEASE", 541, 547], ["h-glucan", "GENE_OR_GENE_PRODUCT", 9, 17], ["immune cells", "CELL", 58, 70], ["monocytes", "CELL", 81, 90], ["macrophages", "CELL", 92, 103], ["neutrophils", "CELL", 105, 116], ["eosinophils", "CELL", 118, 129], ["NK cells", "CELL", 131, 139], ["nonimmune cells", "CELL", 151, 166], ["endothelial cells", "CELL", 177, 194], ["alveolar cells", "CELL", 196, 210], ["fibroblasts", "CELL", 215, 226], ["h-Glucans", "SIMPLE_CHEMICAL", 234, 243], ["tumor necrosis factor (TNF)-a", "GENE_OR_GENE_PRODUCT", 303, 332], ["IL-12", "GENE_OR_GENE_PRODUCT", 337, 342], ["IFN-g", "GENE_OR_GENE_PRODUCT", 367, 372], ["T helper cells", "CELL", 404, 418], ["Th1", "GENE_OR_GENE_PRODUCT", 422, 425], ["h-Glucans", "SIMPLE_CHEMICAL", 441, 450], ["tumors", "CANCER", 541, 547], ["h-glucan receptors", "PROTEIN", 9, 27], ["immune cells", "CELL_TYPE", 58, 70], ["monocytes", "CELL_TYPE", 81, 90], ["macrophages", "CELL_TYPE", 92, 103], ["neutrophils", "CELL_TYPE", 105, 116], ["eosinophils", "CELL_TYPE", 118, 129], ["NK cells", "CELL_TYPE", 131, 139], ["nonimmune cells", "CELL_TYPE", 151, 166], ["endothelial cells", "CELL_TYPE", 177, 194], ["alveolar cells", "CELL_TYPE", 196, 210], ["fibroblasts", "CELL_TYPE", 215, 226], ["TNF", "PROTEIN", 326, 329], ["IFN", "PROTEIN", 367, 370], ["T helper cells", "CELL_TYPE", 404, 418], ["monoclonal antibodies", "PROTEIN", 490, 511], ["Specific h-glucan receptors", "TEST", 0, 27], ["monocytes", "TEST", 81, 90], ["macrophages", "TEST", 92, 103], ["neutrophils", "TEST", 105, 116], ["eosinophils", "TEST", 118, 129], ["NK cells", "TEST", 131, 139], ["nonimmune cells", "PROBLEM", 151, 166], ["endothelial cells", "PROBLEM", 177, 194], ["alveolar cells", "PROBLEM", 196, 210], ["fibroblasts", "PROBLEM", 215, 226], ["h-Glucans", "TEST", 234, 243], ["proinflammatory and antimicrobial responses", "PROBLEM", 251, 294], ["tumor necrosis factor", "PROBLEM", 303, 324], ["TNF", "TEST", 326, 329], ["a and IL-12 synthesis", "TREATMENT", 331, 352], ["IFN-g production", "TREATMENT", 367, 383], ["h-Glucans", "TEST", 441, 450], ["monoclonal antibodies", "TREATMENT", 490, 511], ["eradicate tumors", "PROBLEM", 531, 547], ["macrophages", "ANATOMY", 92, 103], ["NK cells", "OBSERVATION", 131, 139], ["nonimmune cells", "OBSERVATION", 151, 166], ["endothelial cells", "OBSERVATION", 177, 194], ["alveolar cells", "OBSERVATION", 196, 210], ["proinflammatory", "OBSERVATION_MODIFIER", 251, 266]]], ["Yeast h-glucan has already been demonstrated to have significant degree of protection against anthrax (Bacillus anthracis) infection in a mouse model [17] .", [["h-glucan", "CHEMICAL", 6, 14], ["anthrax (Bacillus anthracis) infection", "DISEASE", 94, 132], ["Yeast h-glucan", "GENE_OR_GENE_PRODUCT", 0, 14], ["anthrax (", "ORGANISM", 94, 103], ["Bacillus anthracis", "ORGANISM", 103, 121], ["mouse", "ORGANISM", 138, 143], ["Yeast", "SPECIES", 0, 5], ["Bacillus anthracis", "SPECIES", 103, 121], ["mouse", "SPECIES", 138, 143], ["Yeast", "SPECIES", 0, 5], ["Bacillus anthracis", "SPECIES", 103, 121], ["mouse", "SPECIES", 138, 143], ["Yeast h-glucan", "PROBLEM", 0, 14], ["anthrax (Bacillus anthracis) infection", "PROBLEM", 94, 132], ["significant degree", "OBSERVATION_MODIFIER", 53, 71]]], ["Furthermore, exogenous IFN-g and IFN-a/h are reported to modulate host's innate immune response in human macrophages, for improving the cell viability and reducing the number of germinated intracellular spores of anthrax [18] .IntroductionThe immunomodulatory effects of h-glucans are influenced by the molecular mass, chain length, degree of branching, tertiary structure and solubility of the polymer.", [["macrophages", "ANATOMY", 105, 116], ["cell", "ANATOMY", 136, 140], ["intracellular spores", "ANATOMY", 189, 209], ["anthrax", "DISEASE", 213, 220], ["h-glucans", "CHEMICAL", 271, 280], ["h-glucans", "CHEMICAL", 271, 280], ["IFN-g", "GENE_OR_GENE_PRODUCT", 23, 28], ["IFN", "GENE_OR_GENE_PRODUCT", 33, 36], ["human", "ORGANISM", 99, 104], ["macrophages", "CELL", 105, 116], ["cell", "CELL", 136, 140], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 202], ["h-glucans", "SIMPLE_CHEMICAL", 271, 280], ["IFN", "PROTEIN", 23, 26], ["IFN", "PROTEIN", 33, 36], ["human macrophages", "CELL_TYPE", 99, 116], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["exogenous IFN", "TEST", 13, 26], ["IFN", "TEST", 33, 36], ["the cell viability", "PROBLEM", 132, 150], ["h-glucans", "PROBLEM", 271, 280], ["the molecular mass", "PROBLEM", 299, 317], ["branching, tertiary structure", "PROBLEM", 343, 372], ["solubility of the polymer", "TREATMENT", 377, 402], ["human macrophages", "OBSERVATION", 99, 116], ["cell viability", "OBSERVATION", 136, 150], ["intracellular spores", "OBSERVATION", 189, 209], ["immunomodulatory", "OBSERVATION_MODIFIER", 243, 259], ["molecular", "OBSERVATION_MODIFIER", 303, 312], ["mass", "OBSERVATION", 313, 317], ["chain", "OBSERVATION_MODIFIER", 319, 324], ["length", "OBSERVATION_MODIFIER", 325, 331], ["degree", "OBSERVATION_MODIFIER", 333, 339], ["branching", "OBSERVATION_MODIFIER", 343, 352], ["tertiary structure", "OBSERVATION", 354, 372], ["solubility", "OBSERVATION_MODIFIER", 377, 387]]], ["Although no consensus could be made on the structure-activity relationship [19] , the (1Y3)-h-glycosidic linkage has been described as an explicit requirement for biological activity [20] .", [["(1Y3)-h", "CHEMICAL", 86, 93], ["(1Y3)-h-glycosidic", "SIMPLE_CHEMICAL", 86, 104], ["glycosidic linkage", "PROBLEM", 94, 112]]], ["However, Bao et al. [21] recently reported the isolation, characterization as well as in vitro and in vivo lymphocyte proliferation and antibody production by a branched (1Y3)-a-dglucan.", [["lymphocyte", "ANATOMY", 107, 117], ["(1Y3)-a-dglucan", "CHEMICAL", 170, 185], ["lymphocyte", "CELL", 107, 117], ["branched (1Y3)-a-dglucan", "SIMPLE_CHEMICAL", 161, 185], ["vivo lymphocyte proliferation", "TREATMENT", 102, 131], ["antibody production", "PROBLEM", 136, 155], ["a-dglucan", "TREATMENT", 176, 185], ["lymphocyte proliferation", "OBSERVATION", 107, 131]]], ["Water solubility and lower degree of branching were found to be desirable requirements for biological activity based on the immunological properties of its derivatives.", [["Water solubility", "TREATMENT", 0, 16], ["biological activity", "TREATMENT", 91, 110], ["its derivatives", "TREATMENT", 152, 167], ["lower degree", "OBSERVATION_MODIFIER", 21, 33], ["branching", "OBSERVATION_MODIFIER", 37, 46]]], ["This observation along with the immunological properties of a-(2Y8) linked sialic acid as well as that of heteropolysaccharides having a conformations in the main chain [22, 23] dispute the explicit requirement of (1Y3)-h-glycosidic linkage for the biological activity.", [["sialic acid", "CHEMICAL", 75, 86], ["heteropolysaccharides", "CHEMICAL", 106, 127], ["sialic acid", "CHEMICAL", 75, 86], ["(1Y3)-h-glycosidic", "CHEMICAL", 214, 232], ["sialic acid", "SIMPLE_CHEMICAL", 75, 86], ["heteropolysaccharides", "SIMPLE_CHEMICAL", 106, 127], ["(1Y3)-h-glycosidic", "SIMPLE_CHEMICAL", 214, 232], ["This observation", "TEST", 0, 16], ["sialic acid", "TREATMENT", 75, 86], ["heteropolysaccharides", "PROBLEM", 106, 127], ["main", "OBSERVATION_MODIFIER", 158, 162], ["chain", "OBSERVATION_MODIFIER", 163, 168], ["biological activity", "OBSERVATION", 249, 268]]], ["In this paper, we describe a novel polysaccharide (RR1), an a-glucan, exhibiting unique immune boosting properties.", [["RR1", "SIMPLE_CHEMICAL", 51, 54], ["a-glucan", "SIMPLE_CHEMICAL", 60, 68], ["a novel polysaccharide (RR1)", "PROBLEM", 27, 55], ["an a-glucan", "PROBLEM", 57, 68], ["unique immune boosting properties", "TREATMENT", 81, 114]]], ["RR1 is isolated from a medicinal herb, Tinospora cordifolia (family Minispermaceae), well known in the Indian Ayurvedic System of Medicine for antiinflammatory, antiallergic, antiarthritic, antioxidant and immune stimulating properties [24] [25] [26] [27] [28] .Isolation and characterization of RR1Our preliminary investigations with extracts of the T. cordifolia powder, purchased from Garry and Sun, Reno, NV revealed that the immune stimulating principle is confined in the aqueous fraction.", [["extracts", "ANATOMY", 335, 343], ["aqueous fraction", "ANATOMY", 478, 494], ["RR1", "CHEMICAL", 0, 3], ["Tinospora cordifolia", "CHEMICAL", 39, 59], ["RR1", "GENE_OR_GENE_PRODUCT", 0, 3], ["Tinospora cordifolia", "ORGANISM", 39, 59], ["[24] [25] [26] [27] [28]", "SIMPLE_CHEMICAL", 236, 260], ["extracts", "ORGANISM_SUBSTANCE", 335, 343], ["T. cordifolia", "ORGANISM", 351, 364], ["powder", "ORGANISM", 365, 371], ["aqueous", "ORGANISM_SUBSTANCE", 478, 485], ["Tinospora cordifolia", "SPECIES", 39, 59], ["T. cordifolia", "SPECIES", 351, 364], ["Tinospora cordifolia", "SPECIES", 39, 59], ["T. cordifolia", "SPECIES", 351, 364], ["a medicinal herb", "TREATMENT", 21, 37], ["antiinflammatory", "TREATMENT", 143, 159], ["antiallergic", "TREATMENT", 161, 173], ["antiarthritic, antioxidant", "TREATMENT", 175, 201], ["immune stimulating properties", "TREATMENT", 206, 235], ["RR1Our preliminary investigations", "TEST", 296, 329], ["the T. cordifolia powder", "TREATMENT", 347, 371], ["the immune stimulating principle", "PROBLEM", 426, 458], ["Tinospora cordifolia", "OBSERVATION", 39, 59], ["aqueous fraction", "OBSERVATION", 478, 494]]], ["The aerial part of the plant was air dried and powdered for RR1 extraction.", [["aerial part", "MULTI-TISSUE_STRUCTURE", 4, 15], ["RR1", "SIMPLE_CHEMICAL", 60, 63], ["RR1 extraction", "TREATMENT", 60, 74], ["aerial", "OBSERVATION_MODIFIER", 4, 10], ["plant", "ANATOMY", 23, 28], ["air dried", "OBSERVATION", 33, 42]]], ["The procedure adapted for the isolation is illustrated in the flow chart (Fig. 1) .", [["The procedure", "TREATMENT", 0, 13], ["the isolation", "TREATMENT", 26, 39]]], ["The final compound RR1 was isolated in about 0.1% yield of the total dry material used for extraction as a puffy solid that dissolved in water.", [["RR1", "CHEMICAL", 19, 22], ["RR1", "SIMPLE_CHEMICAL", 19, 22], ["water", "SIMPLE_CHEMICAL", 137, 142], ["the total dry material", "TREATMENT", 59, 81], ["extraction", "TREATMENT", 91, 101], ["a puffy solid", "TREATMENT", 105, 118], ["puffy", "OBSERVATION_MODIFIER", 107, 112], ["solid", "OBSERVATION", 113, 118]]], ["The initial analysis of the final product in our laboratory and the 13 C nuclear magnetic resonance (NMR) spectra revealed that it is a polysaccharide.", [["The initial analysis", "TEST", 0, 20], ["nuclear magnetic resonance (NMR) spectra", "TEST", 73, 113], ["a polysaccharide", "PROBLEM", 134, 150]]], ["Therefore, detailed polysaccharide analyses such as the glycosyl composition, linkage, molecular weight and conformation of the glucose units at the anomeric center were performed at the Complex Carbohydrate Research Center, University of Georgia, Athens, GA.", [["glucose", "CHEMICAL", 128, 135], ["glycosyl", "CHEMICAL", 56, 64], ["glucose", "CHEMICAL", 128, 135], ["Carbohydrate", "CHEMICAL", 195, 207], ["glycosyl", "SIMPLE_CHEMICAL", 56, 64], ["glucose", "SIMPLE_CHEMICAL", 128, 135], ["detailed polysaccharide analyses", "TEST", 11, 43], ["the glycosyl composition", "TREATMENT", 52, 76], ["the glucose units", "TREATMENT", 124, 141]]], ["The glycosyl composition analysis was done by the combined Gas Chromatography/Mass Spectrometry (GC/MS) of the per-O-trimethylsilyl derivatives of the monosaccharide methyl glucosides obtained from RR1 by acidic methanolysis according to the method of York et al. [29] .", [["-O-trimethylsilyl", "CHEMICAL", 114, 131], ["monosaccharide methyl glucosides", "CHEMICAL", 151, 183], ["RR1", "CHEMICAL", 198, 201], ["glycosyl", "CHEMICAL", 4, 12], ["-O-trimethylsilyl", "CHEMICAL", 114, 131], ["monosaccharide methyl glucosides", "CHEMICAL", 151, 183], ["glycosyl", "SIMPLE_CHEMICAL", 4, 12], ["-O-trimethylsilyl derivatives", "SIMPLE_CHEMICAL", 114, 143], ["monosaccharide methyl glucosides", "SIMPLE_CHEMICAL", 151, 183], ["RR1", "SIMPLE_CHEMICAL", 198, 201], ["The glycosyl composition analysis", "TEST", 0, 33], ["the combined Gas Chromatography", "TEST", 46, 77], ["Mass Spectrometry", "TEST", 78, 95], ["the per-O-trimethylsilyl derivatives", "TREATMENT", 107, 143], ["the monosaccharide methyl glucosides", "TREATMENT", 147, 183]]], ["Inositol was used as internal standard in this analysis.", [["Inositol", "CHEMICAL", 0, 8], ["Inositol", "CHEMICAL", 0, 8], ["Inositol", "SIMPLE_CHEMICAL", 0, 8], ["Inositol", "TREATMENT", 0, 8], ["this analysis", "TEST", 42, 55]]], ["The monosaccharide derivatives were identified by their characteristic retention time and further authenticated with their mass spectra.", [["monosaccharide", "CHEMICAL", 4, 18], ["monosaccharide derivatives", "SIMPLE_CHEMICAL", 4, 30], ["The monosaccharide derivatives", "TREATMENT", 0, 30], ["their mass spectra", "PROBLEM", 117, 135], ["monosaccharide derivatives", "OBSERVATION", 4, 30]]], ["To perform glycosyl linkage analysis, the sample was permethylated thrice by the method of Ciucanu and Kerek [30] , hydrolyzed with 2 M trifluoroacetic acid, reduced with NaBD 4 and acetylated with acetic anhydride/ pyridine and the resulted partially methylated alditol acetates (PMAA) were analyzed by GC/ MS. The sugar residues were identified by their characteristic retention times and mass spectral data.", [["sample", "ANATOMY", 42, 48], ["Ciucanu", "CHEMICAL", 91, 98], ["2 M trifluoroacetic acid", "CHEMICAL", 132, 156], ["NaBD 4", "CHEMICAL", 171, 177], ["acetic anhydride", "CHEMICAL", 198, 214], ["pyridine", "CHEMICAL", 216, 224], ["alditol acetates", "CHEMICAL", 263, 279], ["PMAA", "CHEMICAL", 281, 285], ["glycosyl", "CHEMICAL", 11, 19], ["trifluoroacetic acid", "CHEMICAL", 136, 156], ["NaBD", "CHEMICAL", 171, 175], ["acetic anhydride", "CHEMICAL", 198, 214], ["pyridine", "CHEMICAL", 216, 224], ["alditol acetates", "CHEMICAL", 263, 279], ["PMAA", "CHEMICAL", 281, 285], ["sugar", "CHEMICAL", 316, 321], ["Ciucanu", "SIMPLE_CHEMICAL", 91, 98], ["2 M trifluoroacetic acid", "SIMPLE_CHEMICAL", 132, 156], ["NaBD 4", "SIMPLE_CHEMICAL", 171, 177], ["acetic anhydride", "SIMPLE_CHEMICAL", 198, 214], ["pyridine", "SIMPLE_CHEMICAL", 216, 224], ["alditol acetates", "SIMPLE_CHEMICAL", 263, 279], ["PMAA", "SIMPLE_CHEMICAL", 281, 285], ["sugar", "SIMPLE_CHEMICAL", 316, 321], ["glycosyl linkage analysis", "TEST", 11, 36], ["2 M trifluoroacetic acid", "TREATMENT", 132, 156], ["NaBD", "TREATMENT", 171, 175], ["acetic anhydride/ pyridine", "TREATMENT", 198, 224], ["partially methylated alditol acetates", "TREATMENT", 242, 279], ["The sugar residues", "TEST", 312, 330], ["mass spectral data", "TEST", 391, 409], ["sugar residues", "OBSERVATION", 316, 330]]], ["The conformations at the anomeric center of the glucopyranosyl units were obtained based on the 500-MHz proton NMR spectra recorded in D 2 O and by comparison with the anomeric proton signals of standard samples.", [["samples", "ANATOMY", 204, 211], ["glucopyranosyl", "CHEMICAL", 48, 62], ["glucopyranosyl", "CHEMICAL", 48, 62], ["D 2 O", "CHEMICAL", 135, 140], ["glucopyranosyl", "SIMPLE_CHEMICAL", 48, 62], ["D 2 O", "SIMPLE_CHEMICAL", 135, 140]]], ["The molecular mass was obtained from the size exclusion chromatography using Supelco silica column (1.0\u00c230 cm), eluting with 50 mM ammonium formate buffer at a rate of 0.5 ml/min and detected by the refractive index.", [["Supelco silica", "CHEMICAL", 77, 91], ["ammonium formate", "CHEMICAL", 131, 147], ["silica", "CHEMICAL", 85, 91], ["ammonium formate", "CHEMICAL", 131, 147], ["ammonium formate", "SIMPLE_CHEMICAL", 131, 147], ["The molecular mass", "PROBLEM", 0, 18], ["the size exclusion chromatography", "TEST", 37, 70], ["Supelco silica column", "TREATMENT", 77, 98], ["50 mM ammonium formate buffer", "TREATMENT", 125, 154], ["the refractive index", "TEST", 195, 215], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 14, 18], ["size", "OBSERVATION_MODIFIER", 41, 45], ["silica column", "OBSERVATION", 85, 98], ["refractive index", "OBSERVATION", 199, 215]]], ["Dextran samples were used as standards and the molecular mass was obtained by comparing the retention time of the eluted peak with the standards.Immune stimulating propertiesRR1 samples were tested for any endotoxin contamination by the Limulus Amoebocyte Lysate (LAL) assay before the immune stimulation experiments and tests showed insignificant levels.", [["samples", "ANATOMY", 8, 15], ["RR1 samples", "ANATOMY", 174, 185], ["Dextran", "CHEMICAL", 0, 7], ["endotoxin", "CHEMICAL", 206, 215], ["Dextran", "SIMPLE_CHEMICAL", 0, 7], ["endotoxin", "SIMPLE_CHEMICAL", 206, 215], ["Dextran samples", "TREATMENT", 0, 15], ["the molecular mass", "PROBLEM", 43, 61], ["Immune stimulating propertiesRR1 samples", "TEST", 145, 185], ["any endotoxin contamination", "PROBLEM", 202, 229], ["the Limulus Amoebocyte Lysate", "TEST", 233, 262], ["the immune stimulation experiments", "TEST", 282, 316], ["tests", "TEST", 321, 326], ["insignificant levels", "PROBLEM", 334, 354], ["mass", "OBSERVATION", 57, 61]]], ["To measure the immune stimulating property of RR1, we analyzed the activation of the different subsets of lymphocytes, syntheses of cytokines such as interleukin (IL)-1h, IL-2, IL-4, IL-6, IL-10, IL-12 p70 and p40, IL-18, interferon (IFN)-a and g, tumor necrosis factor (TNF)-a and -h, monocyte chemoattractant protein (MCP)-1, synthesis of nitric oxide (NO) and the extent of oxidative stress elicited in human lymphocytes.", [["lymphocytes", "ANATOMY", 106, 117], ["lymphocytes", "ANATOMY", 412, 423], ["necrosis", "DISEASE", 254, 262], ["nitric oxide", "CHEMICAL", 341, 353], ["NO", "CHEMICAL", 355, 357], ["nitric oxide", "CHEMICAL", 341, 353], ["NO", "CHEMICAL", 355, 357], ["RR1", "GENE_OR_GENE_PRODUCT", 46, 49], ["lymphocytes", "CELL", 106, 117], ["interleukin (IL)-1h", "GENE_OR_GENE_PRODUCT", 150, 169], ["IL-2", "GENE_OR_GENE_PRODUCT", 171, 175], ["IL-4", "GENE_OR_GENE_PRODUCT", 177, 181], ["IL-6", "GENE_OR_GENE_PRODUCT", 183, 187], ["IL-10", "GENE_OR_GENE_PRODUCT", 189, 194], ["IL-12 p70", "GENE_OR_GENE_PRODUCT", 196, 205], ["p40", "GENE_OR_GENE_PRODUCT", 210, 213], ["IL-18", "GENE_OR_GENE_PRODUCT", 215, 220], ["interferon (IFN)-a", "GENE_OR_GENE_PRODUCT", 222, 240], ["tumor necrosis factor (TNF)-a", "GENE_OR_GENE_PRODUCT", 248, 277], ["monocyte chemoattractant protein (MCP)-1", "GENE_OR_GENE_PRODUCT", 286, 326], ["nitric oxide", "SIMPLE_CHEMICAL", 341, 353], ["NO", "SIMPLE_CHEMICAL", 355, 357], ["human", "ORGANISM", 406, 411], ["lymphocytes", "CELL", 412, 423], ["RR1", "PROTEIN", 46, 49], ["lymphocytes", "CELL_TYPE", 106, 117], ["cytokines", "PROTEIN", 132, 141], ["interleukin (IL)-1h, IL-2, IL-4, IL-6", "PROTEIN", 150, 187], ["p70", "PROTEIN", 202, 205], ["p40", "PROTEIN", 210, 213], ["IL-18", "PROTEIN", 215, 220], ["interferon", "PROTEIN", 222, 232], ["IFN", "PROTEIN", 234, 237], ["TNF", "PROTEIN", 271, 274], ["monocyte chemoattractant protein (MCP)-1", "PROTEIN", 286, 326], ["human lymphocytes", "CELL_TYPE", 406, 423], ["human", "SPECIES", 406, 411], ["human", "SPECIES", 406, 411], ["syntheses of cytokines", "TREATMENT", 119, 141], ["interleukin (IL)", "TREATMENT", 150, 166], ["IL", "TEST", 171, 173], ["IL", "TEST", 177, 179], ["IL", "TEST", 183, 185], ["IL", "TEST", 189, 191], ["IL", "TEST", 196, 198], ["IL", "TEST", 215, 217], ["interferon (IFN", "TREATMENT", 222, 237], ["tumor necrosis factor", "PROBLEM", 248, 269], ["TNF", "TEST", 271, 274], ["a and -h, monocyte chemoattractant protein", "TEST", 276, 318], ["MCP", "TEST", 320, 323], ["synthesis of nitric oxide", "TREATMENT", 328, 353], ["oxidative stress", "PROBLEM", 377, 393], ["lymphocytes", "OBSERVATION", 106, 117], ["tumor", "ANATOMY", 248, 253], ["necrosis", "OBSERVATION", 254, 262], ["oxidative stress", "OBSERVATION", 377, 393], ["human lymphocytes", "OBSERVATION", 406, 423]]], ["Normal lymphocytes were isolated by histopaque 1077 density gradient method from fresh blood drawn from healthy volunteers and utilized for various assays.", [["lymphocytes", "ANATOMY", 7, 18], ["blood", "ANATOMY", 87, 92], ["lymphocytes", "CELL", 7, 18], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["volunteers", "ORGANISM", 112, 122], ["Normal lymphocytes", "CELL_TYPE", 0, 18], ["fresh blood", "TEST", 81, 92], ["various assays", "TEST", 140, 154], ["lymphocytes", "OBSERVATION", 7, 18], ["density", "OBSERVATION_MODIFIER", 52, 59], ["gradient", "OBSERVATION_MODIFIER", 60, 68]]], ["Human leukemic (CEM) and multidrug resistant (CEM/VLB) cell lines were grown in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal bovine serum and antibiotics in a 5% CO 2 incubator at 37 8C.Activation of lymphocytesNormal lymphocytes (10 6 /ml) were treated with 0-100 Ag of RR1 for 24 h in a CO 2 incubator maintained at 37 8C in RPMI medium.", [["leukemic", "ANATOMY", 6, 14], ["CEM", "ANATOMY", 16, 19], ["CEM/VLB) cell lines", "ANATOMY", 46, 65], ["fetal bovine serum", "ANATOMY", 148, 166], ["lymphocytes", "ANATOMY", 229, 240], ["lymphocytes", "ANATOMY", 247, 258], ["RR1", "CHEMICAL", 300, 303], ["CO 2", "CHEMICAL", 191, 195], ["Ag", "CHEMICAL", 294, 296], ["CO 2", "CHEMICAL", 318, 322], ["Human", "ORGANISM", 0, 5], ["CEM", "CELL", 16, 19], ["multidrug resistant (CEM/VLB) cell lines", "CELL", 25, 65], ["bovine", "ORGANISM", 154, 160], ["serum", "ORGANISM_SUBSTANCE", 161, 166], ["lymphocytesNormal lymphocytes", "CELL", 229, 258], ["RR1", "SIMPLE_CHEMICAL", 300, 303], ["Human leukemic (CEM) and multidrug resistant (CEM/VLB) cell lines", "CELL_LINE", 0, 65], ["lymphocytes", "CELL_TYPE", 229, 240], ["Normal lymphocytes", "CELL_TYPE", 240, 258], ["Human", "SPECIES", 0, 5], ["bovine", "SPECIES", 154, 160], ["Human", "SPECIES", 0, 5], ["bovine", "SPECIES", 154, 160], ["Human leukemic (CEM)", "PROBLEM", 0, 20], ["multidrug resistant (CEM/VLB) cell lines", "PROBLEM", 25, 65], ["10% fetal bovine serum", "TREATMENT", 144, 166], ["antibiotics", "TREATMENT", 171, 182], ["a 5% CO 2 incubator", "TREATMENT", 186, 205], ["lymphocytes", "TEST", 229, 240], ["leukemic", "OBSERVATION", 6, 14], ["multidrug resistant", "OBSERVATION_MODIFIER", 25, 44], ["cell lines", "OBSERVATION", 55, 65], ["lymphocytes", "ANATOMY", 229, 240], ["lymphocytes", "ANATOMY", 247, 258]]], ["The cells were then stained with specific fluorochrome-conjugated monoclonal antibodies for 30 min at room temperature and analyzed in a Coulter Elite Flow Cytometer by fourand five-color immunotyping assay protocol of Alamo and Melnick [31] .", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["fluorochrome", "SIMPLE_CHEMICAL", 42, 54], ["fluorochrome-conjugated monoclonal antibodies", "PROTEIN", 42, 87], ["specific fluorochrome", "TEST", 33, 54], ["conjugated monoclonal antibodies", "TREATMENT", 55, 87]]], ["The percentage of activation of lymphocyte subsets such as NK, T and B cells was calculated.Cytotoxicity of RR1-treated lymphocytesTo evaluate the enhanced cytotoxicity of activated lymphocytes, a functional assay was adopted using RR1 activated lymphocytes as effecter cells and human leukemic cells (CEM) as targets [32, 33] .", [["lymphocyte", "ANATOMY", 32, 42], ["NK", "ANATOMY", 59, 61], ["T", "ANATOMY", 63, 64], ["B cells", "ANATOMY", 69, 76], ["lymphocytes", "ANATOMY", 120, 131], ["lymphocytes", "ANATOMY", 182, 193], ["lymphocytes", "ANATOMY", 246, 257], ["effecter cells", "ANATOMY", 261, 275], ["leukemic cells", "ANATOMY", 286, 300], ["CEM", "ANATOMY", 302, 305], ["RR1", "CHEMICAL", 108, 111], ["lymphocyte", "CELL", 32, 42], ["NK", "CELL", 59, 61], ["T", "CELL", 63, 64], ["B cells", "CELL", 69, 76], ["RR1", "SIMPLE_CHEMICAL", 108, 111], ["lymphocytes", "CELL", 120, 131], ["lymphocytes", "CELL", 182, 193], ["lymphocytes", "CELL", 246, 257], ["effecter cells", "CELL", 261, 275], ["human", "ORGANISM", 280, 285], ["leukemic cells", "CELL", 286, 300], ["CEM", "CELL", 302, 305], ["lymphocyte subsets", "CELL_TYPE", 32, 50], ["NK, T and B cells", "CELL_TYPE", 59, 76], ["RR1-treated lymphocytes", "CELL_LINE", 108, 131], ["activated lymphocytes", "CELL_TYPE", 172, 193], ["RR1 activated lymphocytes", "CELL_LINE", 232, 257], ["effecter cells", "CELL_TYPE", 261, 275], ["human leukemic cells", "CELL_TYPE", 280, 300], ["CEM", "CELL_LINE", 302, 305], ["human", "SPECIES", 280, 285], ["human", "SPECIES", 280, 285], ["lymphocyte subsets", "PROBLEM", 32, 50], ["NK", "TEST", 59, 61], ["Cytotoxicity", "TEST", 92, 104], ["RR1", "TEST", 108, 111], ["lymphocytes", "PROBLEM", 120, 131], ["activated lymphocytes", "PROBLEM", 172, 193], ["a functional assay", "TEST", 195, 213], ["RR1 activated lymphocytes", "PROBLEM", 232, 257], ["human leukemic cells", "PROBLEM", 280, 300], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["activation of lymphocyte subsets", "OBSERVATION", 18, 50], ["lymphocytes", "OBSERVATION", 120, 131], ["activated lymphocytes", "OBSERVATION", 172, 193], ["leukemic cells", "OBSERVATION", 286, 300]]], ["Briefly, normal lymphocytes (10 6 /ml) were treated with different concentrations of RR1 in RPMI medium for 24 h in a CO 2 incubator at 37 8C.", [["lymphocytes", "ANATOMY", 16, 27], ["RR1", "CHEMICAL", 85, 88], ["CO 2", "CHEMICAL", 118, 122], ["lymphocytes", "CELL", 16, 27], ["RR1", "SIMPLE_CHEMICAL", 85, 88], ["normal lymphocytes", "CELL_TYPE", 9, 27], ["RR1 in RPMI medium", "TREATMENT", 85, 103], ["normal lymphocytes", "OBSERVATION", 9, 27]]], ["On the next day, target cells (CEM 1\u00c210 6 /ml) were labeled with 4.6 AM membrane labeling dye PKH26 (Sigma) in 1 ml phosphate-buffered saline (PBS) at room temperature for 3 min.", [["cells", "ANATOMY", 24, 29], ["CEM", "ANATOMY", 31, 34], ["membrane", "ANATOMY", 72, 80], ["phosphate", "CHEMICAL", 116, 125], ["PKH26", "CHEMICAL", 94, 99], ["phosphate", "CHEMICAL", 116, 125], ["cells", "CELL", 24, 29], ["CEM 1\u00c210", "CELL", 31, 39], ["dye PKH26", "SIMPLE_CHEMICAL", 90, 99], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 116, 141], ["target cells", "CELL_TYPE", 17, 29], ["CEM 1\u00c210 6", "CELL_LINE", 31, 41], ["target cells", "TEST", 17, 29], ["CEM", "TEST", 31, 34], ["phosphate", "TEST", 116, 125], ["buffered saline (PBS", "TREATMENT", 126, 146]]], ["The labeling was stopped by adding an equal volume of fetal bovine serum (GIBCO, Life Sciences, MD) for 1 min.", [["fetal bovine serum", "ANATOMY", 54, 72], ["bovine", "ORGANISM", 60, 66], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["bovine", "SPECIES", 60, 66], ["bovine", "SPECIES", 60, 66], ["The labeling", "TREATMENT", 0, 12]]], ["The labeled tumor cells were then incubated with RR1 treated lymphocytes in an effecter to target ratio 1:1 for 4 h and untreated lymphocytes were used as control.", [["tumor cells", "ANATOMY", 12, 23], ["lymphocytes", "ANATOMY", 61, 72], ["lymphocytes", "ANATOMY", 130, 141], ["tumor", "DISEASE", 12, 17], ["RR1", "CHEMICAL", 49, 52], ["tumor cells", "CELL", 12, 23], ["RR1", "SIMPLE_CHEMICAL", 49, 52], ["lymphocytes", "CELL", 61, 72], ["lymphocytes", "CELL", 130, 141], ["labeled tumor cells", "CELL_LINE", 4, 23], ["RR1 treated lymphocytes", "CELL_LINE", 49, 72], ["untreated lymphocytes", "CELL_TYPE", 120, 141], ["The labeled tumor cells", "PROBLEM", 0, 23], ["RR1 treated lymphocytes", "TREATMENT", 49, 72], ["untreated lymphocytes", "TREATMENT", 120, 141], ["tumor cells", "OBSERVATION", 12, 23]]], ["The percentage of cells killed by the activated NK cells was determined by fixing the mixture with 1 ml of 2% Para formaldehyde solution for 30 min on ice followed by suspending in 0.5% Tween 20 in PBS.", [["cells", "ANATOMY", 18, 23], ["NK cells", "ANATOMY", 48, 56], ["formaldehyde", "CHEMICAL", 115, 127], ["formaldehyde", "CHEMICAL", 115, 127], ["Tween 20", "CHEMICAL", 186, 194], ["cells", "CELL", 18, 23], ["NK cells", "CELL", 48, 56], ["formaldehyde", "SIMPLE_CHEMICAL", 115, 127], ["activated NK cells", "CELL_TYPE", 38, 56], ["the activated NK cells", "PROBLEM", 34, 56], ["2% Para formaldehyde solution", "TREATMENT", 107, 136], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["activated NK cells", "OBSERVATION", 38, 56]]], ["The cell mixture was stained with 7.5 Al of antiactive caspase-3-fluorescein isothiocyanate (FITC) antibody (BD Biosciences, CA) for 30 min at room temperature, washed with PBS and analyzed in a Coulter Elite Flow Cytometer.Quantification of cytokine and chemokine synthesisCytokines such as IL-1h, IL-2, IL-4, IL-6, IL-10, IL-12 p40, IL-12 p70, IL-18, IFN-g and TNFa, h and MCP-1 were quantified by ELISA procedure using kits from BD Biosciences, according to manufacturer's protocols.", [["cell", "ANATOMY", 4, 8], ["fluorescein isothiocyanate", "CHEMICAL", 65, 91], ["Al", "CHEMICAL", 38, 40], ["fluorescein isothiocyanate", "CHEMICAL", 65, 91], ["FITC", "CHEMICAL", 93, 97], ["cell", "CELL", 4, 8], ["caspase-3-fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 55, 91], ["FITC", "SIMPLE_CHEMICAL", 93, 97], ["IL-1h", "GENE_OR_GENE_PRODUCT", 292, 297], ["IL-2", "GENE_OR_GENE_PRODUCT", 299, 303], ["IL-4", "GENE_OR_GENE_PRODUCT", 305, 309], ["IL-6", "GENE_OR_GENE_PRODUCT", 311, 315], ["IL-10", "GENE_OR_GENE_PRODUCT", 317, 322], ["IL-12 p40", "GENE_OR_GENE_PRODUCT", 324, 333], ["IL-12 p70", "GENE_OR_GENE_PRODUCT", 335, 344], ["IL-18", "GENE_OR_GENE_PRODUCT", 346, 351], ["IFN-g", "GENE_OR_GENE_PRODUCT", 353, 358], ["TNFa", "GENE_OR_GENE_PRODUCT", 363, 367], ["MCP-1", "GENE_OR_GENE_PRODUCT", 375, 380], ["antiactive caspase-3-fluorescein isothiocyanate (FITC) antibody", "PROTEIN", 44, 107], ["CA", "PROTEIN", 125, 127], ["cytokine", "PROTEIN", 242, 250], ["chemokine", "PROTEIN", 255, 264], ["Cytokines", "PROTEIN", 274, 283], ["p40", "PROTEIN", 330, 333], ["IFN", "PROTEIN", 353, 356], ["TNFa", "PROTEIN", 363, 367], ["MCP", "PROTEIN", 375, 378], ["antiactive caspase", "TREATMENT", 44, 62], ["fluorescein isothiocyanate", "TREATMENT", 65, 91], ["BD Biosciences", "TEST", 109, 123], ["PBS", "TREATMENT", 173, 176], ["cytokine and chemokine synthesisCytokines", "TEST", 242, 283], ["IL", "TEST", 292, 294], ["IL", "TEST", 299, 301], ["IL", "TEST", 305, 307], ["IL", "TEST", 311, 313], ["IL", "TEST", 317, 319], ["IL", "TEST", 324, 326], ["IL", "TEST", 335, 337], ["IL", "TEST", 346, 348], ["IFN", "TEST", 353, 356], ["TNFa", "TEST", 363, 367], ["MCP", "TEST", 375, 378], ["ELISA procedure", "TREATMENT", 400, 415]]], ["IFN-a was assayed using the ELISA kit of Research Diagnostics (NJ).", [["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["IFN", "PROTEIN", 0, 3]]], ["In short, 50 Al of ELISA diluent is pipetted into antibody coated wells of 96-well plates followed by 100 Al of each standard and test samples, shaken for 5 s to mix the contents in the wells, covered with plate sealer and incubated for 2 h at room temperature.", [["samples", "ANATOMY", 135, 142], ["Al", "CHEMICAL", 13, 15], ["Al", "CHEMICAL", 13, 15], ["Al", "CHEMICAL", 106, 108], ["ELISA diluent", "TREATMENT", 19, 32], ["antibody coated wells", "TEST", 50, 71], ["test samples", "TEST", 130, 142], ["plate sealer", "TREATMENT", 206, 218], ["plate sealer", "OBSERVATION", 206, 218]]], ["After incubation, the contents of the wells were aspirated and washed five times with wash solution.", [["incubation", "TREATMENT", 6, 16], ["the contents of the wells", "TREATMENT", 18, 43], ["wash solution", "TREATMENT", 86, 99]]], ["After complete removal of the wash solution in the final wash 100 Al of detection solution was added, covered with plate sealer and incubated for 1 h.", [["Al", "CHEMICAL", 66, 68], ["Al", "CHEMICAL", 66, 68], ["the wash solution", "TREATMENT", 26, 43], ["detection solution", "TREATMENT", 72, 90], ["plate sealer", "TREATMENT", 115, 127], ["plate sealer", "OBSERVATION", 115, 127]]], ["The wells were washed seven times with wash solution and added 100 Al of one step substrate reagent and incubated for 30 min in dark.", [["Al", "CHEMICAL", 67, 69], ["The wells", "TREATMENT", 0, 9], ["wash solution", "TREATMENT", 39, 52], ["one step substrate reagent", "TREATMENT", 73, 99]]], ["The color development was stopped by adding 50 Al of stop solution and the absorbance were recorded at 450 nm with a reference wavelength of 570 nm in a Bio-Rad Benchmark plate reader.Complement activation pathwayHuman complement C3a des Arg and C4a des Arg correlate EIAk Kits (Assay Design, Ann Arbor, MI) were used to measure the cleaved complement components (C3a des Arg and C4a des Arg) according to the manufacturer's protocol.", [["Al", "CHEMICAL", 47, 49], ["Arg", "CHEMICAL", 238, 241], ["Arg", "CHEMICAL", 372, 375], ["Arg", "CHEMICAL", 388, 391], ["C3a", "GENE_OR_GENE_PRODUCT", 230, 233], ["Arg", "AMINO_ACID", 238, 241], ["C4a des Arg", "SIMPLE_CHEMICAL", 246, 257], ["C3a des Arg", "GENE_OR_GENE_PRODUCT", 364, 375], ["C4a des Arg", "GENE_OR_GENE_PRODUCT", 380, 391], ["Complement activation pathwayHuman complement C3a", "PROTEIN", 184, 233], ["cleaved complement components", "PROTEIN", 333, 362], ["C3a", "PROTEIN", 364, 367], ["C4a", "PROTEIN", 380, 383], ["a Bio-Rad Benchmark plate", "TREATMENT", 151, 176], ["Complement activation", "TEST", 184, 205], ["C3a des Arg", "TEST", 230, 241], ["C4a des", "TEST", 246, 253], ["EIAk Kits", "TEST", 268, 277], ["Ann Arbor, MI)", "TREATMENT", 293, 307], ["C3a des Arg and C4a des Arg", "TREATMENT", 364, 391], ["the manufacturer's protocol", "TREATMENT", 406, 433], ["color", "OBSERVATION_MODIFIER", 4, 9]]], ["In brief, 1 ml normal blood, drawn from healthy volunteer was incubated with 0-100 Ag/ml of RR1 in a CO 2 incubator at 37 8C for 24 h.", [["blood", "ANATOMY", 22, 27], ["RR1", "CHEMICAL", 92, 95], ["Ag", "CHEMICAL", 83, 85], ["CO 2", "CHEMICAL", 101, 105], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["RR1", "SIMPLE_CHEMICAL", 92, 95], ["a CO 2 incubator", "TREATMENT", 99, 115], ["blood", "ANATOMY", 22, 27]]], ["The treated blood samples were centrifuged at 2000\u00c2g at 4 8C and 225 Al of complement reagent dAT was added to an equal volume of the sample supernatant and vortexed thoroughly.", [["blood samples", "ANATOMY", 12, 25], ["supernatant", "ANATOMY", 141, 152], ["Al", "CHEMICAL", 69, 71], ["blood samples", "ORGANISM_SUBSTANCE", 12, 25], ["dAT", "SIMPLE_CHEMICAL", 94, 97], ["The treated blood samples", "TEST", 0, 25], ["complement reagent dAT", "TEST", 75, 97]]], ["To this mixture, 50 Al of 10 N HCl was added, vortexed again and incubated at room temperature for 1 h.", [["Al", "CHEMICAL", 20, 22], ["N HCl", "CHEMICAL", 29, 34], ["Al", "CHEMICAL", 20, 22], ["HCl", "CHEMICAL", 31, 34], ["N HCl", "SIMPLE_CHEMICAL", 29, 34], ["HCl", "TREATMENT", 31, 34]]], ["The samples were centrifuged at 10,000 rpm in a micro centrifuge at room temperature for 5 min, 180 Al of the supernatant was transferred to a 15 ml tube, 20 Al of 9 N NaOH was added and vortexed thoroughly.", [["samples", "ANATOMY", 4, 11], ["supernatant", "ANATOMY", 110, 121], ["Al of 9 N NaOH", "CHEMICAL", 158, 172], ["Al", "CHEMICAL", 100, 102], ["Al", "CHEMICAL", 158, 160], ["NaOH", "CHEMICAL", 168, 172], ["tube", "TISSUE", 149, 153], ["The samples", "TEST", 0, 11], ["a 15 ml tube", "TREATMENT", 141, 153], ["9 N NaOH", "TREATMENT", 164, 172]]], ["To this mixture 600 Al of complement reagent dBT was added followed by 10.7 ml of assay buffer, vortexed and used for the analysis.", [["dBT", "CHEMICAL", 45, 48], ["Al", "CHEMICAL", 20, 22], ["dBT", "SIMPLE_CHEMICAL", 45, 48], ["complement reagent dBT", "TREATMENT", 26, 48], ["assay buffer", "TREATMENT", 82, 94], ["the analysis", "TEST", 118, 130]]], ["Assay sample (100 Al) was pipetted into wells in a 96-well microplate followed by 50 Al of blue conjugate and 50 Al of yellow antibody.", [["sample", "ANATOMY", 6, 12], ["Al", "CHEMICAL", 18, 20], ["Al of blue", "CHEMICAL", 85, 95], ["Al", "CHEMICAL", 18, 20], ["Al of blue", "CHEMICAL", 85, 95], ["Al", "CHEMICAL", 113, 115], ["blue conjugate", "SIMPLE_CHEMICAL", 91, 105], ["yellow antibody", "PROTEIN", 119, 134], ["Assay sample", "TEST", 0, 12], ["blue conjugate", "TEST", 91, 105], ["yellow antibody", "TEST", 119, 134]]], ["The plates were shaken on a platform shaker at 500 rpm for 2 h.", [["a platform shaker", "TREATMENT", 26, 43], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The wells were aspirated to remove the unbound materials, washed thrice with 200 Al of wash solution and added 200 Al of p-Npp substrate solution.", [["Al of p-Npp", "CHEMICAL", 115, 126], ["Al", "CHEMICAL", 81, 83], ["Al", "CHEMICAL", 115, 117], ["p-Npp", "CHEMICAL", 121, 126], ["the unbound materials", "TREATMENT", 35, 56], ["wash solution", "TREATMENT", 87, 100], ["p-Npp substrate solution", "TREATMENT", 121, 145]]], ["The plate was incubated at 37 8C for 1 h without shaking, added 50 Al of stop solution and absorbance was taken at 405 nm with a reference wavelength of 570 nm in a Bio-Rad Bench top plate reader.Nitric oxide (NO) and inducible nitric oxide synthase (iNOS)The NO quantification was performed by Nitric Oxide quantification kit (Active Motif, Carlsbad, CA) as per the manufacturer's protocol.", [["Nitric oxide", "CHEMICAL", 196, 208], ["NO", "CHEMICAL", 210, 212], ["nitric oxide", "CHEMICAL", 228, 240], ["NO", "CHEMICAL", 260, 262], ["Nitric Oxide", "CHEMICAL", 295, 307], ["Al", "CHEMICAL", 67, 69], ["Nitric oxide", "CHEMICAL", 196, 208], ["NO", "CHEMICAL", 210, 212], ["nitric oxide", "CHEMICAL", 228, 240], ["NO", "CHEMICAL", 260, 262], ["Nitric Oxide", "CHEMICAL", 295, 307], ["Nitric oxide", "SIMPLE_CHEMICAL", 196, 208], ["NO", "SIMPLE_CHEMICAL", 210, 212], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 218, 249], ["iNOS", "GENE_OR_GENE_PRODUCT", 251, 255], ["NO", "SIMPLE_CHEMICAL", 260, 262], ["Nitric Oxide", "SIMPLE_CHEMICAL", 295, 307], ["nitric oxide synthase", "PROTEIN", 228, 249], ["iNOS", "PROTEIN", 251, 255], ["shaking", "PROBLEM", 49, 56], ["a Bio-Rad Bench top plate reader", "TREATMENT", 163, 195], ["Nitric oxide", "TREATMENT", 196, 208], ["inducible nitric oxide synthase", "TREATMENT", 218, 249], ["the manufacturer's protocol", "TREATMENT", 363, 390], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["Briefly, lymphocytes (10 6 /ml) were incubated with varying concen-trations of RR1 (0-100 Ag/ml) for 24 h in a nitratefree medium (Dubelco Minimum Essential Medium) at 37 8C.", [["lymphocytes", "ANATOMY", 9, 20], ["RR1", "CHEMICAL", 79, 82], ["RR1", "CHEMICAL", 79, 82], ["Ag", "CHEMICAL", 90, 92], ["lymphocytes", "CELL", 9, 20], ["RR1", "SIMPLE_CHEMICAL", 79, 82], ["lymphocytes", "CELL_TYPE", 9, 20], ["lymphocytes", "TEST", 9, 20], ["RR1", "TEST", 79, 82], ["a nitratefree medium", "TREATMENT", 109, 129], ["lymphocytes", "ANATOMY", 9, 20]]], ["The cell culture supernatant (70 Al) was pipetted into the wells of a 96-well plate along with 20 Al reconstituted cofactor and 10 Al nitrate reductase enzyme solution.", [["cell culture supernatant", "ANATOMY", 4, 28], ["Al", "CHEMICAL", 98, 100], ["Al nitrate", "CHEMICAL", 131, 141], ["Al", "CHEMICAL", 33, 35], ["Al", "CHEMICAL", 98, 100], ["Al nitrate", "CHEMICAL", 131, 141], ["cell", "CELL", 4, 8], ["nitrate reductase", "GENE_OR_GENE_PRODUCT", 134, 151], ["20 Al reconstituted cofactor", "PROTEIN", 95, 123], ["Al nitrate reductase", "PROTEIN", 131, 151], ["The cell culture", "TEST", 0, 16], ["20 Al reconstituted cofactor", "TREATMENT", 95, 123], ["10 Al nitrate reductase enzyme solution", "TREATMENT", 128, 167]]], ["The plate was shaken at 150 rpm on a plate shaker for 30 min at room temperature.", [["a plate shaker", "TREATMENT", 35, 49], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["Griess reagents A and B (50 Al each) were added into each well, allowed the color to develop for 20 min and the absorbance was taken at 540 nm with a reference wavelength of 620 nm in the Bio-Rad plate reader.Nitric oxide (NO) and inducible nitric oxide synthase (iNOS)Higher and long-lasting release of NO is resulted by the enzyme iNOS from arginine on stimulation.", [["Nitric oxide", "CHEMICAL", 209, 221], ["NO", "CHEMICAL", 223, 225], ["nitric oxide", "CHEMICAL", 241, 253], ["NO", "CHEMICAL", 304, 306], ["arginine", "CHEMICAL", 343, 351], ["Al", "CHEMICAL", 28, 30], ["Nitric oxide", "CHEMICAL", 209, 221], ["NO", "CHEMICAL", 223, 225], ["nitric oxide", "CHEMICAL", 241, 253], ["NO", "CHEMICAL", 304, 306], ["arginine", "CHEMICAL", 343, 351], ["B", "SIMPLE_CHEMICAL", 22, 23], ["Nitric oxide", "SIMPLE_CHEMICAL", 209, 221], ["NO", "SIMPLE_CHEMICAL", 223, 225], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 231, 262], ["iNOS", "GENE_OR_GENE_PRODUCT", 264, 268], ["NO", "SIMPLE_CHEMICAL", 304, 306], ["iNOS", "GENE_OR_GENE_PRODUCT", 333, 337], ["arginine", "SIMPLE_CHEMICAL", 343, 351], ["nitric oxide synthase", "PROTEIN", 241, 262], ["iNOS", "PROTEIN", 264, 268], ["iNOS", "PROTEIN", 333, 337], ["the absorbance", "TEST", 108, 122], ["Nitric oxide", "TREATMENT", 209, 221], ["inducible nitric oxide synthase", "TREATMENT", 231, 262], ["the enzyme iNOS", "TEST", 322, 337], ["arginine on stimulation", "TREATMENT", 343, 366]]], ["RR1-induced iNOS was assayed by Quantikine iNOS immunoassay kit (R&D systems, Minneapolis, MN) that employs a sandwich enzyme immunoassay technique.", [["RR1", "CHEMICAL", 0, 3], ["RR1", "SIMPLE_CHEMICAL", 0, 3], ["iNOS", "GENE_OR_GENE_PRODUCT", 12, 16], ["iNOS", "GENE_OR_GENE_PRODUCT", 43, 47], ["RR1", "PROTEIN", 0, 3], ["iNOS", "PROTEIN", 12, 16], ["iNOS", "PROTEIN", 43, 47], ["a sandwich enzyme immunoassay technique", "TEST", 108, 147]]], ["The iNOS was assayed from the cytoplasmic extract of the cells treated with different concentrations of RR1.", [["cytoplasmic extract", "ANATOMY", 30, 49], ["cells", "ANATOMY", 57, 62], ["iNOS", "GENE_OR_GENE_PRODUCT", 4, 8], ["cytoplasmic", "ORGANISM_SUBSTANCE", 30, 41], ["extract", "ORGANISM_SUBSTANCE", 42, 49], ["cells", "CELL", 57, 62], ["RR1", "SIMPLE_CHEMICAL", 104, 107], ["iNOS", "PROTEIN", 4, 8], ["The iNOS", "TEST", 0, 8], ["different concentrations of RR1", "TREATMENT", 76, 107], ["iNOS", "OBSERVATION", 4, 8]]], ["Briefly, the samples and standards were pipetted in to the wells of the 96-well plate and any iNOS present bound to the immobilized antibody.", [["samples", "ANATOMY", 13, 20], ["iNOS", "GENE_OR_GENE_PRODUCT", 94, 98], ["iNOS", "PROTEIN", 94, 98], ["immobilized antibody", "PROTEIN", 120, 140], ["the samples", "TEST", 9, 20], ["any iNOS", "PROBLEM", 90, 98]]], ["After washing away the unbound substances an enzyme linked monoclonal antibody specific for iNOS was added.", [["iNOS", "GENE_OR_GENE_PRODUCT", 92, 96], ["enzyme linked monoclonal antibody", "PROTEIN", 45, 78], ["iNOS", "PROTEIN", 92, 96], ["the unbound substances", "PROBLEM", 19, 41], ["an enzyme", "TEST", 42, 51], ["monoclonal antibody", "TEST", 59, 78], ["iNOS", "PROBLEM", 92, 96]]], ["After washing away the unbound antibody enzyme reagent, the color developing substrate solution was added, the color development was stopped by stop solution and the absorbance was read at 450 nm with a reference wavelength of 570 nm in the Bio-Rad plate reader.Oxidative stress (GSH/GSSG levels)The measure of the reduced (GSH) as well as oxidized (GSSG) levels of glutathione and their ratio are useful indicators for oxidative stress.", [["GSH", "CHEMICAL", 280, 283], ["GSSG", "CHEMICAL", 284, 288], ["GSH", "CHEMICAL", 324, 327], ["GSSG", "CHEMICAL", 350, 354], ["glutathione", "CHEMICAL", 366, 377], ["GSH", "CHEMICAL", 280, 283], ["GSSG", "CHEMICAL", 284, 288], ["GSH", "CHEMICAL", 324, 327], ["GSSG", "CHEMICAL", 350, 354], ["glutathione", "CHEMICAL", 366, 377], ["GSH", "SIMPLE_CHEMICAL", 280, 283], ["GSSG", "SIMPLE_CHEMICAL", 284, 288], ["GSH", "SIMPLE_CHEMICAL", 324, 327], ["GSSG", "SIMPLE_CHEMICAL", 350, 354], ["glutathione", "SIMPLE_CHEMICAL", 366, 377], ["the unbound antibody enzyme reagent", "TEST", 19, 54], ["substrate solution", "TREATMENT", 77, 95], ["the absorbance", "TEST", 162, 176], ["Oxidative stress", "TEST", 262, 278], ["GSH/GSSG levels", "TEST", 280, 295], ["oxidized (GSSG) levels of glutathione", "TEST", 340, 377], ["oxidative stress", "PROBLEM", 420, 436], ["reduced", "OBSERVATION_MODIFIER", 315, 322]]], ["The levels of GSH and GSSG were assayed by a colorimetric method using Biotech GSH/GSSG-412 kit (Oxis Research, Portland, OR) according to manufacturer's protocol.", [["GSH", "CHEMICAL", 14, 17], ["GSSG", "CHEMICAL", 22, 26], ["GSH", "CHEMICAL", 79, 82], ["GSSG-412", "CHEMICAL", 83, 91], ["GSH", "CHEMICAL", 14, 17], ["GSSG", "CHEMICAL", 22, 26], ["GSH", "CHEMICAL", 79, 82], ["GSSG-412", "CHEMICAL", 83, 91], ["GSH", "SIMPLE_CHEMICAL", 14, 17], ["GSSG", "SIMPLE_CHEMICAL", 22, 26], ["GSH", "SIMPLE_CHEMICAL", 79, 82], ["GSSG", "SIMPLE_CHEMICAL", 83, 87], ["GSH", "TEST", 14, 17], ["GSSG", "TEST", 22, 26], ["a colorimetric method", "TEST", 43, 64], ["GSSG", "TEST", 83, 87]]], ["Briefly, normal blood samples from healthy donors were incubated with different concentrations of RR1 for 24 h in a 5% CO 2 incubator at 37 8C.", [["blood samples", "ANATOMY", 16, 29], ["RR1", "CHEMICAL", 98, 101], ["CO 2", "CHEMICAL", 119, 123], ["blood samples", "ORGANISM_SUBSTANCE", 16, 29], ["donors", "ORGANISM", 43, 49], ["RR1", "SIMPLE_CHEMICAL", 98, 101], ["RR1", "TREATMENT", 98, 101]]], ["For GSSG, 100 Al of each of the treated sample was frozen at \u00c070 8C for 4 h, thawed and added 290 Al of 5% meta phosphoric acid (MPA).", [["sample", "ANATOMY", 40, 46], ["GSSG", "CHEMICAL", 4, 8], ["Al", "CHEMICAL", 14, 16], ["meta phosphoric acid", "CHEMICAL", 107, 127], ["MPA", "CHEMICAL", 129, 132], ["GSSG", "CHEMICAL", 4, 8], ["Al", "CHEMICAL", 14, 16], ["Al", "CHEMICAL", 98, 100], ["meta phosphoric acid", "CHEMICAL", 107, 127], ["MPA", "CHEMICAL", 129, 132], ["GSSG", "SIMPLE_CHEMICAL", 4, 8], ["meta phosphoric acid", "SIMPLE_CHEMICAL", 107, 127], ["MPA", "SIMPLE_CHEMICAL", 129, 132], ["GSSG", "TEST", 4, 8], ["5% meta phosphoric acid (MPA)", "TREATMENT", 104, 133]]], ["The samples were vortexed for 15-20 s and centrifuged at 1000\u00c2g for 10 min.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["MPA extract (50 Al) was added to 700 Al of GSSG buffer that was used for the colorimetric assay.", [["MPA extract", "CHEMICAL", 0, 11], ["Al", "CHEMICAL", 16, 18], ["GSSG", "CHEMICAL", 43, 47], ["MPA", "CHEMICAL", 0, 3], ["Al", "CHEMICAL", 16, 18], ["Al", "CHEMICAL", 37, 39], ["GSSG", "CHEMICAL", 43, 47], ["MPA", "SIMPLE_CHEMICAL", 0, 3], ["GSSG", "SIMPLE_CHEMICAL", 43, 47], ["MPA extract", "TREATMENT", 0, 11], ["GSSG buffer", "TREATMENT", 43, 54], ["the colorimetric assay", "TEST", 73, 95]]], ["For GSH measurement 50 Al of the whole blood was frozen at \u00c070 8C, thawed and added 350 Al of 5% MPA, vortexed for 15-20 s and centrifuged at 10,000\u00c2g for 10 min.", [["whole blood", "ANATOMY", 33, 44], ["GSH", "CHEMICAL", 4, 7], ["MPA", "CHEMICAL", 97, 100], ["GSH", "CHEMICAL", 4, 7], ["Al", "CHEMICAL", 23, 25], ["Al", "CHEMICAL", 88, 90], ["MPA", "CHEMICAL", 97, 100], ["GSH", "SIMPLE_CHEMICAL", 4, 7], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["MPA", "SIMPLE_CHEMICAL", 97, 100], ["GSH measurement", "TEST", 4, 19], ["vortexed", "TEST", 102, 110]]], ["MPA extract (50 Al) was added to 3 ml of the assay buffer and used for further analysis.", [["MPA extract", "CHEMICAL", 0, 11], ["Al", "CHEMICAL", 16, 18], ["MPA", "CHEMICAL", 0, 3], ["Al", "CHEMICAL", 16, 18], ["MPA", "SIMPLE_CHEMICAL", 0, 3], ["MPA extract", "TREATMENT", 0, 11], ["the assay buffer", "TREATMENT", 41, 57], ["further analysis", "TEST", 71, 87]]], ["MPA buffer mixture (200 Al) of each standard and sample was transferred to a spectrophotometer cuvette, added 200 Al of chromogen followed by 200 Al of enzyme in the order and incubated at room temperature for 5 min.", [["sample", "ANATOMY", 49, 55], ["MPA", "CHEMICAL", 0, 3], ["Al of chromogen", "CHEMICAL", 114, 129], ["MPA", "CHEMICAL", 0, 3], ["Al", "CHEMICAL", 24, 26], ["Al", "CHEMICAL", 114, 116], ["chromogen", "CHEMICAL", 120, 129], ["Al", "CHEMICAL", 146, 148], ["MPA", "SIMPLE_CHEMICAL", 0, 3], ["chromogen", "SIMPLE_CHEMICAL", 120, 129], ["enzyme", "PROTEIN", 152, 158], ["MPA buffer mixture", "TREATMENT", 0, 18], ["a spectrophotometer cuvette", "TREATMENT", 75, 102], ["chromogen", "TREATMENT", 120, 129]]], ["Afterwards, 200 Al of NADPH was added into the cuvette and changes in the absorbance at 412 nm were recorded in a Beckman spectrophotometer.", [["Al", "CHEMICAL", 16, 18], ["NADPH", "CHEMICAL", 22, 27], ["Al", "CHEMICAL", 16, 18], ["NADPH", "CHEMICAL", 22, 27], ["NADPH", "SIMPLE_CHEMICAL", 22, 27], ["NADPH", "TREATMENT", 22, 27], ["a Beckman spectrophotometer", "TEST", 112, 139]]], ["The reaction rates were plotted using the absorbance values and the levels of GSH and GSSG were determined.Statistical analysisAll experiments were repeated thrice with three replications in each.", [["GSH", "CHEMICAL", 78, 81], ["GSSG", "CHEMICAL", 86, 90], ["GSH", "CHEMICAL", 78, 81], ["GSSG", "CHEMICAL", 86, 90], ["GSH", "SIMPLE_CHEMICAL", 78, 81], ["GSSG", "SIMPLE_CHEMICAL", 86, 90], ["The reaction rates", "TEST", 0, 18], ["the absorbance values", "TEST", 38, 59], ["the levels", "TEST", 64, 74], ["GSH", "TEST", 78, 81], ["GSSG", "TEST", 86, 90], ["Statistical analysis", "TEST", 107, 127]]], ["Mean and standard deviation were estimated using Excel software and single-factor ANOVA was used for data analysis.", [["Mean", "TEST", 0, 4], ["standard deviation", "PROBLEM", 9, 27], ["Excel software", "TEST", 49, 63], ["single-factor ANOVA", "TEST", 68, 87], ["data analysis", "TEST", 101, 114], ["standard deviation", "OBSERVATION", 9, 27]]], ["The data was also analyzed by Student's t test to compare the effectiveness of RR1 concentrations.Characterization of RR1The results of the glycosyl composition and linkage analyses corroborated our initial findings and the 13 C NMR spectral data on the carbohydrate composition of RR1.", [["RR1", "CHEMICAL", 79, 82], ["glycosyl", "CHEMICAL", 140, 148], ["13 C", "CHEMICAL", 224, 228], ["carbohydrate", "CHEMICAL", 254, 266], ["RR1", "SIMPLE_CHEMICAL", 79, 82], ["RR1", "PROTEIN", 79, 82], ["RR1", "PROTEIN", 118, 121], ["RR1", "PROTEIN", 282, 285], ["Student's t test", "TEST", 30, 46], ["RR1 concentrations", "PROBLEM", 79, 97], ["RR1", "TEST", 118, 121], ["the glycosyl composition", "TEST", 136, 160], ["linkage analyses", "TEST", 165, 181], ["NMR spectral data", "TEST", 229, 246]]], ["The glycosyl composition analysis showed glucose as the only component in RR1 while linkage analysis revealed three types of glucopyranosyl residues corresponding to three types of linkages: 4-linked glucopyranosyl residue (80%), 4,6-linked glucopyranosyl residue (12%) and terminal glucopyranosyl residue (8%).", [["glucose", "CHEMICAL", 41, 48], ["glucopyranosyl", "CHEMICAL", 125, 139], ["glucopyranosyl", "CHEMICAL", 241, 255], ["glucopyranosyl", "CHEMICAL", 283, 297], ["glycosyl", "CHEMICAL", 4, 12], ["glucose", "CHEMICAL", 41, 48], ["glucopyranosyl", "CHEMICAL", 125, 139], ["glucopyranosyl", "CHEMICAL", 200, 214], ["glucopyranosyl", "CHEMICAL", 241, 255], ["glucopyranosyl", "CHEMICAL", 283, 297], ["glucose", "SIMPLE_CHEMICAL", 41, 48], ["RR1", "SIMPLE_CHEMICAL", 74, 77], ["4-linked glucopyranosyl residue", "SIMPLE_CHEMICAL", 191, 222], ["4,6-linked glucopyranosyl residue", "SIMPLE_CHEMICAL", 230, 263], ["terminal glucopyranosyl residue", "SIMPLE_CHEMICAL", 274, 305], ["RR1", "PROTEIN", 74, 77], ["The glycosyl composition analysis", "TEST", 0, 33], ["glucose", "TEST", 41, 48], ["linkage analysis", "TEST", 84, 100], ["glucopyranosyl residues", "PROBLEM", 125, 148], ["linked glucopyranosyl residue", "PROBLEM", 193, 222], ["linked glucopyranosyl residue", "PROBLEM", 234, 263], ["terminal glucopyranosyl residue", "TREATMENT", 274, 305]]], ["The 13 C NMR spectra (Fig. 2a) Fig. 2b) are due to the a proton associated with the anomeric carbon of the glucopyranosyl units.", [["glucopyranosyl", "CHEMICAL", 107, 121], ["C", "CHEMICAL", 7, 8], ["carbon", "CHEMICAL", 93, 99], ["glucopyranosyl", "CHEMICAL", 107, 121], ["glucopyranosyl", "SIMPLE_CHEMICAL", 107, 121], ["The 13 C NMR spectra (Fig. 2a)", "TREATMENT", 0, 30], ["the anomeric carbon of the glucopyranosyl units", "TREATMENT", 80, 127]]], ["On the other hand, the very weak signal at d 4.66 ppm may be due to that of the h anomer.", [["the very weak signal", "PROBLEM", 19, 39]]], ["However, the ratio of the signals of a-d-glucose to h-d-glucose is about 99.9:1, and hence almost all glucose units appeared to be in the a configuration.", [["a-d-glucose", "CHEMICAL", 37, 48], ["h-d-", "CHEMICAL", 52, 56], ["glucose", "CHEMICAL", 56, 63], ["glucose", "CHEMICAL", 102, 109], ["a-d-glucose", "CHEMICAL", 37, 48], ["h-d-glucose", "CHEMICAL", 52, 63], ["glucose", "CHEMICAL", 102, 109], ["a-d-glucose", "SIMPLE_CHEMICAL", 37, 48], ["h-d-glucose", "SIMPLE_CHEMICAL", 52, 63], ["glucose", "SIMPLE_CHEMICAL", 102, 109], ["a-d", "TEST", 37, 40], ["h-d-glucose", "TEST", 52, 63]]], ["Therefore, RR1 is an a-dglucan with (1Y4) linked glucopyranosyl units in the main chain with (1Y6) linked glucopyranosyl unit branches and a 0.15 degree of branching (Fig. 3) .", [["glucopyranosyl", "CHEMICAL", 49, 63], ["a-dglucan", "CHEMICAL", 21, 30], ["glucopyranosyl", "CHEMICAL", 49, 63], ["glucopyranosyl", "CHEMICAL", 106, 120], ["RR1", "SIMPLE_CHEMICAL", 11, 14], ["a-dglucan", "SIMPLE_CHEMICAL", 21, 30], ["RR1", "PROTEIN", 11, 14], ["linked glucopyranosyl units", "TREATMENT", 42, 69], ["main", "ANATOMY_MODIFIER", 77, 81], ["chain", "ANATOMY_MODIFIER", 82, 87], ["branches", "ANATOMY_MODIFIER", 126, 134], ["0.15 degree", "OBSERVATION_MODIFIER", 141, 152], ["branching", "OBSERVATION_MODIFIER", 156, 165]]], ["In the size exclusion chromatography RR1 eluted as single peak at 12.32 min which was very close to the peak for the 511-kDa dextran sample (retention time 12.72 min).", [["dextran", "CHEMICAL", 125, 132], ["Da dextran sample", "TREATMENT", 122, 139], ["size", "OBSERVATION_MODIFIER", 7, 11]]], ["Therefore, RR1 is assigned a molecular weight N550 kDa.Noncytotoxic/cell proliferation effectThe results of MTT assay given in Fig. 4a and b show that RR1 has no direct cytotoxic or cell-proliferating effect either on normal lymphocytes or on tumor cell lines (CEM and CEM/VLB) even at a concentration as high as 1000 Ag/ml.Lymphocyte activationLymphocytes are the key effecter cells of mammalian immune system and our studies show that the different subpopulations of lymphocytes are activated by RR1 at varying levels.", [["cell", "ANATOMY", 68, 72], ["cell", "ANATOMY", 182, 186], ["lymphocytes", "ANATOMY", 225, 236], ["tumor cell lines", "ANATOMY", 243, 259], ["CEM", "ANATOMY", 261, 264], ["CEM", "ANATOMY", 269, 272], ["VLB", "ANATOMY", 273, 276], ["Lymphocyte", "ANATOMY", 324, 334], ["effecter cells", "ANATOMY", 369, 383], ["immune system", "ANATOMY", 397, 410], ["lymphocytes", "ANATOMY", 469, 480], ["RR1", "CHEMICAL", 151, 154], ["tumor", "DISEASE", 243, 248], ["MTT", "CHEMICAL", 108, 111], ["RR1", "CHEMICAL", 151, 154], ["Ag", "CHEMICAL", 318, 320], ["RR1", "SIMPLE_CHEMICAL", 11, 14], ["cell", "CELL", 68, 72], ["RR1", "SIMPLE_CHEMICAL", 151, 154], ["cell", "CELL", 182, 186], ["lymphocytes", "CELL", 225, 236], ["tumor cell lines", "CELL", 243, 259], ["CEM", "CELL", 261, 264], ["CEM/VLB", "CELL", 269, 276], ["Lymphocyte", "CELL", 324, 334], ["effecter cells", "CELL", 369, 383], ["mammalian immune system", "ANATOMICAL_SYSTEM", 387, 410], ["lymphocytes", "CELL", 469, 480], ["RR1", "GENE_OR_GENE_PRODUCT", 498, 501], ["RR1", "PROTEIN", 11, 14], ["molecular weight N550 kDa", "PROTEIN", 29, 54], ["RR1", "PROTEIN", 151, 154], ["normal lymphocytes", "CELL_TYPE", 218, 236], ["tumor cell lines", "CELL_LINE", 243, 259], ["CEM", "CELL_LINE", 261, 264], ["CEM", "CELL_LINE", 269, 272], ["VLB", "CELL_LINE", 273, 276], ["Lymphocyte activationLymphocytes", "CELL_TYPE", 324, 356], ["effecter cells", "CELL_TYPE", 369, 383], ["lymphocytes", "CELL_TYPE", 469, 480], ["RR1", "PROTEIN", 498, 501], ["Noncytotoxic/cell proliferation effect", "PROBLEM", 55, 93], ["MTT assay", "TEST", 108, 117], ["direct cytotoxic or cell", "PROBLEM", 162, 186], ["tumor cell lines", "PROBLEM", 243, 259], ["CEM", "TEST", 261, 264], ["CEM/VLB", "TEST", 269, 276], ["Lymphocyte activationLymphocytes", "TEST", 324, 356], ["our studies", "TEST", 415, 426], ["the different subpopulations of lymphocytes", "PROBLEM", 437, 480], ["cell proliferation effect", "OBSERVATION", 68, 93], ["no", "UNCERTAINTY", 159, 161], ["normal lymphocytes", "OBSERVATION", 218, 236], ["tumor cell lines", "OBSERVATION", 243, 259], ["mammalian immune system", "OBSERVATION", 387, 410], ["different", "OBSERVATION_MODIFIER", 441, 450], ["subpopulations", "OBSERVATION_MODIFIER", 451, 465], ["lymphocytes", "OBSERVATION", 469, 480]]], ["B cells are activated by 39%, T cells by 102% and NK cells 331% with 100 Ag/ml of RR1 (Fig. 5) .", [["B cells", "ANATOMY", 0, 7], ["T cells", "ANATOMY", 30, 37], ["NK cells", "ANATOMY", 50, 58], ["Ag", "CHEMICAL", 73, 75], ["B cells", "CELL", 0, 7], ["T cells", "CELL", 30, 37], ["NK cells", "CELL", 50, 58], ["B cells", "CELL_TYPE", 0, 7], ["T cells", "CELL_TYPE", 30, 37], ["NK cells", "CELL_TYPE", 50, 58], ["B cells", "TEST", 0, 7], ["T cells", "TEST", 30, 37], ["NK cells", "TEST", 50, 58], ["Ag", "TEST", 73, 75], ["RR1", "TEST", 82, 85]]], ["The higher activation of NK cells is quite important as NK cells are the main effecters of innate immune system that comes into contact with antigens/mitogens before antibody production and recognition by the adaptive immune system.", [["NK cells", "ANATOMY", 25, 33], ["NK cells", "ANATOMY", 56, 64], ["immune system", "ANATOMY", 98, 111], ["NK cells", "CELL", 25, 33], ["NK cells", "CELL", 56, 64], ["immune system", "ANATOMICAL_SYSTEM", 218, 231], ["NK cells", "CELL_TYPE", 25, 33], ["NK cells", "CELL_TYPE", 56, 64], ["antigens", "PROTEIN", 141, 149], ["mitogens", "PROTEIN", 150, 158], ["The higher activation of NK cells", "PROBLEM", 0, 33], ["antibody production", "PROBLEM", 166, 185], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["activation of NK cells", "OBSERVATION", 11, 33]]], ["The increased activity of NK cells by RR1 is quite evident from the results of functional cytotoxic assay given in Fig. 6 .", [["NK cells", "ANATOMY", 26, 34], ["NK cells", "CELL", 26, 34], ["RR1", "SIMPLE_CHEMICAL", 38, 41], ["NK cells", "CELL_TYPE", 26, 34], ["RR1", "PROTEIN", 38, 41], ["The increased activity of NK cells", "PROBLEM", 0, 34], ["functional cytotoxic assay", "TEST", 79, 105], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["activity", "OBSERVATION_MODIFIER", 14, 22], ["NK cells", "OBSERVATION", 26, 34]]], ["RR1-treated normal lymphocytes were able to kill a higher percentage of tumor cells compared to untreated cells and a dosedependent enhancement of cytotoxicity of activated lymphocytes was evident.Complement activation pathwayA stepwise increase in the levels of C3a des Arg of the alternative pathway was noticed with increase in concentrations of RR1 (Fig. 7) .", [["lymphocytes", "ANATOMY", 19, 30], ["tumor cells", "ANATOMY", 72, 83], ["cells", "ANATOMY", 106, 111], ["lymphocytes", "ANATOMY", 173, 184], ["RR1", "CHEMICAL", 0, 3], ["tumor", "DISEASE", 72, 77], ["Arg", "CHEMICAL", 271, 274], ["RR1", "SIMPLE_CHEMICAL", 0, 3], ["lymphocytes", "CELL", 19, 30], ["tumor cells", "CELL", 72, 83], ["cells", "CELL", 106, 111], ["lymphocytes", "CELL", 173, 184], ["Complement", "GENE_OR_GENE_PRODUCT", 197, 207], ["C3a des Arg", "GENE_OR_GENE_PRODUCT", 263, 274], ["RR1-treated normal lymphocytes", "CELL_LINE", 0, 30], ["tumor cells", "CELL_TYPE", 72, 83], ["untreated cells", "CELL_TYPE", 96, 111], ["activated lymphocytes", "CELL_TYPE", 163, 184], ["C3a", "PROTEIN", 263, 266], ["RR1", "TEST", 0, 3], ["tumor cells", "PROBLEM", 72, 83], ["untreated cells", "PROBLEM", 96, 111], ["cytotoxicity of activated lymphocytes", "PROBLEM", 147, 184], ["Complement activation pathway", "PROBLEM", 197, 226], ["A stepwise increase", "PROBLEM", 226, 245], ["C3a des", "TREATMENT", 263, 270], ["lymphocytes", "OBSERVATION", 19, 30], ["tumor cells", "OBSERVATION", 72, 83], ["cytotoxicity", "OBSERVATION_MODIFIER", 147, 159], ["activated lymphocytes", "OBSERVATION", 163, 184], ["stepwise", "OBSERVATION_MODIFIER", 228, 236], ["increase", "OBSERVATION_MODIFIER", 237, 245]]], ["However, there was no significant difference in C4 des Arg levels (classical pathway) with increasing RR1 concentrations.", [["Arg", "CHEMICAL", 55, 58], ["RR1", "CHEMICAL", 102, 105], ["C4 des Arg", "SIMPLE_CHEMICAL", 48, 58], ["RR1", "SIMPLE_CHEMICAL", 102, 105], ["RR1", "PROTEIN", 102, 105], ["significant difference in C4 des Arg levels", "PROBLEM", 22, 65], ["increasing RR1 concentrations", "PROBLEM", 91, 120], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["difference", "OBSERVATION_MODIFIER", 34, 44]]], ["(Fig. 8) while it did not induce the production of IL-2, IL-4, IL-10, TNF-h and IFN-a.", [["IL-2", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL-4", "GENE_OR_GENE_PRODUCT", 57, 61], ["IL-10", "GENE_OR_GENE_PRODUCT", 63, 68], ["TNF-h", "GENE_OR_GENE_PRODUCT", 70, 75], ["TNF", "PROTEIN", 70, 73], ["IFN", "PROTEIN", 80, 83], ["IL", "TEST", 51, 53], ["IL", "TEST", 57, 59], ["IL", "TEST", 63, 65], ["TNF", "TEST", 70, 73]]], ["In general, a dose-dependent increase in the production of cytokines was observed with RR1 except for IL-12 p40 which recorded the maximum at 10 Ag/ml ( pb0.05) and further increase in the RR1 exhibited a decreasing trend with no significant difference between 50 Ag and 100 Ag/ml concentrations ( pN0.05).", [["Ag", "CHEMICAL", 145, 147], ["Ag", "CHEMICAL", 264, 266], ["Ag", "CHEMICAL", 275, 277], ["RR1", "SIMPLE_CHEMICAL", 87, 90], ["IL-12 p40", "GENE_OR_GENE_PRODUCT", 102, 111], ["RR1", "SIMPLE_CHEMICAL", 189, 192], ["cytokines", "PROTEIN", 59, 68], ["RR1", "PROTEIN", 87, 90], ["IL", "PROTEIN", 102, 104], ["p40", "PROTEIN", 108, 111], ["RR1", "PROTEIN", 189, 192], ["Ag", "PROTEIN", 264, 266], ["a dose-dependent increase", "PROBLEM", 12, 37], ["the production of cytokines", "PROBLEM", 41, 68], ["IL", "TEST", 102, 104], ["further increase in the RR1", "PROBLEM", 165, 192], ["dependent", "OBSERVATION_MODIFIER", 19, 28], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["increase", "OBSERVATION_MODIFIER", 173, 181], ["decreasing", "OBSERVATION_MODIFIER", 205, 215]]], ["MCP-1 production was very significant up to 10 Ag/ml of RR-1 ( pb0.05) and higher RR1 concentration produced only little increase in MCP-1 level ( pN0.05).", [["Ag", "CHEMICAL", 47, 49], ["RR1", "CHEMICAL", 82, 85], ["MCP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["RR-1", "GENE_OR_GENE_PRODUCT", 56, 60], ["RR1", "SIMPLE_CHEMICAL", 82, 85], ["MCP-1", "GENE_OR_GENE_PRODUCT", 133, 138], ["MCP", "PROTEIN", 0, 3], ["RR1", "PROTEIN", 82, 85], ["MCP", "PROTEIN", 133, 136], ["MCP", "TEST", 0, 3], ["RR", "TEST", 56, 58], ["higher RR1 concentration", "PROBLEM", 75, 99], ["little increase in MCP", "PROBLEM", 114, 136], ["little", "OBSERVATION_MODIFIER", 114, 120], ["increase", "OBSERVATION_MODIFIER", 121, 129]]], ["In general proinflammatory cytokines IL-1h, IL-6 and TNF-a and the regulatory cytokine IL-12 p40 exhibited higher levels of production compare to other cytokines.NO synthesis and iNOS inductionRR1 stimulation caused only b20% increase in NO level compared to untreated cells.", [["cells", "ANATOMY", 269, 274], ["NO", "CHEMICAL", 162, 164], ["NO", "CHEMICAL", 238, 240], ["NO", "CHEMICAL", 162, 164], ["NO", "CHEMICAL", 238, 240], ["IL-1h", "GENE_OR_GENE_PRODUCT", 37, 42], ["IL-6", "GENE_OR_GENE_PRODUCT", 44, 48], ["TNF-a", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL-12 p40", "GENE_OR_GENE_PRODUCT", 87, 96], ["NO", "SIMPLE_CHEMICAL", 162, 164], ["iNOS", "GENE_OR_GENE_PRODUCT", 179, 183], ["RR1", "SIMPLE_CHEMICAL", 193, 196], ["NO", "SIMPLE_CHEMICAL", 238, 240], ["cells", "CELL", 269, 274], ["proinflammatory cytokines", "PROTEIN", 11, 36], ["IL", "PROTEIN", 37, 39], ["IL-6", "PROTEIN", 44, 48], ["TNF", "PROTEIN", 53, 56], ["regulatory cytokine IL-12 p40", "PROTEIN", 67, 96], ["cytokines", "PROTEIN", 152, 161], ["iNOS", "PROTEIN", 179, 183], ["RR1", "PROTEIN", 193, 196], ["untreated cells", "CELL_TYPE", 259, 274], ["general proinflammatory cytokines IL", "TEST", 3, 39], ["IL", "TEST", 44, 46], ["TNF", "TEST", 53, 56], ["the regulatory cytokine IL", "TEST", 63, 89], ["higher levels of production", "PROBLEM", 107, 134], ["synthesis", "PROBLEM", 165, 174], ["iNOS inductionRR1 stimulation", "TREATMENT", 179, 208], ["b20% increase", "PROBLEM", 221, 234], ["proinflammatory", "OBSERVATION_MODIFIER", 11, 26], ["iNOS", "OBSERVATION", 179, 183]]], ["In addition, there was no significant induction of iNOS at 0-100 Ag/ml of RR1 (data not shown).DiscussionMammalian immune system recognizes antigens, pathogens and nonself molecules and trigger defense mechanism by the activation of immune competent cells, production of chemical messengers (the cytokines and chemokines), activation of complement cascade pathway and synthesis of nitric oxide (NO).", [["immune system", "ANATOMY", 115, 128], ["cells", "ANATOMY", 250, 255], ["nitric oxide", "CHEMICAL", 381, 393], ["NO", "CHEMICAL", 395, 397], ["Ag", "CHEMICAL", 65, 67], ["nitric oxide", "CHEMICAL", 381, 393], ["NO", "CHEMICAL", 395, 397], ["iNOS", "GENE_OR_GENE_PRODUCT", 51, 55], ["cells", "CELL", 250, 255], ["nitric oxide", "SIMPLE_CHEMICAL", 381, 393], ["NO", "SIMPLE_CHEMICAL", 395, 397], ["iNOS", "PROTEIN", 51, 55], ["antigens", "PROTEIN", 140, 148], ["nonself molecules", "PROTEIN", 164, 181], ["immune competent cells", "CELL_TYPE", 233, 255], ["chemical messengers", "PROTEIN", 271, 290], ["cytokines", "PROTEIN", 296, 305], ["chemokines", "PROTEIN", 310, 320], ["iNOS", "TEST", 51, 55], ["RR1", "TEST", 74, 77], ["pathogens", "PROBLEM", 150, 159], ["nonself molecules", "PROBLEM", 164, 181], ["immune competent cells", "TREATMENT", 233, 255], ["the cytokines and chemokines)", "TREATMENT", 292, 321], ["complement cascade pathway", "TREATMENT", 337, 363], ["synthesis of nitric oxide", "TREATMENT", 368, 393], ["no", "UNCERTAINTY", 23, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["Cytokines are a group of low molecular weight regulatory nonantibody proteins secreted by immune component cells in response to stimulation.", [["immune component cells", "ANATOMY", 90, 112], ["immune component cells", "CELL", 90, 112], ["Cytokines", "PROTEIN", 0, 9], ["low molecular weight regulatory nonantibody proteins", "PROTEIN", 25, 77], ["immune component cells", "CELL_TYPE", 90, 112], ["stimulation", "TEST", 128, 139]]], ["They bind to specific receptors of target cells triggering signal transduction pathways that ultimately lead to gene expression in target cells.", [["cells", "ANATOMY", 42, 47], ["cells", "ANATOMY", 138, 143], ["cells", "CELL", 42, 47], ["cells", "CELL", 138, 143], ["target cells", "CELL_TYPE", 35, 47], ["target cells", "CELL_TYPE", 131, 143], ["signal transduction pathways", "PROBLEM", 59, 87], ["gene expression in target cells", "PROBLEM", 112, 143], ["target cells", "OBSERVATION", 131, 143]]], ["Cytokines regulate the intensity and duration of immune responses by stimulating or inhibiting activation, proliferation and/or differentiation of various cells and by regulating the secretion of antibodies or other cytokines.", [["cells", "ANATOMY", 155, 160], ["cells", "CELL", 155, 160], ["Cytokines", "PROTEIN", 0, 9], ["antibodies", "PROTEIN", 196, 206], ["cytokines", "PROTEIN", 216, 225], ["immune responses", "TREATMENT", 49, 65], ["proliferation", "PROBLEM", 107, 120], ["various cells", "PROBLEM", 147, 160], ["other cytokines", "PROBLEM", 210, 225], ["intensity", "OBSERVATION_MODIFIER", 23, 32]]], ["The pleiotropy, redundancy, synergy and antagonism exhibited by cytokines permit them to coordinate and regulate cellular activities.", [["cellular", "ANATOMY", 113, 121], ["cellular", "CELL", 113, 121], ["cytokines", "PROTEIN", 64, 73], ["The pleiotropy", "PROBLEM", 0, 14], ["synergy", "PROBLEM", 28, 35], ["antagonism", "PROBLEM", 40, 50], ["redundancy", "OBSERVATION", 16, 26]]], ["Inflammatory responses are crucial in controlling and eliminating infectious agents as well as in promoting wound healing for restoration of tissue integrity.DiscussionIL-1h and TNF-a induce the production of each other as well as that of IL-6, and act synergistically and regulate several biological actions besides IL-1 being self-inductive [34] .", [["wound", "ANATOMY", 108, 113], ["tissue", "ANATOMY", 141, 147], ["wound", "PATHOLOGICAL_FORMATION", 108, 113], ["tissue", "TISSUE", 141, 147], ["DiscussionIL-1h", "GENE_OR_GENE_PRODUCT", 158, 173], ["TNF", "GENE_OR_GENE_PRODUCT", 178, 181], ["IL-6", "GENE_OR_GENE_PRODUCT", 239, 243], ["IL-1", "GENE_OR_GENE_PRODUCT", 317, 321], ["TNF", "PROTEIN", 178, 181], ["IL-6", "PROTEIN", 239, 243], ["IL", "PROTEIN", 317, 319], ["Inflammatory responses", "PROBLEM", 0, 22], ["infectious agents", "TREATMENT", 66, 83], ["promoting wound healing", "PROBLEM", 98, 121], ["tissue integrity", "PROBLEM", 141, 157], ["infectious", "OBSERVATION", 66, 76], ["wound", "ANATOMY", 108, 113], ["healing", "OBSERVATION", 114, 121], ["tissue integrity", "OBSERVATION", 141, 157]]], ["The production of IL-1h and TNF-a in RR1-treated lymphocytes is consistent with that in the LPS stimulated human monocyte cell lines (THP-1) [35] .", [["lymphocytes", "ANATOMY", 49, 60], ["monocyte cell lines", "ANATOMY", 113, 132], ["RR1", "CHEMICAL", 37, 40], ["LPS", "CHEMICAL", 92, 95], ["IL-1h", "GENE_OR_GENE_PRODUCT", 18, 23], ["TNF", "GENE_OR_GENE_PRODUCT", 28, 31], ["RR1", "SIMPLE_CHEMICAL", 37, 40], ["lymphocytes", "CELL", 49, 60], ["LPS", "SIMPLE_CHEMICAL", 92, 95], ["human", "ORGANISM", 107, 112], ["monocyte cell lines", "CELL", 113, 132], ["THP-1", "CELL", 134, 139], ["IL", "PROTEIN", 18, 20], ["TNF", "PROTEIN", 28, 31], ["RR1-treated lymphocytes", "CELL_LINE", 37, 60], ["LPS stimulated human monocyte cell lines", "CELL_LINE", 92, 132], ["THP-1", "CELL_LINE", 134, 139], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["IL", "TEST", 18, 20], ["TNF", "TEST", 28, 31], ["lymphocytes", "PROBLEM", 49, 60], ["the LPS stimulated human monocyte cell lines", "TREATMENT", 88, 132], ["THP", "TEST", 134, 137], ["consistent with", "UNCERTAINTY", 64, 79], ["monocyte cell lines", "OBSERVATION", 113, 132]]], ["IL-12 p70 is the bioactive isoform of IL-12 and is an important factor in the differentiation of naRve T cells into effecter T helper type 1 (Th1) CD4+ lymphocytes secreting IFN-g [36] .", [["naRve T cells", "ANATOMY", 97, 110], ["T helper type 1 (Th1) CD4+ lymphocytes", "ANATOMY", 125, 163], ["IL-12 p70", "GENE_OR_GENE_PRODUCT", 0, 9], ["IL-12", "GENE_OR_GENE_PRODUCT", 38, 43], ["naRve T cells", "CELL", 97, 110], ["T helper type 1", "GENE_OR_GENE_PRODUCT", 125, 140], ["Th1", "GENE_OR_GENE_PRODUCT", 142, 145], ["CD4", "GENE_OR_GENE_PRODUCT", 147, 150], ["IL-12 p70", "PROTEIN", 0, 9], ["IL-12", "PROTEIN", 38, 43], ["naRve T cells", "CELL_TYPE", 97, 110], ["effecter T helper type 1 (Th1) CD4+ lymphocytes", "CELL_TYPE", 116, 163], ["IFN", "PROTEIN", 174, 177], ["IL", "TEST", 0, 2], ["CD4", "TEST", 147, 150], ["lymphocytes", "TEST", 152, 163], ["secreting IFN", "TEST", 164, 177]]], ["Besides, it is also reported to have stimulatory effects on NK cells [2] .", [["NK cells", "ANATOMY", 60, 68], ["NK cells", "CELL", 60, 68], ["NK cells", "CELL_TYPE", 60, 68], ["stimulatory effects on NK cells", "PROBLEM", 37, 68]]], ["Recently, IL-12 p70 has emerged as an efficient and minimally toxic antitumor cytokine due to its ability to elicit the Th1 response [37] .", [["antitumor", "ANATOMY", 68, 77], ["IL-12 p70", "GENE_OR_GENE_PRODUCT", 10, 19], ["antitumor", "CANCER", 68, 77], ["IL-12 p70", "PROTEIN", 10, 19], ["antitumor cytokine", "PROTEIN", 68, 86], ["IL", "TREATMENT", 10, 12], ["minimally toxic antitumor cytokine", "TREATMENT", 52, 86]]], ["Beyond the immune system, this cytokine is also reported to have the capacity to inhibit UV-induced apoptosis and initiation of DNA repair in UVdamaged keratinocytes which ultimately protect the cells from malignancy [38] .", [["immune system", "ANATOMY", 11, 24], ["keratinocytes", "ANATOMY", 152, 165], ["cells", "ANATOMY", 195, 200], ["UV", "CHEMICAL", 89, 91], ["malignancy", "DISEASE", 206, 216], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["UVdamaged keratinocytes", "CELL", 142, 165], ["cells", "CELL", 195, 200], ["cytokine", "PROTEIN", 31, 39], ["UVdamaged keratinocytes", "CELL_LINE", 142, 165], ["the capacity", "PROBLEM", 65, 77], ["UV", "TREATMENT", 89, 91], ["apoptosis", "PROBLEM", 100, 109], ["DNA repair", "TREATMENT", 128, 138], ["UVdamaged keratinocytes", "PROBLEM", 142, 165], ["malignancy", "PROBLEM", 206, 216], ["DNA repair", "OBSERVATION", 128, 138], ["malignancy", "OBSERVATION", 206, 216]]], ["IL-12 p40, the homodimeric isoform, is a receptor antagonist of the bioactive heterodimeric isoform p70 in mouse [39] .", [["IL-12 p40", "GENE_OR_GENE_PRODUCT", 0, 9], ["p70", "GENE_OR_GENE_PRODUCT", 100, 103], ["mouse", "ORGANISM", 107, 112], ["IL-12 p40", "PROTEIN", 0, 9], ["homodimeric isoform", "PROTEIN", 15, 34], ["heterodimeric isoform p70", "PROTEIN", 78, 103], ["mouse", "SPECIES", 107, 112], ["mouse", "SPECIES", 107, 112], ["IL", "TEST", 0, 2], ["a receptor antagonist", "TREATMENT", 39, 60], ["the bioactive heterodimeric isoform", "TREATMENT", 64, 99]]], ["In the RR1treated cells, IL-12 p40, the regulatory cytokine is produced in many-fold excess to the bioactive form which may be natural mechanism to control the over production of the bioactive form p70.", [["RR1treated cells", "ANATOMY", 7, 23], ["RR1treated cells", "CELL", 7, 23], ["IL-12 p40", "GENE_OR_GENE_PRODUCT", 25, 34], ["p70", "GENE_OR_GENE_PRODUCT", 198, 201], ["RR1treated cells", "CELL_LINE", 7, 23], ["IL-12 p40", "PROTEIN", 25, 34], ["regulatory cytokine", "PROTEIN", 40, 59], ["p70", "PROTEIN", 198, 201], ["IL", "TEST", 25, 27]]], ["IL-18 is another potent inducer of IFN-g and apparently NK cells [40] .", [["NK cells", "ANATOMY", 56, 64], ["IL-18", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-g", "GENE_OR_GENE_PRODUCT", 35, 40], ["NK cells", "CELL", 56, 64], ["IL-18", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 35, 38], ["NK cells", "CELL_TYPE", 56, 64], ["IL", "TEST", 0, 2], ["IFN", "TEST", 35, 38], ["NK cells", "OBSERVATION", 56, 64]]], ["RR1 induction of IL-18 production may be an early response in the development of Th1 response acting in consonance with IL-12 and IFN-g.DiscussionMCP-1 is a potent chemoattractant for monocytes and activated CD4 and CD8 T cells that is reported to induce granule release from NK and CD8+ cells, activate NK function in CD56+ cells, and act as a potent releasing factor for histamine from basophiles [41] .", [["monocytes", "ANATOMY", 184, 193], ["CD4", "ANATOMY", 208, 211], ["CD8 T cells", "ANATOMY", 216, 227], ["granule", "ANATOMY", 255, 262], ["NK", "ANATOMY", 276, 278], ["CD8+ cells", "ANATOMY", 283, 293], ["NK", "ANATOMY", 304, 306], ["CD56+ cells", "ANATOMY", 319, 330], ["histamine", "CHEMICAL", 373, 382], ["histamine", "CHEMICAL", 373, 382], ["IL-18", "GENE_OR_GENE_PRODUCT", 17, 22], ["Th1", "GENE_OR_GENE_PRODUCT", 81, 84], ["IL-12", "GENE_OR_GENE_PRODUCT", 120, 125], ["IFN", "GENE_OR_GENE_PRODUCT", 130, 133], ["DiscussionMCP-1", "GENE_OR_GENE_PRODUCT", 136, 151], ["monocytes", "CELL", 184, 193], ["CD4", "CELL", 208, 211], ["CD8", "GENE_OR_GENE_PRODUCT", 216, 219], ["granule", "CELLULAR_COMPONENT", 255, 262], ["NK", "CELL", 276, 278], ["CD8", "GENE_OR_GENE_PRODUCT", 283, 286], ["NK", "CELL", 304, 306], ["CD56", "GENE_OR_GENE_PRODUCT", 319, 323], ["histamine", "SIMPLE_CHEMICAL", 373, 382], ["RR1", "PROTEIN", 0, 3], ["IL-18", "PROTEIN", 17, 22], ["IL", "PROTEIN", 120, 122], ["IFN", "PROTEIN", 130, 133], ["monocytes", "CELL_TYPE", 184, 193], ["activated CD4 and CD8 T cells", "CELL_TYPE", 198, 227], ["NK and CD8+ cells", "CELL_TYPE", 276, 293], ["CD56+ cells", "CELL_TYPE", 319, 330], ["Th1 response", "PROBLEM", 81, 93], ["IL", "TEST", 120, 122], ["IFN", "TREATMENT", 130, 133], ["monocytes", "PROBLEM", 184, 193], ["activated CD4", "TEST", 198, 211], ["CD8 T cells", "TEST", 216, 227], ["granule release", "TEST", 255, 270], ["NK", "TEST", 276, 278], ["NK function", "TEST", 304, 315], ["CD56", "TEST", 319, 323], ["cells", "TEST", 325, 330], ["early", "OBSERVATION_MODIFIER", 44, 49], ["response", "OBSERVATION_MODIFIER", 50, 58], ["Th1 response", "OBSERVATION", 81, 93]]], ["Furthermore, it is reported to exhibit antitumor effects by enhancing tumor specific immunity, presumably in a T-cell-dependent manner [42] .", [["antitumor", "ANATOMY", 39, 48], ["tumor", "ANATOMY", 70, 75], ["T-cell", "ANATOMY", 111, 117], ["tumor", "DISEASE", 70, 75], ["antitumor", "CANCER", 39, 48], ["tumor", "CANCER", 70, 75], ["T-cell", "CELL", 111, 117], ["antitumor effects", "PROBLEM", 39, 56], ["enhancing tumor specific immunity", "PROBLEM", 60, 93], ["antitumor", "OBSERVATION", 39, 48], ["enhancing", "OBSERVATION_MODIFIER", 60, 69], ["tumor", "OBSERVATION", 70, 75]]], ["Our observations indicate that RR1 induces the production of this cytokine significantly at 10 Ag/ml.", [["RR1", "CHEMICAL", 31, 34], ["Ag", "CHEMICAL", 95, 97], ["RR1", "SIMPLE_CHEMICAL", 31, 34], ["RR1", "PROTEIN", 31, 34], ["cytokine", "PROTEIN", 66, 74], ["this cytokine", "PROBLEM", 61, 74]]], ["The significant synthesis of TNF-a by RR1 stimulation can play a critical role in host resistance to infections and to the growth of malignancy.", [["malignancy", "ANATOMY", 133, 143], ["infections", "DISEASE", 101, 111], ["malignancy", "DISEASE", 133, 143], ["TNF", "GENE_OR_GENE_PRODUCT", 29, 32], ["RR1", "GENE_OR_GENE_PRODUCT", 38, 41], ["malignancy", "CANCER", 133, 143], ["TNF", "PROTEIN", 29, 32], ["RR1", "PROTEIN", 38, 41], ["TNF", "TEST", 29, 32], ["infections", "PROBLEM", 101, 111], ["malignancy", "PROBLEM", 133, 143], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["synthesis", "OBSERVATION_MODIFIER", 16, 25], ["malignancy", "OBSERVATION", 133, 143]]], ["TNF-a and its receptors are essential for protection against tuberculosis and for NO synthesis in macrophages early in infection [43] .", [["macrophages", "ANATOMY", 98, 109], ["tuberculosis", "DISEASE", 61, 73], ["NO", "CHEMICAL", 82, 84], ["infection", "DISEASE", 119, 128], ["NO", "CHEMICAL", 82, 84], ["TNF-a", "GENE_OR_GENE_PRODUCT", 0, 5], ["NO", "SIMPLE_CHEMICAL", 82, 84], ["macrophages", "CELL", 98, 109], ["TNF", "PROTEIN", 0, 3], ["macrophages", "CELL_TYPE", 98, 109], ["TNF", "TEST", 0, 3], ["its receptors", "TEST", 10, 23], ["tuberculosis", "PROBLEM", 61, 73], ["synthesis in macrophages", "PROBLEM", 85, 109], ["infection", "PROBLEM", 119, 128]]], ["RR1-induced IFN-g production may function in part to promote the activity of the components of the cell-mediated immune system such as cytotoxic T lymphocytes (CTLs), macrophages and NK cells in addition to its inhibitory role in Th2 response.", [["cell", "ANATOMY", 99, 103], ["immune system", "ANATOMY", 113, 126], ["cytotoxic T lymphocytes", "ANATOMY", 135, 158], ["CTLs", "ANATOMY", 160, 164], ["macrophages", "ANATOMY", 167, 178], ["NK cells", "ANATOMY", 183, 191], ["RR1", "CHEMICAL", 0, 3], ["RR1", "SIMPLE_CHEMICAL", 0, 3], ["IFN-g", "GENE_OR_GENE_PRODUCT", 12, 17], ["cell", "CELL", 99, 103], ["cytotoxic T lymphocytes", "CELL", 135, 158], ["CTLs", "CELL", 160, 164], ["macrophages", "CELL", 167, 178], ["NK cells", "CELL", 183, 191], ["RR1", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 12, 15], ["cytotoxic T lymphocytes", "CELL_TYPE", 135, 158], ["CTLs", "CELL_TYPE", 160, 164], ["macrophages", "CELL_TYPE", 167, 178], ["NK cells", "CELL_TYPE", 183, 191], ["RR1", "TEST", 0, 3], ["cytotoxic T lymphocytes", "TEST", 135, 158], ["CTLs", "TEST", 160, 164], ["macrophages and NK cells", "PROBLEM", 167, 191], ["NK cells", "OBSERVATION", 183, 191], ["Th2 response", "OBSERVATION", 230, 242]]], ["It stimulates the bactericidal activity of phagocytic cells and, therefore, boosts the innate immune response [5] .", [["phagocytic cells", "ANATOMY", 43, 59], ["phagocytic cells", "CELL", 43, 59], ["phagocytic cells", "CELL_TYPE", 43, 59], ["bactericidal activity", "OBSERVATION", 18, 39], ["phagocytic cells", "OBSERVATION", 43, 59]]], ["Moreover, it may modulate MCP-1 synthesis in macrophages by LPS [44] .", [["macrophages", "ANATOMY", 45, 56], ["LPS", "CHEMICAL", 60, 63], ["MCP-1", "GENE_OR_GENE_PRODUCT", 26, 31], ["macrophages", "CELL", 45, 56], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["MCP", "PROTEIN", 26, 29], ["macrophages", "CELL_TYPE", 45, 56], ["MCP", "TEST", 26, 29]]], ["CD4+ T cells contribute to the regulation of antigen specific (adaptive) immune system through the recognition of antigens and consequent production of cytokines.", [["CD4+ T cells", "ANATOMY", 0, 12], ["immune system", "ANATOMY", 73, 86], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["antigens", "PROTEIN", 114, 122], ["cytokines", "PROTEIN", 152, 161], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 5, 12], ["immune system", "TREATMENT", 73, 86], ["cytokines", "PROBLEM", 152, 161], ["T cells", "OBSERVATION", 5, 12]]], ["The distinct pattern of cytokine production by CD4+ cells form a dichotomy, Type 1 (Th1) characterized by IFN-g production and promotes elimination of intracellular pathogens and Type 2 (Th2) characterized by IL-4 production, involves IgE and eosinophils suitable for elimination of extra cellular pathogens.", [["CD4+ cells", "ANATOMY", 47, 57], ["intracellular", "ANATOMY", 151, 164], ["eosinophils", "ANATOMY", 243, 254], ["cellular", "ANATOMY", 289, 297], ["CD4", "GENE_OR_GENE_PRODUCT", 47, 50], ["Type 1", "GENE_OR_GENE_PRODUCT", 76, 82], ["IFN-g", "GENE_OR_GENE_PRODUCT", 106, 111], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 151, 164], ["Type 2", "CELL", 179, 185], ["IL-4", "GENE_OR_GENE_PRODUCT", 209, 213], ["IgE", "GENE_OR_GENE_PRODUCT", 235, 238], ["eosinophils", "CELL", 243, 254], ["cellular", "CELL", 289, 297], ["cytokine", "PROTEIN", 24, 32], ["CD4+ cells", "CELL_TYPE", 47, 57], ["IFN", "PROTEIN", 106, 109], ["IL", "PROTEIN", 209, 211], ["IgE", "PROTEIN", 235, 238], ["eosinophils", "CELL_TYPE", 243, 254], ["cytokine production", "PROBLEM", 24, 43], ["CD4+ cells", "PROBLEM", 47, 57], ["a dichotomy", "TEST", 63, 74], ["Type 1 (Th1)", "PROBLEM", 76, 88], ["IFN", "PROBLEM", 106, 109], ["intracellular pathogens", "PROBLEM", 151, 174], ["Type 2 (Th2)", "PROBLEM", 179, 191], ["IgE and eosinophils", "TEST", 235, 254], ["extra cellular pathogens", "PROBLEM", 283, 307], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["pattern", "OBSERVATION_MODIFIER", 13, 20], ["cytokine production", "OBSERVATION", 24, 43], ["intracellular pathogens", "OBSERVATION", 151, 174], ["cellular pathogens", "OBSERVATION", 289, 307]]], ["Cytokines act directly on T cells during primary activation and appears to be the most direct mediator among the factors influencing the terminal differentiation.", [["T cells", "ANATOMY", 26, 33], ["T cells", "CELL", 26, 33], ["Cytokines", "PROTEIN", 0, 9], ["T cells", "CELL_TYPE", 26, 33], ["Cytokines act", "PROBLEM", 0, 13], ["terminal differentiation", "OBSERVATION", 137, 161]]], ["The presence of IL-12 leads to Th1 response while IL-4 leads to Th2 development and the two pathways express mutually suppressive effect as well.", [["IL-12", "GENE_OR_GENE_PRODUCT", 16, 21], ["Th1", "GENE_OR_GENE_PRODUCT", 31, 34], ["IL-4", "GENE_OR_GENE_PRODUCT", 50, 54], ["Th2", "GENE_OR_GENE_PRODUCT", 64, 67], ["IL-12", "PROTEIN", 16, 21], ["IL-4", "PROTEIN", 50, 54], ["IL", "TREATMENT", 16, 18], ["IL", "OBSERVATION_MODIFIER", 16, 18], ["Th1 response", "OBSERVATION", 31, 43], ["suppressive effect", "OBSERVATION", 118, 136]]], ["IL-1 is identified as an inducer of IL-12 [41] while IL-18 is an early response in the development of Th1 cells by induction of IFN-g.", [["Th1 cells", "ANATOMY", 102, 111], ["IL-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-12", "GENE_OR_GENE_PRODUCT", 36, 41], ["IL-18", "GENE_OR_GENE_PRODUCT", 53, 58], ["Th1 cells", "CELL", 102, 111], ["IL-1", "PROTEIN", 0, 4], ["IL-18", "PROTEIN", 53, 58], ["Th1 cells", "CELL_TYPE", 102, 111], ["IFN", "PROTEIN", 128, 131], ["an inducer of IL", "TEST", 22, 38], ["IL", "TEST", 53, 55], ["Th1 cells", "PROBLEM", 102, 111], ["IFN", "TEST", 128, 131], ["Th1 cells", "OBSERVATION", 102, 111]]], ["The cytokine profile, IL-12, IL-18, IFN-g together with IL-1 by RR1 stimulation and the dose-dependent synthesis of these cytokines clearly demonstrate the Th1 pathway which is essential for cellular immunity and killing of intracellular pathogens and malignant cells.", [["cellular", "ANATOMY", 191, 199], ["intracellular", "ANATOMY", 224, 237], ["malignant cells", "ANATOMY", 252, 267], ["IL-12", "GENE_OR_GENE_PRODUCT", 22, 27], ["IL-18", "GENE_OR_GENE_PRODUCT", 29, 34], ["IFN-g", "GENE_OR_GENE_PRODUCT", 36, 41], ["IL-1", "GENE_OR_GENE_PRODUCT", 56, 60], ["RR1", "GENE_OR_GENE_PRODUCT", 64, 67], ["Th1", "GENE_OR_GENE_PRODUCT", 156, 159], ["cellular", "CELL", 191, 199], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 224, 237], ["malignant cells", "CELL", 252, 267], ["cytokine", "PROTEIN", 4, 12], ["IFN", "PROTEIN", 36, 39], ["IL-1", "PROTEIN", 56, 60], ["RR1", "PROTEIN", 64, 67], ["cytokines", "PROTEIN", 122, 131], ["malignant cells", "CELL_TYPE", 252, 267], ["The cytokine profile", "TEST", 0, 20], ["IL", "TEST", 22, 24], ["IL", "TEST", 29, 31], ["IFN", "TREATMENT", 36, 39], ["IL", "TREATMENT", 56, 58], ["these cytokines", "TEST", 116, 131], ["the Th1 pathway", "TEST", 152, 167], ["cellular immunity", "PROBLEM", 191, 208], ["intracellular pathogens", "PROBLEM", 224, 247], ["malignant cells", "PROBLEM", 252, 267], ["malignant cells", "OBSERVATION", 252, 267]]], ["This observation is in conformity with IL-12 induced IFN-g-dependent T cell development to Th1 and CD8+ cytotoxic effector cells [45] [46] [47] .", [["T cell", "ANATOMY", 69, 75], ["CD8+ cytotoxic effector cells", "ANATOMY", 99, 128], ["IL-12", "GENE_OR_GENE_PRODUCT", 39, 44], ["IFN-g", "GENE_OR_GENE_PRODUCT", 53, 58], ["T cell", "CELL", 69, 75], ["Th1", "CELL", 91, 94], ["CD8", "GENE_OR_GENE_PRODUCT", 99, 102], ["IL", "PROTEIN", 39, 41], ["IFN", "PROTEIN", 53, 56], ["Th1 and CD8+ cytotoxic effector cells", "CELL_TYPE", 91, 128], ["This observation", "TEST", 0, 16], ["IL", "TEST", 39, 41], ["IFN", "TEST", 53, 56], ["dependent T cell development", "PROBLEM", 59, 87], ["Th1", "TEST", 91, 94], ["cytotoxic effector cells", "TEST", 104, 128]]], ["Concurrent signaling as well as synergistic action by IL-12 and IL-18 induces prolonged IFN-g production and the continuous strong expression of IL-18R mRNA in T cells [46] .", [["T cells", "ANATOMY", 160, 167], ["IL-12", "GENE_OR_GENE_PRODUCT", 54, 59], ["IL-18", "GENE_OR_GENE_PRODUCT", 64, 69], ["IFN-g", "GENE_OR_GENE_PRODUCT", 88, 93], ["IL-18R", "GENE_OR_GENE_PRODUCT", 145, 151], ["T cells", "CELL", 160, 167], ["IL", "PROTEIN", 54, 56], ["IL-18", "PROTEIN", 64, 69], ["IFN", "PROTEIN", 88, 91], ["IL-18R mRNA", "RNA", 145, 156], ["T cells", "CELL_TYPE", 160, 167], ["IL", "TEST", 54, 56], ["IL", "TEST", 64, 66], ["prolonged IFN", "PROBLEM", 78, 91]]], ["The early inflammatory events, such as T cell adhesion to inflammatory sites, were also reported for IL-12 and IL-18 [48] .", [["T cell", "ANATOMY", 39, 45], ["T cell", "CELL", 39, 45], ["IL-12", "GENE_OR_GENE_PRODUCT", 101, 106], ["IL-18", "GENE_OR_GENE_PRODUCT", 111, 116], ["IL", "PROTEIN", 101, 103], ["The early inflammatory events", "PROBLEM", 0, 29], ["T cell adhesion to inflammatory sites", "PROBLEM", 39, 76], ["IL", "TEST", 101, 103], ["IL", "TEST", 111, 113], ["early", "OBSERVATION_MODIFIER", 4, 9], ["inflammatory", "OBSERVATION_MODIFIER", 10, 22], ["cell adhesion", "OBSERVATION", 41, 54], ["inflammatory", "OBSERVATION_MODIFIER", 58, 70]]], ["The higher level of the synthesis of the regulatory isoform IL-12 p40 may be a natural mechanism to contain the excessive production of Th1 response.", [["IL-12 p40", "GENE_OR_GENE_PRODUCT", 60, 69], ["Th1", "GENE_OR_GENE_PRODUCT", 136, 139], ["regulatory isoform IL-12 p40", "PROTEIN", 41, 69], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["excessive", "OBSERVATION_MODIFIER", 112, 121], ["Th1 response", "OBSERVATION", 136, 148]]], ["Synthesis of cytokines and chemokine in RR1-induced normal lymphocytes.", [["lymphocytes", "ANATOMY", 59, 70], ["RR1", "GENE_OR_GENE_PRODUCT", 40, 43], ["lymphocytes", "CELL", 59, 70], ["cytokines", "PROTEIN", 13, 22], ["chemokine", "PROTEIN", 27, 36], ["RR1-induced normal lymphocytes", "CELL_LINE", 40, 70], ["Synthesis of cytokines", "TEST", 0, 22], ["chemokine in RR1", "TEST", 27, 43], ["normal lymphocytes", "OBSERVATION", 52, 70]]], ["Normal lymphocytes from healthy volunteers were treated with RR1 (0-100 Ag) at 37 8C for 24 in a CO 2 incubator in RPMI medium.", [["lymphocytes", "ANATOMY", 7, 18], ["RR1", "CHEMICAL", 61, 64], ["RR1", "CHEMICAL", 61, 64], ["Ag", "CHEMICAL", 72, 74], ["CO 2", "CHEMICAL", 97, 101], ["lymphocytes", "CELL", 7, 18], ["volunteers", "ORGANISM", 32, 42], ["Normal lymphocytes", "CELL_TYPE", 0, 18], ["RR1", "TEST", 61, 64], ["a CO 2 incubator in RPMI medium", "TREATMENT", 95, 126], ["lymphocytes", "OBSERVATION", 7, 18]]], ["The supernatant medium was analyzed for the production of cytokines and chemokine in an ELISA procedure using reagent kits BD Biosciences.", [["supernatant", "ANATOMY", 4, 15], ["cytokines", "PROTEIN", 58, 67], ["chemokine", "PROTEIN", 72, 81], ["The supernatant medium", "TREATMENT", 0, 22], ["cytokines", "TREATMENT", 58, 67], ["chemokine", "TREATMENT", 72, 81], ["an ELISA procedure", "TREATMENT", 85, 103]]], ["RR1 induced the synthesis of IL-1h, IL-6, IL-12 p40, IL-12 p70, and IL-18, TNF-a, IFN-g, and MCP-1 significantly (***pb0.001).DiscussionThe iNOS enzyme controls the production of NO in macrophages.", [["macrophages", "ANATOMY", 185, 196], ["RR1", "CHEMICAL", 0, 3], ["NO", "CHEMICAL", 179, 181], ["NO", "CHEMICAL", 179, 181], ["RR1", "SIMPLE_CHEMICAL", 0, 3], ["IL-1h", "GENE_OR_GENE_PRODUCT", 29, 34], ["IL-6", "GENE_OR_GENE_PRODUCT", 36, 40], ["IL-12 p40", "GENE_OR_GENE_PRODUCT", 42, 51], ["IL-12 p70", "GENE_OR_GENE_PRODUCT", 53, 62], ["IL-18", "GENE_OR_GENE_PRODUCT", 68, 73], ["TNF-a", "GENE_OR_GENE_PRODUCT", 75, 80], ["IFN-g", "GENE_OR_GENE_PRODUCT", 82, 87], ["MCP-1", "GENE_OR_GENE_PRODUCT", 93, 98], ["iNOS", "GENE_OR_GENE_PRODUCT", 140, 144], ["NO", "SIMPLE_CHEMICAL", 179, 181], ["macrophages", "CELL", 185, 196], ["RR1", "PROTEIN", 0, 3], ["IL", "PROTEIN", 29, 31], ["TNF", "PROTEIN", 75, 78], ["IFN", "PROTEIN", 82, 85], ["MCP", "PROTEIN", 93, 96], ["iNOS enzyme", "PROTEIN", 140, 151], ["macrophages", "CELL_TYPE", 185, 196], ["the synthesis", "TEST", 12, 25], ["IL", "TEST", 29, 31], ["IL", "TEST", 36, 38], ["IL", "TEST", 42, 44], ["IL", "TEST", 53, 55], ["IL", "TEST", 68, 70], ["TNF", "TEST", 75, 78], ["IFN", "TEST", 82, 85], ["MCP", "TEST", 93, 96], ["The iNOS enzyme", "TEST", 136, 151], ["macrophages", "OBSERVATION", 185, 196]]], ["The insignificant level of iNOS induction by RR1 in the present investigation supports the insignificant increase in the production of NO.", [["RR1", "CHEMICAL", 45, 48], ["NO", "CHEMICAL", 135, 137], ["NO", "CHEMICAL", 135, 137], ["iNOS", "GENE_OR_GENE_PRODUCT", 27, 31], ["RR1", "SIMPLE_CHEMICAL", 45, 48], ["NO", "SIMPLE_CHEMICAL", 135, 137], ["iNOS", "PROTEIN", 27, 31], ["RR1", "PROTEIN", 45, 48], ["iNOS induction", "TREATMENT", 27, 41], ["insignificant", "OBSERVATION_MODIFIER", 4, 17], ["iNOS", "OBSERVATION", 27, 31], ["insignificant", "OBSERVATION_MODIFIER", 91, 104], ["increase", "OBSERVATION_MODIFIER", 105, 113]]], ["Our studies with monocytes isolated from peripheral blood mononuclear cells by Monocyte Isolation kit II (Miltenyi Biotec, Germany) or with human monocyte cell line THP-1 (ATCC) also did not induce any high level of NO with RR1 treatment (data not shown).", [["monocytes", "ANATOMY", 17, 26], ["peripheral blood mononuclear cells", "ANATOMY", 41, 75], ["monocyte cell line THP-1", "ANATOMY", 146, 170], ["ATCC", "ANATOMY", 172, 176], ["NO", "CHEMICAL", 216, 218], ["RR1", "CHEMICAL", 224, 227], ["NO", "CHEMICAL", 216, 218], ["RR1", "CHEMICAL", 224, 227], ["monocytes", "CELL", 17, 26], ["peripheral blood mononuclear cells", "CELL", 41, 75], ["Monocyte", "CELL", 79, 87], ["human", "ORGANISM", 140, 145], ["monocyte cell line THP-1", "CELL", 146, 170], ["ATCC", "CELL", 172, 176], ["NO", "SIMPLE_CHEMICAL", 216, 218], ["RR1", "SIMPLE_CHEMICAL", 224, 227], ["monocytes", "CELL_TYPE", 17, 26], ["peripheral blood mononuclear cells", "CELL_TYPE", 41, 75], ["Monocyte Isolation kit II", "PROTEIN", 79, 104], ["Miltenyi Biotec", "PROTEIN", 106, 121], ["human monocyte cell line THP-1", "CELL_LINE", 140, 170], ["ATCC", "CELL_LINE", 172, 176], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["Our studies", "TEST", 0, 11], ["monocytes", "TEST", 17, 26], ["peripheral blood mononuclear cells", "TEST", 41, 75], ["Monocyte Isolation", "TEST", 79, 97], ["human monocyte cell line THP", "TREATMENT", 140, 168], ["RR1 treatment", "TREATMENT", 224, 237], ["peripheral", "ANATOMY_MODIFIER", 41, 51], ["blood", "ANATOMY", 52, 57], ["mononuclear cells", "OBSERVATION", 58, 75]]], ["NO is reported to play an important role in the modulation of T helper cell differentiation and polarization.", [["T helper cell", "ANATOMY", 62, 75], ["NO", "CHEMICAL", 0, 2], ["NO", "CHEMICAL", 0, 2], ["NO", "GENE_OR_GENE_PRODUCT", 0, 2], ["T helper cell", "CELL", 62, 75]]], ["Yamasaki et al. [49] and Taylor-Robinson et al. [50] reported an inhibitory role of NO on Th1 cytokines while Bauer et al. [51] reported the same for Th1 as well as Th2 cytokines by NO from activated T cells.", [["T cells", "ANATOMY", 200, 207], ["NO", "CHEMICAL", 84, 86], ["NO", "CHEMICAL", 182, 184], ["NO", "CHEMICAL", 84, 86], ["NO", "CHEMICAL", 182, 184], ["NO", "SIMPLE_CHEMICAL", 84, 86], ["Th1", "GENE_OR_GENE_PRODUCT", 150, 153], ["NO", "SIMPLE_CHEMICAL", 182, 184], ["T cells", "CELL", 200, 207], ["Th1 cytokines", "PROTEIN", 90, 103], ["Th2 cytokines", "PROTEIN", 165, 178], ["activated T cells", "CELL_TYPE", 190, 207], ["Th2 cytokines", "TEST", 165, 178], ["activated T cells", "PROBLEM", 190, 207]]], ["The low level of NO synthesis by RR1 does not appear to exert any inhibition of Th1 pathway.", [["NO", "CHEMICAL", 17, 19], ["RR1", "CHEMICAL", 33, 36], ["NO", "CHEMICAL", 17, 19], ["NO", "SIMPLE_CHEMICAL", 17, 19], ["RR1", "SIMPLE_CHEMICAL", 33, 36], ["Th1", "GENE_OR_GENE_PRODUCT", 80, 83], ["RR1", "PROTEIN", 33, 36], ["low level", "OBSERVATION_MODIFIER", 4, 13]]], ["IFN-a, IFN-g and TNF-a are known upregulators of NO synthesis [52, 53] .", [["NO", "CHEMICAL", 49, 51], ["NO", "CHEMICAL", 49, 51], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["IFN-g", "GENE_OR_GENE_PRODUCT", 7, 12], ["TNF", "GENE_OR_GENE_PRODUCT", 17, 20], ["NO", "SIMPLE_CHEMICAL", 49, 51], ["IFN", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 7, 10], ["TNF", "PROTEIN", 17, 20], ["IFN", "TEST", 0, 3], ["IFN", "TEST", 7, 10], ["TNF", "TEST", 17, 20]]], ["As RR1 stimulation resulted in the synthesis of IFN-g and TNF-a and very little IFN-a, it is reasonable to assume that IFN-a priming may be a necessary step for triggering the production of higher levels of NO by polysaccharides [54] .DiscussionRR1 stimulation does not produce any oxidative stress in lymphocytes, indicated by the levels of the GSH, GSSG and their ratio, corresponding to the NO synthesis data.", [["lymphocytes", "ANATOMY", 302, 313], ["IFN", "CHEMICAL", 119, 122], ["NO", "CHEMICAL", 207, 209], ["GSH", "CHEMICAL", 346, 349], ["GSSG", "CHEMICAL", 351, 355], ["NO", "CHEMICAL", 394, 396], ["NO", "CHEMICAL", 207, 209], ["GSH", "CHEMICAL", 346, 349], ["GSSG", "CHEMICAL", 351, 355], ["NO", "CHEMICAL", 394, 396], ["RR1", "GENE_OR_GENE_PRODUCT", 3, 6], ["IFN-g", "GENE_OR_GENE_PRODUCT", 48, 53], ["TNF", "GENE_OR_GENE_PRODUCT", 58, 61], ["IFN", "GENE_OR_GENE_PRODUCT", 80, 83], ["IFN", "GENE_OR_GENE_PRODUCT", 119, 122], ["NO", "SIMPLE_CHEMICAL", 207, 209], ["lymphocytes", "CELL", 302, 313], ["GSH", "SIMPLE_CHEMICAL", 346, 349], ["GSSG", "SIMPLE_CHEMICAL", 351, 355], ["NO", "SIMPLE_CHEMICAL", 394, 396], ["RR1", "PROTEIN", 3, 6], ["IFN", "PROTEIN", 48, 51], ["TNF", "PROTEIN", 58, 61], ["IFN", "PROTEIN", 80, 83], ["IFN", "PROTEIN", 119, 122], ["lymphocytes", "CELL_TYPE", 302, 313], ["RR1 stimulation", "TREATMENT", 3, 18], ["the synthesis", "TEST", 31, 44], ["IFN", "TEST", 48, 51], ["TNF", "TEST", 58, 61], ["IFN", "PROBLEM", 119, 122], ["any oxidative stress in lymphocytes", "PROBLEM", 278, 313], ["the GSH", "TEST", 342, 349], ["GSSG", "TEST", 351, 355], ["their ratio", "TEST", 360, 371], ["synthesis data", "TEST", 397, 411]]], ["In addition, we could not observe any significant elevation in the amount of hydrogen peroxide in our investigations (data not shown).", [["hydrogen peroxide", "CHEMICAL", 77, 94], ["hydrogen peroxide", "CHEMICAL", 77, 94], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 77, 94], ["any significant elevation", "PROBLEM", 34, 59], ["hydrogen peroxide", "TREATMENT", 77, 94], ["our investigations", "TEST", 98, 116], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["elevation", "OBSERVATION", 50, 59]]], ["In this context, the low level of NO synthesis by RR1 suggests an immune mediatory role for NO.", [["NO", "CHEMICAL", 34, 36], ["RR1", "CHEMICAL", 50, 53], ["NO", "CHEMICAL", 92, 94], ["NO", "CHEMICAL", 34, 36], ["NO", "CHEMICAL", 92, 94], ["NO", "SIMPLE_CHEMICAL", 34, 36], ["RR1", "GENE_OR_GENE_PRODUCT", 50, 53], ["NO", "SIMPLE_CHEMICAL", 92, 94], ["RR1", "PROTEIN", 50, 53]]], ["The noncytotoxic nature of RR1, even at fairly high concentrations (1000 Ag/ml), may be attributed to the low level production of NO together with the ability of this polysaccharide not to induce oxidative stress in the cells.DiscussionIn the present investigation, RR1 has activated the alternate pathway (C3a) of complement activation and there was very little effect on classical pathway (C4a).", [["cells", "ANATOMY", 220, 225], ["RR1", "CHEMICAL", 27, 30], ["NO", "CHEMICAL", 130, 132], ["RR1", "CHEMICAL", 266, 269], ["Ag", "CHEMICAL", 73, 75], ["NO", "CHEMICAL", 130, 132], ["RR1", "SIMPLE_CHEMICAL", 27, 30], ["NO", "SIMPLE_CHEMICAL", 130, 132], ["cells", "CELL", 220, 225], ["RR1", "GENE_OR_GENE_PRODUCT", 266, 269], ["C3a", "GENE_OR_GENE_PRODUCT", 307, 310], ["RR1", "PROTEIN", 266, 269], ["C3a", "PROTEIN", 307, 310], ["RR1", "TEST", 27, 30], ["this polysaccharide", "TREATMENT", 162, 181], ["oxidative stress in the cells", "PROBLEM", 196, 225], ["noncytotoxic", "OBSERVATION_MODIFIER", 4, 16], ["cells", "ANATOMY", 220, 225]]], ["C3a and C4a are bioactive cleavage products released from plasma components C3 and C4 during complement activation cascade in alternative and classical pathways [55] which are quickly converted to less active C3a des Arg and C4a des Arg forms and are involved in the mediation of cellular immune responses .", [["plasma", "ANATOMY", 58, 64], ["cellular", "ANATOMY", 280, 288], ["Arg", "CHEMICAL", 217, 220], ["Arg", "CHEMICAL", 233, 236], ["C3a", "GENE_OR_GENE_PRODUCT", 0, 3], ["C4a", "GENE_OR_GENE_PRODUCT", 8, 11], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["C3", "GENE_OR_GENE_PRODUCT", 76, 78], ["C4", "GENE_OR_GENE_PRODUCT", 83, 85], ["C3a des Arg", "SIMPLE_CHEMICAL", 209, 220], ["C4a des Arg forms", "GENE_OR_GENE_PRODUCT", 225, 242], ["cellular", "CELL", 280, 288], ["C3a", "PROTEIN", 0, 3], ["C4a", "PROTEIN", 8, 11], ["C3", "PROTEIN", 76, 78], ["C4", "PROTEIN", 83, 85], ["C3a", "PROTEIN", 209, 212], ["C4a", "PROTEIN", 225, 228], ["C3a and C4a", "TREATMENT", 0, 11], ["bioactive cleavage products", "TREATMENT", 16, 43], ["complement activation cascade", "TREATMENT", 93, 122], ["C4a", "ANATOMY", 8, 11]]], ["The alternative pathway is self-amplifying and is impor-tant in the clearance and recognition of pathogens in the absence of antibodies [56] . h-Glucans are reported to activate the alternative pathway and the host mediated antitumor activity exhibited by these polymers were correlated with the activation of the complement system [57] .", [["antitumor", "ANATOMY", 224, 233], ["h-Glucans", "CHEMICAL", 143, 152], ["h-Glucans", "SIMPLE_CHEMICAL", 143, 152], ["antitumor", "CANCER", 224, 233], ["antibodies", "PROTEIN", 125, 135], ["pathogens", "PROBLEM", 97, 106], ["h-Glucans", "TEST", 143, 152]]], ["Lipopolysaccharides activate the complement system via alternative as well as classical pathways; the lipid part activates the classical pathway while the polysaccharide moiety activates the alternative pathway [58] .DiscussionImmune stimulation by induction of cytokines and synthesis of NO, activation of macrophages, induction of phagocytic, cytotoxic and antitumor activities have been reported recently in polysaccharide or polysaccharide containing fractions of Phanax ginseng, Morinda citrifolia, and Echinacea [52, 53, 59] .", [["macrophages", "ANATOMY", 307, 318], ["antitumor", "ANATOMY", 359, 368], ["NO", "CHEMICAL", 289, 291], ["Lipopolysaccharides", "CHEMICAL", 0, 19], ["NO", "CHEMICAL", 289, 291], ["Lipopolysaccharides", "SIMPLE_CHEMICAL", 0, 19], ["NO", "SIMPLE_CHEMICAL", 289, 291], ["macrophages", "CELL", 307, 318], ["antitumor", "CANCER", 359, 368], ["polysaccharide", "SIMPLE_CHEMICAL", 411, 425], ["polysaccharide", "SIMPLE_CHEMICAL", 429, 443], ["Phanax ginseng", "ORGANISM", 468, 482], ["Morinda citrifolia", "ORGANISM", 484, 502], ["Echinacea", "ORGANISM", 508, 517], ["cytokines", "PROTEIN", 262, 271], ["macrophages", "CELL_TYPE", 307, 318], ["Phanax ginseng", "SPECIES", 468, 482], ["Morinda citrifolia", "SPECIES", 484, 502], ["Echinacea", "SPECIES", 508, 517], ["Phanax ginseng", "SPECIES", 468, 482], ["Morinda citrifolia", "SPECIES", 484, 502], ["Lipopolysaccharides", "TREATMENT", 0, 19], ["the polysaccharide moiety", "TREATMENT", 151, 176], ["DiscussionImmune stimulation", "TREATMENT", 217, 245], ["cytokines", "TREATMENT", 262, 271], ["synthesis", "TREATMENT", 276, 285], ["macrophages", "PROBLEM", 307, 318], ["phagocytic", "TREATMENT", 333, 343], ["antitumor activities", "PROBLEM", 359, 379], ["polysaccharide", "TREATMENT", 411, 425], ["polysaccharide", "TREATMENT", 429, 443], ["macrophages", "OBSERVATION", 307, 318], ["Morinda citrifolia", "OBSERVATION", 484, 502]]], ["RR1 is a branched a-d-glucan structurally distinct from amylopectin and pullalan as no immune stimulation is reported by either amylopectin or pullalan.", [["amylopectin", "CHEMICAL", 56, 67], ["pullalan", "CHEMICAL", 72, 80], ["pullalan", "CHEMICAL", 143, 151], ["RR1", "SIMPLE_CHEMICAL", 0, 3], ["a-d-glucan", "SIMPLE_CHEMICAL", 18, 28], ["amylopectin", "SIMPLE_CHEMICAL", 56, 67], ["pullalan", "SIMPLE_CHEMICAL", 72, 80], ["amylopectin", "SIMPLE_CHEMICAL", 128, 139], ["pullalan", "SIMPLE_CHEMICAL", 143, 151], ["RR1", "PROTEIN", 0, 3], ["amylopectin", "TREATMENT", 56, 67], ["pullalan", "TREATMENT", 72, 80], ["immune stimulation", "PROBLEM", 87, 105], ["pullalan", "TREATMENT", 143, 151], ["distinct", "OBSERVATION_MODIFIER", 42, 50], ["no", "UNCERTAINTY", 84, 86], ["immune stimulation", "OBSERVATION", 87, 105]]], ["The similarity of its structure to the conserved molecular pattern of the cell wall components of fungal hglucans may be the reason for the activation of immune system.", [["cell wall", "ANATOMY", 74, 83], ["immune system", "ANATOMY", 154, 167], ["cell wall", "CELLULAR_COMPONENT", 74, 83], ["fungal hglucans", "GENE_OR_GENE_PRODUCT", 98, 113], ["fungal hglucans", "PROBLEM", 98, 113], ["the activation of immune system", "PROBLEM", 136, 167], ["molecular", "OBSERVATION_MODIFIER", 49, 58], ["pattern", "OBSERVATION_MODIFIER", 59, 66], ["cell", "OBSERVATION", 74, 78], ["wall", "ANATOMY_MODIFIER", 79, 83], ["fungal hglucans", "OBSERVATION", 98, 113]]], ["On the other hand, the differences, the a conformation and the (1Y4) linkages, may account for the non-induction of iNOS [49] and the consequent noncytotoxicity and the absence of oxidative stress.", [["iNOS [49]", "GENE_OR_GENE_PRODUCT", 116, 125], ["iNOS", "PROTEIN", 116, 120], ["the consequent noncytotoxicity", "PROBLEM", 130, 160], ["oxidative stress", "PROBLEM", 180, 196], ["may account for", "UNCERTAINTY", 79, 94]]], ["This water soluble neutral a-glucan has molecular mass and branching sequence well within the range of the polysaccharides exhibiting significant immune stimulating properties [11, 12, 19, 21] .", [["a-glucan", "CHEMICAL", 27, 35], ["a-glucan", "SIMPLE_CHEMICAL", 27, 35], ["polysaccharides", "SIMPLE_CHEMICAL", 107, 122], ["This water soluble neutral a-glucan", "TREATMENT", 0, 35], ["molecular mass", "PROBLEM", 40, 54], ["branching sequence", "PROBLEM", 59, 77], ["mass", "OBSERVATION", 50, 54], ["branching", "OBSERVATION_MODIFIER", 59, 68], ["significant", "OBSERVATION_MODIFIER", 134, 145], ["immune stimulating", "OBSERVATION", 146, 164]]], ["The water solubility can overcome the granuloma formations exhibited by particulate h-glucans while the high molecular mass, being in the most potent range, may enable it to be retained by the host's organs for longer period without degradation [60, 61] .", [["granuloma", "ANATOMY", 38, 47], ["organs", "ANATOMY", 200, 206], ["granuloma", "DISEASE", 38, 47], ["water", "SIMPLE_CHEMICAL", 4, 9], ["granuloma", "PATHOLOGICAL_FORMATION", 38, 47], ["h-glucans", "SIMPLE_CHEMICAL", 84, 93], ["organs", "ORGAN", 200, 206], ["The water solubility", "TREATMENT", 0, 20], ["the granuloma formations", "PROBLEM", 34, 58], ["the high molecular mass", "PROBLEM", 100, 123], ["water solubility", "OBSERVATION_MODIFIER", 4, 20], ["granuloma", "OBSERVATION", 38, 47], ["high", "OBSERVATION_MODIFIER", 104, 108], ["molecular", "OBSERVATION_MODIFIER", 109, 118], ["mass", "OBSERVATION", 119, 123], ["most potent", "OBSERVATION_MODIFIER", 138, 149]]], ["While the noncytotoxic nature, the significant activation of the lymphocytes, especially the NK cells and the alternate pathway of complement activation demonstrate the stimulation of the innate immune system, the cytokine profile resulting from the activation proclaims the stimulation of the antigen specific cell mediated (adaptive) immunity (Th1 pathway) with a selfregulating mechanism of its overrun.", [["lymphocytes", "ANATOMY", 65, 76], ["NK cells", "ANATOMY", 93, 101], ["cell", "ANATOMY", 311, 315], ["lymphocytes", "CELL", 65, 76], ["NK cells", "CELL", 93, 101], ["cell", "CELL", 311, 315], ["lymphocytes", "CELL_TYPE", 65, 76], ["NK cells", "CELL_TYPE", 93, 101], ["cytokine", "PROTEIN", 214, 222], ["the lymphocytes", "PROBLEM", 61, 76], ["the NK cells", "PROBLEM", 89, 101], ["the cytokine profile", "TEST", 210, 230], ["immunity (Th1 pathway", "TREATMENT", 336, 357], ["a selfregulating mechanism", "TREATMENT", 364, 390], ["noncytotoxic", "OBSERVATION_MODIFIER", 10, 22], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["activation", "OBSERVATION", 47, 57], ["lymphocytes", "ANATOMY", 65, 76], ["NK cells", "OBSERVATION", 93, 101]]], ["The absence of IL-4 synthesis (Th1 suppressor cytokine) and IL-10 (the inhibitor of IL-12) on stimulation with RR1 is in good agreement with the Th1 pathway of T cell differentiation.", [["T cell", "ANATOMY", 160, 166], ["IL-4", "GENE_OR_GENE_PRODUCT", 15, 19], ["Th1", "GENE_OR_GENE_PRODUCT", 31, 34], ["IL-10", "GENE_OR_GENE_PRODUCT", 60, 65], ["IL-12", "GENE_OR_GENE_PRODUCT", 84, 89], ["RR1", "GENE_OR_GENE_PRODUCT", 111, 114], ["T cell", "CELL", 160, 166], ["IL-4", "PROTEIN", 15, 19], ["Th1 suppressor cytokine", "PROTEIN", 31, 54], ["IL-10", "PROTEIN", 60, 65], ["IL-12", "PROTEIN", 84, 89], ["RR1", "PROTEIN", 111, 114], ["IL-4 synthesis (Th1 suppressor cytokine)", "TREATMENT", 15, 55], ["IL", "TREATMENT", 60, 62], ["the inhibitor of IL", "TREATMENT", 67, 86]]], ["The IFN-g production by the concurrent signaling of IL-12 and IL-18 may serve as a potent anti anthrax agent, devoid of side effects, if any, of the exogenous IFN treatment as well.", [["IFN", "CHEMICAL", 159, 162], ["IFN-g", "GENE_OR_GENE_PRODUCT", 4, 9], ["IL-12", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL-18", "GENE_OR_GENE_PRODUCT", 62, 67], ["IFN", "GENE_OR_GENE_PRODUCT", 159, 162], ["IFN", "PROTEIN", 4, 7], ["IL-12", "PROTEIN", 52, 57], ["IL-18", "PROTEIN", 62, 67], ["IFN", "PROTEIN", 159, 162], ["The IFN-g production", "TREATMENT", 0, 20], ["IL", "TEST", 52, 54], ["IL", "TREATMENT", 62, 64], ["a potent anti anthrax agent", "TREATMENT", 81, 108], ["side effects", "PROBLEM", 120, 132], ["the exogenous IFN treatment", "TREATMENT", 145, 172]]], ["A stimulated innate immune system can fight the entry of any pathogens into the host and has the capacity to prevent primary infections from actually causing disease [62] .", [["immune system", "ANATOMY", 20, 33], ["primary infections", "DISEASE", 117, 135], ["A stimulated innate immune system", "TREATMENT", 0, 33], ["the capacity", "PROBLEM", 93, 105], ["primary infections", "PROBLEM", 117, 135], ["disease", "PROBLEM", 158, 165], ["infections", "OBSERVATION", 125, 135]]], ["The unique immune stimulating properties of RR1 without exerting oxidative stress and any direct cytotoxic effect, thus far described, may make it a potent biodefense agent against a number of pathogens and human malignancies.", [["malignancies", "ANATOMY", 213, 225], ["RR1", "CHEMICAL", 44, 47], ["malignancies", "DISEASE", 213, 225], ["RR1", "SIMPLE_CHEMICAL", 44, 47], ["human", "ORGANISM", 207, 212], ["malignancies", "CANCER", 213, 225], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 207, 212], ["exerting oxidative stress", "PROBLEM", 56, 81], ["any direct cytotoxic effect", "PROBLEM", 86, 113], ["pathogens", "PROBLEM", 193, 202], ["human malignancies", "PROBLEM", 207, 225], ["malignancies", "OBSERVATION", 213, 225]]]], "e2fe1575e8b7592b1017d6714e46b0d595ff7a9c": [["We read with great interest the study by Hao et al. on liver enzyme elevation in coronavirus disease 2019 (COVID-19) (1) .", [["liver", "ANATOMY", 55, 60], ["coronavirus disease", "DISEASE", 81, 100], ["liver", "ORGAN", 55, 60], ["the study", "TEST", 28, 37], ["liver enzyme elevation", "PROBLEM", 55, 77], ["coronavirus disease", "PROBLEM", 81, 100], ["COVID", "TEST", 107, 112], ["liver", "ANATOMY", 55, 60], ["elevation", "OBSERVATION", 68, 77], ["coronavirus disease", "OBSERVATION", 81, 100]]], ["The authors have collated data from a large number of COVID-19 patients from multiple centers across China.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["large", "OBSERVATION_MODIFIER", 38, 43]]], ["The authors have shown that around 28% of patients with COVID-19 have deranged liver function tests (LFTs) at admission, and furthermore, 32% of patients developed elevated liver chemistries during illness.", [["liver", "ANATOMY", 79, 84], ["liver", "ANATOMY", 173, 178], ["deranged liver function", "DISEASE", 70, 93], ["elevated liver chemistries", "DISEASE", 164, 190], ["patients", "ORGANISM", 42, 50], ["liver", "ORGAN", 79, 84], ["patients", "ORGANISM", 145, 153], ["liver", "ORGAN", 173, 178], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 145, 153], ["COVID", "TEST", 56, 61], ["deranged liver function tests", "PROBLEM", 70, 99], ["LFTs", "TEST", 101, 105], ["elevated liver chemistries", "PROBLEM", 164, 190], ["illness", "PROBLEM", 198, 205], ["liver", "ANATOMY", 79, 84], ["elevated", "OBSERVATION", 164, 172], ["liver", "ANATOMY", 173, 178]]], ["Male patients, overweight individuals, and smokers are at higher risk of developing enzyme elevation.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["developing enzyme elevation", "PROBLEM", 73, 100], ["enzyme elevation", "OBSERVATION", 84, 100]]], ["Another interesting observation made in this study was that deranged LFT has no impact on the outcome of COVID-19 patients.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["this study", "TEST", 40, 50], ["deranged LFT", "PROBLEM", 60, 72], ["COVID", "TEST", 105, 110]]]], "PMC7267416": [["Competing interestsNo relevant disclosures.", [["relevant", "OBSERVATION_MODIFIER", 22, 30], ["disclosures", "OBSERVATION", 31, 42]]]], "a52f29e2fed01c567bfb7ce69fc1d9f489d5b8ae": [["Hospital outbreaks of epidemiologically important pathogens such as respiratory viruses (eg, influenza virus, respiratory syncytial virus), gastrointestinal viruses (eg, norovirus, rotavirus), and multiple-drug-resistant organisms (MDROs) (eg, methicillinresistant Staphylococcus aureus [MRSA], vancomycin-resistant enterococci", [["respiratory viruses", "DISEASE", 68, 87], ["influenza virus", "DISEASE", 93, 108], ["respiratory syncytial virus", "DISEASE", 110, 137], ["gastrointestinal viruses", "DISEASE", 140, 164], ["norovirus", "DISEASE", 170, 179], ["rotavirus", "DISEASE", 181, 190], ["MDROs", "DISEASE", 232, 237], ["Staphylococcus aureus", "DISEASE", 265, 286], ["MRSA", "CHEMICAL", 288, 292], ["vancomycin", "CHEMICAL", 295, 305], ["enterococci", "DISEASE", 316, 327], ["vancomycin", "CHEMICAL", 295, 305], ["influenza virus", "ORGANISM", 93, 108], ["respiratory syncytial virus", "ORGANISM", 110, 137], ["gastrointestinal viruses", "ORGANISM", 140, 164], ["methicillinresistant Staphylococcus aureus", "ORGANISM", 244, 286], ["vancomycin", "SIMPLE_CHEMICAL", 295, 305], ["influenza virus", "SPECIES", 93, 108], ["respiratory syncytial virus", "SPECIES", 110, 137], ["Staphylococcus aureus", "SPECIES", 265, 286], ["MRSA", "SPECIES", 288, 292], ["respiratory syncytial virus", "SPECIES", 110, 137], ["rotavirus", "SPECIES", 181, 190], ["Staphylococcus aureus", "SPECIES", 265, 286], ["MRSA", "SPECIES", 288, 292], ["epidemiologically important pathogens", "PROBLEM", 22, 59], ["respiratory viruses (eg, influenza virus", "PROBLEM", 68, 108], ["respiratory syncytial virus", "PROBLEM", 110, 137], ["gastrointestinal viruses", "PROBLEM", 140, 164], ["norovirus", "PROBLEM", 170, 179], ["rotavirus", "PROBLEM", 181, 190], ["resistant organisms", "PROBLEM", 211, 230], ["MDROs", "TEST", 232, 237], ["methicillinresistant Staphylococcus aureus", "PROBLEM", 244, 286], ["MRSA", "PROBLEM", 288, 292], ["vancomycin", "TREATMENT", 295, 305], ["resistant enterococci", "PROBLEM", 306, 327], ["gastrointestinal", "ANATOMY", 140, 156], ["resistant enterococci", "OBSERVATION", 306, 327]]]], "PMC7329659": [["CLABSI \u2013 Increases expectedThe highest impact to HAI from COVID-19 is expected to be CLABSI rates, and two of our facilities have seen rates increases (comparing several months of COVID to rates the prior 15 months, Hospital A saw a 420% increase to rate = 5.38 cases per 1000 central line days, while Hospital B saw a 327% increase to rate = 3.79 cases per 1000 central line days).", [["COVID", "TEST", 58, 63], ["CLABSI rates", "TEST", 85, 97], ["rate", "TEST", 250, 254], ["rate", "TEST", 336, 340], ["highest", "OBSERVATION_MODIFIER", 31, 38]]], ["Several factors are expected to increase the number of CLABSI cases, while decreasing low-risk central line denominators, resulting in overall increases in rates and standardized infection rates (SIRs).", [["CLABSI", "DISEASE", 55, 61], ["infection", "DISEASE", 179, 188], ["CLABSI cases", "TEST", 55, 67], ["overall increases in rates", "PROBLEM", 135, 161], ["standardized infection rates", "PROBLEM", 166, 194], ["central line", "OBSERVATION", 95, 107], ["overall", "OBSERVATION_MODIFIER", 135, 142], ["increases", "OBSERVATION_MODIFIER", 143, 152], ["infection", "OBSERVATION", 179, 188]]], ["As stay at home orders proliferated around the country, many hospitals saw major decreases in overall census.", [["major", "OBSERVATION_MODIFIER", 75, 80], ["decreases", "OBSERVATION_MODIFIER", 81, 90], ["overall census", "OBSERVATION", 94, 108]]], ["Patients not coming to receive care are those that are lower acuity, such as those seeking elective procedures, and likely have a lower risk of developing bacteremia.", [["bacteremia", "DISEASE", 155, 165], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["elective procedures", "TREATMENT", 91, 110], ["developing bacteremia", "PROBLEM", 144, 165], ["bacteremia", "OBSERVATION", 155, 165]]], ["This will result in a decrease of the central line denominator, and a shifting of the denominator toward high risk patients.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["a decrease of the central line denominator", "PROBLEM", 20, 62], ["decrease", "OBSERVATION_MODIFIER", 22, 30], ["central line", "OBSERVATION", 38, 50]]], ["Similar impact will likely be seen in the hospital-onset Methicillin resistant Staphylococcus aureus (MRSA) bacteremia rates.CLABSI \u2013 Increases expectedCOVID-19 patients are at higher risk of CLABSI for many reasons, including several related to the disease process and medical staff decision-making.", [["Methicillin", "CHEMICAL", 57, 68], ["Staphylococcus aureus", "DISEASE", 79, 100], ["MRSA", "DISEASE", 102, 106], ["bacteremia", "DISEASE", 108, 118], ["CLABSI", "DISEASE", 192, 198], ["Methicillin resistant Staphylococcus aureus", "ORGANISM", 57, 100], ["MRSA", "CANCER", 102, 106], ["patients", "ORGANISM", 161, 169], ["Staphylococcus aureus", "SPECIES", 79, 100], ["MRSA", "SPECIES", 102, 106], ["patients", "SPECIES", 161, 169], ["Staphylococcus aureus", "SPECIES", 79, 100], ["MRSA", "SPECIES", 102, 106], ["Methicillin resistant Staphylococcus aureus (MRSA) bacteremia rates", "PROBLEM", 57, 124], ["CLABSI", "TEST", 125, 131], ["expectedCOVID", "TEST", 144, 157], ["CLABSI", "PROBLEM", 192, 198], ["the disease process", "PROBLEM", 246, 265], ["will likely be seen", "UNCERTAINTY", 15, 34], ["Methicillin resistant", "OBSERVATION_MODIFIER", 57, 78], ["Staphylococcus aureus", "OBSERVATION", 79, 100], ["CLABSI", "OBSERVATION", 192, 198]]], ["The patients that require hospitalization have increased acuity and longer lengths of stay.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["increased acuity", "PROBLEM", 47, 63]]], ["There may be increased use of femoral lines for central access, as the insertion process is easier in patients presenting with overwhelming critical illness.", [["femoral lines", "ANATOMY", 30, 43], ["femoral lines", "CELL", 30, 43], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["femoral lines", "TREATMENT", 30, 43], ["central access", "TREATMENT", 48, 62], ["the insertion process", "TREATMENT", 67, 88], ["overwhelming critical illness", "PROBLEM", 127, 156], ["may be", "UNCERTAINTY", 6, 12], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["femoral lines", "OBSERVATION", 30, 43], ["illness", "OBSERVATION", 149, 156]]], ["Additionally, practitioners may believe it is safer than an insertion in the subclavian or internal jugular veins since the femoral site is away from the mouth and respiratory tract.", [["subclavian", "ANATOMY", 77, 87], ["internal jugular veins", "ANATOMY", 91, 113], ["femoral site", "ANATOMY", 124, 136], ["mouth", "ANATOMY", 154, 159], ["respiratory tract", "ANATOMY", 164, 181], ["subclavian", "MULTI-TISSUE_STRUCTURE", 77, 87], ["internal jugular veins", "MULTI-TISSUE_STRUCTURE", 91, 113], ["femoral site", "MULTI-TISSUE_STRUCTURE", 124, 136], ["mouth", "ORGANISM_SUBDIVISION", 154, 159], ["respiratory tract", "ORGANISM_SUBDIVISION", 164, 181], ["an insertion in the subclavian", "TREATMENT", 57, 87], ["subclavian", "ANATOMY", 77, 87], ["internal jugular veins", "ANATOMY", 91, 113], ["femoral", "ANATOMY", 124, 131], ["mouth", "ANATOMY", 154, 159], ["respiratory tract", "ANATOMY", 164, 181]]], ["COVID-19 also leads to an increased incidence of acute kidney injury,3 requiring high numbers of patients to have central access for dialysis.", [["kidney", "ANATOMY", 55, 61], ["COVID-19", "CHEMICAL", 0, 8], ["acute kidney injury", "DISEASE", 49, 68], ["COVID-19", "CHEMICAL", 0, 8], ["kidney", "ORGAN", 55, 61], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["COVID", "TEST", 0, 5], ["acute kidney injury", "PROBLEM", 49, 68], ["central access", "TREATMENT", 114, 128], ["dialysis", "TREATMENT", 133, 141], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["kidney", "ANATOMY", 55, 61], ["injury", "OBSERVATION", 62, 68]]], ["There will be decreased provider focus on removing central lines, and likely a reluctance to try to manage patients with lower risk venous access, such as midlines or peripheral catheters.CLABSI \u2013 Increases expectedFurthermore, several hallmarks of care of COVID-19 patients are important factors that increase risk of CLABSI.", [["central lines", "ANATOMY", 51, 64], ["venous", "ANATOMY", 132, 138], ["midlines", "ANATOMY", 155, 163], ["CLABSI", "DISEASE", 319, 325], ["central lines", "CELL", 51, 64], ["patients", "ORGANISM", 107, 115], ["venous", "MULTI-TISSUE_STRUCTURE", 132, 138], ["peripheral catheters", "MULTI-TISSUE_STRUCTURE", 167, 187], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 266, 274], ["central lines", "TREATMENT", 51, 64], ["lower risk venous access", "TREATMENT", 121, 145], ["peripheral catheters", "TREATMENT", 167, 187], ["COVID", "TREATMENT", 257, 262], ["CLABSI", "PROBLEM", 319, 325], ["decreased", "OBSERVATION_MODIFIER", 14, 23], ["central lines", "OBSERVATION", 51, 64], ["venous", "ANATOMY", 132, 138], ["access", "OBSERVATION", 139, 145], ["peripheral catheters", "OBSERVATION", 167, 187], ["CLABSI", "OBSERVATION", 319, 325]]], ["In order to minimize exposures of healthcare personnel to COVID-19, many facilities are limiting completion of imaging studies that may be deemed less critical.", [["imaging studies", "TEST", 111, 126]]], ["These missing imaging studies would have been important to support alternative HAI definitions (for example, lack of abdominal imaging to support an intraabdominal infection process).", [["abdominal", "ANATOMY", 117, 126], ["intraabdominal", "ANATOMY", 149, 163], ["intraabdominal infection", "DISEASE", 149, 173], ["abdominal", "ORGANISM_SUBDIVISION", 117, 126], ["intraabdominal", "ORGANISM_SUBDIVISION", 149, 163], ["These missing imaging studies", "TEST", 0, 29], ["abdominal imaging", "TEST", 117, 134], ["an intraabdominal infection process", "PROBLEM", 146, 181], ["abdominal", "ANATOMY", 117, 126], ["intraabdominal", "ANATOMY", 149, 163], ["infection", "OBSERVATION", 164, 173]]], ["There have been good results with increasing oxygenation to patients through prone positioning.4 However, the process to turn these patients can result in pulling, tugging and friction at central line insertion sites.", [["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 132, 140], ["increasing oxygenation", "TREATMENT", 34, 56], ["friction at central line insertion sites", "TREATMENT", 176, 216], ["good", "OBSERVATION_MODIFIER", 16, 20], ["friction", "OBSERVATION_MODIFIER", 176, 184], ["central line", "OBSERVATION", 188, 200]]], ["Also as patients lay prone for many hours, there will be decreased visualization of the insertion site and other fluid buildup to compromise dressing integrity.4", [["fluid", "ANATOMY", 113, 118], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["the insertion site", "TREATMENT", 84, 102], ["other fluid buildup", "PROBLEM", 107, 126], ["dressing integrity", "TREATMENT", 141, 159], ["fluid buildup", "OBSERVATION", 113, 126]]]], "af22a223e1a244000f6f2a78d9f1a9c04f824bf1": [["a1111111111 a1111111111 a1111111111 a1111111111 a1111111111IntroductionCoronavirus disease-2019 (COVID-19) is a disease that was detected in December 2019 in Wuhan, China, and led to the risk of mortality of about 2% [1] .", [["COVID", "TEST", 97, 102], ["a disease", "PROBLEM", 110, 119], ["disease", "OBSERVATION", 112, 119]]], ["This disease is caused due to infection with a recently arising zoonotic virus known as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [2] .", [["infection", "DISEASE", 30, 39], ["zoonotic virus", "DISEASE", 64, 78], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 99, 137], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 92, 151], ["This disease", "PROBLEM", 0, 12], ["infection", "PROBLEM", 30, 39], ["a recently arising zoonotic virus", "PROBLEM", 45, 78], ["the Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 88, 137], ["SARS-CoV", "TEST", 141, 149], ["disease", "OBSERVATION", 5, 12], ["caused due to", "UNCERTAINTY", 16, 29], ["infection", "OBSERVATION", 30, 39], ["Severe", "OBSERVATION_MODIFIER", 92, 98], ["Acute", "OBSERVATION_MODIFIER", 99, 104], ["Respiratory Syndrome", "OBSERVATION", 105, 125]]], ["Previously, infection with coronaviruses appeared in 2002 within China in the form of SARS-CoV, and it appeared later also in 2012 within Saudi Arabia that was known as Middle East Respiratory Syndrome (MERS-CoV) [3, 4] .", [["infection", "DISEASE", 12, 21], ["SARS-CoV", "DISEASE", 86, 94], ["Middle East Respiratory Syndrome", "DISEASE", 169, 201], ["SARS-CoV", "ORGANISM", 86, 94], ["SARS-CoV", "SPECIES", 86, 94], ["Middle East Respiratory Syndrome (MERS-CoV", "SPECIES", 169, 211], ["infection", "PROBLEM", 12, 21], ["coronaviruses", "PROBLEM", 27, 40], ["SARS", "PROBLEM", 86, 90], ["CoV", "PROBLEM", 91, 94], ["Middle East Respiratory Syndrome", "PROBLEM", 169, 201], ["infection", "OBSERVATION", 12, 21], ["coronaviruses", "OBSERVATION", 27, 40], ["SARS", "OBSERVATION", 86, 90], ["Middle", "ANATOMY_MODIFIER", 169, 175], ["Respiratory Syndrome", "OBSERVATION", 181, 201]]], ["All these coronaviruses are enveloped positive-strand RNA viruses that are isolated from bats that can be transferred from animals to humans, human to human, and animals to animals [5] .", [["coronaviruses", "ORGANISM", 10, 23], ["bats", "ORGANISM", 89, 93], ["humans", "ORGANISM", 134, 140], ["human", "ORGANISM", 142, 147], ["human", "ORGANISM", 151, 156], ["humans", "SPECIES", 134, 140], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 151, 156], ["humans", "SPECIES", 134, 140], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 151, 156], ["All these coronaviruses", "PROBLEM", 0, 23], ["strand RNA viruses", "PROBLEM", 47, 65], ["coronaviruses", "OBSERVATION", 10, 23], ["strand RNA viruses", "OBSERVATION", 47, 65]]], ["They share a similarity in the clinical symptoms in addition to specific differences that have been recently observed [5] [6] [7] .", [["[5] [6] [7]", "SIMPLE_CHEMICAL", 118, 129], ["the clinical symptoms", "PROBLEM", 27, 48]]], ["The symptoms of this disease appear with different degrees that start in the first seven days with mild symptoms such as fever, cough, shortness of breath, and fatigue [8] .", [["fever", "DISEASE", 121, 126], ["cough", "DISEASE", 128, 133], ["shortness of breath", "DISEASE", 135, 154], ["fatigue", "DISEASE", 160, 167], ["The symptoms", "PROBLEM", 0, 12], ["this disease", "PROBLEM", 16, 28], ["mild symptoms", "PROBLEM", 99, 112], ["fever", "PROBLEM", 121, 126], ["cough", "PROBLEM", 128, 133], ["shortness of breath", "PROBLEM", 135, 154], ["fatigue", "PROBLEM", 160, 167], ["different degrees", "OBSERVATION_MODIFIER", 41, 58], ["mild", "OBSERVATION_MODIFIER", 99, 103]]], ["Afterward, critical symptoms may develop in some patients involving dyspnea and pneumonia that require patient's management in intensive care units to avoid the serious respiratory complications that may lead to death [9] .", [["respiratory", "ANATOMY", 169, 180], ["dyspnea", "DISEASE", 68, 75], ["pneumonia", "DISEASE", 80, 89], ["death", "DISEASE", 212, 217], ["patients", "ORGANISM", 49, 57], ["patient", "ORGANISM", 103, 110], ["patients", "SPECIES", 49, 57], ["patient", "SPECIES", 103, 110], ["critical symptoms", "PROBLEM", 11, 28], ["dyspnea", "PROBLEM", 68, 75], ["pneumonia", "PROBLEM", 80, 89], ["patient's management", "TREATMENT", 103, 123], ["the serious respiratory complications", "PROBLEM", 157, 194], ["death", "PROBLEM", 212, 217], ["pneumonia", "OBSERVATION", 80, 89]]], ["However, there are no specific symptoms to diagnose coronavirus infection, and accurate testing depends on the detection of the viral genome using the reverse transcription-polymerase chain reaction (RT-PCR) analysis [10] .IntroductionUnfortunately, COVID-19 is not limited to its country of origin, but it has spread all over the world.", [["coronavirus infection", "DISEASE", 52, 73], ["coronavirus", "ORGANISM", 52, 63], ["viral genome", "DNA", 128, 140], ["specific symptoms", "PROBLEM", 22, 39], ["coronavirus infection", "PROBLEM", 52, 73], ["accurate testing", "TEST", 79, 95], ["the viral genome", "PROBLEM", 124, 140], ["the reverse transcription", "TREATMENT", 147, 172], ["polymerase chain reaction", "TEST", 173, 198], ["RT-PCR) analysis", "TEST", 200, 216], ["COVID", "TEST", 250, 255], ["no", "UNCERTAINTY", 19, 21], ["infection", "OBSERVATION", 64, 73], ["viral genome", "OBSERVATION", 128, 140]]], ["Therefore, there is no wonder emerging research has been directed to provide information and clinical data of patients infected with this virus that may help to not only to the early detection in different patient categories, but it will also help in the characterization of the viral complications with other chronic diseases [1, 2, 6, 9] .", [["patients", "ORGANISM", 110, 118], ["patient", "ORGANISM", 206, 213], ["patients", "SPECIES", 110, 118], ["patient", "SPECIES", 206, 213], ["clinical data", "TEST", 93, 106], ["this virus", "PROBLEM", 133, 143], ["the viral complications", "PROBLEM", 275, 298], ["other chronic diseases", "PROBLEM", 304, 326], ["no", "UNCERTAINTY", 20, 22], ["viral complications", "OBSERVATION", 279, 298], ["chronic", "OBSERVATION_MODIFIER", 310, 317], ["diseases", "OBSERVATION", 318, 326]]], ["However, there is no sufficient data that characterize the changes in the hematological and immunological parameters in COVID-19 patients.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["immunological parameters", "TEST", 92, 116], ["COVID", "TEST", 120, 125], ["no", "UNCERTAINTY", 18, 20]]], ["In the current comprehensive meta-analysis study, we aimed to analyze different hematological, inflammatory, and immunological markers in COVID-19 patients at different clinical stages in different countries that may help in the early detection of COVID-19 infection and to discriminate between severity status of the disease to decrease the death risk.Search strategyThis current meta-analysis was carried out according to the Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) statement [11] (S1 Table) .", [["infection", "DISEASE", 257, 266], ["death", "DISEASE", 342, 347], ["patients", "ORGANISM", 147, 155], ["COVID-19", "CELL", 248, 256], ["patients", "SPECIES", 147, 155], ["COVID-19", "SPECIES", 248, 256], ["the current comprehensive meta-analysis study", "TEST", 3, 48], ["different hematological, inflammatory", "PROBLEM", 70, 107], ["immunological markers", "TEST", 113, 134], ["COVID", "TEST", 138, 143], ["COVID-19 infection", "PROBLEM", 248, 266], ["the disease", "PROBLEM", 314, 325], ["the death risk", "PROBLEM", 338, 352], ["This current meta-analysis", "TEST", 368, 394], ["inflammatory", "OBSERVATION_MODIFIER", 95, 107], ["infection", "OBSERVATION", 257, 266]]], ["Our search strategy included the following terms: \"Novel coronavirus 2019\", \"2019 nCoV\", \"COVID-19\", \"Wuhan coronavirus,\" \"Wuhan pneumonia,\" or \"SARS-CoV-2\".", [["Wuhan coronavirus", "DISEASE", 102, 119], ["pneumonia", "DISEASE", 129, 138], ["SARS", "DISEASE", 145, 149], ["Wuhan coronavirus", "SPECIES", 102, 119], ["SARS-CoV", "SPECIES", 145, 153], ["pneumonia", "PROBLEM", 129, 138], ["pneumonia", "OBSERVATION", 129, 138]]], ["The above process was performed independently by three participants.Study selectionNo time or language restriction was applied.", [["participants", "SPECIES", 55, 67], ["Study selection", "TEST", 68, 83], ["language restriction", "TREATMENT", 94, 114]]], ["Inclusion criteria were as follows: (1) Types of Studies: retrospective, prospective, observational, descriptive or case control studies reporting laboratory features of COVID-19 patients; (2) Subjects: diagnosed patients with COVID-19 (3) Exposure intervention: COVID-19 patients diagnosed with Real Time-Polymerase Chain Reaction, radiological imaging, or both; with hematological testing included: complete blood picture (white blood cells, neutrophil count, lymphocyte count, monocyte count, eosinophils count, basophils, red blood cells, hemoglobin, hematocrit, and platelet count), coagulation profile (prothrombin time, international normalized ratio, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimer) or immunological parameters including inflammatory markers (ferritin, erythrocyte sedimentation rate, procalcitonin, and C-reactive protein), immunoglobulins (IgA, IgG, and IgM), complement tests (C3 and C4), interleukins (IL-4, IL-6, IL-8, IL-10, IL-2R, and TNF-\u03b1), and immune cells (B lymphocytes, T lymphocytes, CD4 + T cells, and CD8 + T cells); and (4) Outcome indicator: the mean and standard deviation or median and interquartile range for each laboratory test.", [["blood", "ANATOMY", 410, 415], ["white blood cells", "ANATOMY", 425, 442], ["neutrophil", "ANATOMY", 444, 454], ["lymphocyte", "ANATOMY", 462, 472], ["monocyte", "ANATOMY", 480, 488], ["eosinophils", "ANATOMY", 496, 507], ["basophils", "ANATOMY", 515, 524], ["red blood cells", "ANATOMY", 526, 541], ["platelet", "ANATOMY", 571, 579], ["erythrocyte", "ANATOMY", 808, 819], ["immune cells", "ANATOMY", 1009, 1021], ["B lymphocytes", "ANATOMY", 1023, 1036], ["T lymphocytes", "ANATOMY", 1038, 1051], ["CD4 + T cells", "ANATOMY", 1053, 1066], ["CD8 + T cells", "ANATOMY", 1072, 1085], ["patients", "ORGANISM", 179, 187], ["Subjects", "ORGANISM", 193, 201], ["patients", "ORGANISM", 213, 221], ["patients", "ORGANISM", 272, 280], ["blood", "ORGANISM_SUBSTANCE", 410, 415], ["white blood cells", "CELL", 425, 442], ["neutrophil", "CELL", 444, 454], ["lymphocyte", "CELL", 462, 472], ["monocyte", "CELL", 480, 488], ["eosinophils", "CELL", 496, 507], ["basophils", "CELL", 515, 524], ["red blood cells", "CELL", 526, 541], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 543, 553], ["platelet", "CELL", 571, 579], ["prothrombin", "GENE_OR_GENE_PRODUCT", 609, 620], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 677, 691], ["thrombin", "GENE_OR_GENE_PRODUCT", 698, 706], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 713, 723], ["D-dimer", "SIMPLE_CHEMICAL", 729, 736], ["ferritin", "GENE_OR_GENE_PRODUCT", 798, 806], ["erythrocyte", "CELL", 808, 819], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 840, 853], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 859, 877], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 880, 895], ["IgA", "GENE_OR_GENE_PRODUCT", 897, 900], ["IgG", "GENE_OR_GENE_PRODUCT", 902, 905], ["IgM", "GENE_OR_GENE_PRODUCT", 911, 914], ["interleukins", "GENE_OR_GENE_PRODUCT", 947, 959], ["IL-4", "GENE_OR_GENE_PRODUCT", 961, 965], ["IL-6", "GENE_OR_GENE_PRODUCT", 967, 971], ["IL-8", "GENE_OR_GENE_PRODUCT", 973, 977], ["IL-10", "GENE_OR_GENE_PRODUCT", 979, 984], ["IL-2R", "GENE_OR_GENE_PRODUCT", 986, 991], ["TNF", "GENE_OR_GENE_PRODUCT", 997, 1000], ["immune cells", "CELL", 1009, 1021], ["B lymphocytes", "CELL", 1023, 1036], ["T lymphocytes", "CELL", 1038, 1051], ["CD4", "GENE_OR_GENE_PRODUCT", 1053, 1056], ["CD8", "GENE_OR_GENE_PRODUCT", 1072, 1075], ["white blood cells", "CELL_TYPE", 425, 442], ["eosinophils", "CELL_TYPE", 496, 507], ["basophils", "CELL_TYPE", 515, 524], ["red blood cells", "CELL_TYPE", 526, 541], ["hemoglobin", "PROTEIN", 543, 553], ["thrombin", "PROTEIN", 698, 706], ["fibrinogen", "PROTEIN", 713, 723], ["D-dimer", "PROTEIN", 729, 736], ["inflammatory markers", "PROTEIN", 776, 796], ["ferritin", "PROTEIN", 798, 806], ["procalcitonin", "PROTEIN", 840, 853], ["C-reactive protein", "PROTEIN", 859, 877], ["immunoglobulins", "PROTEIN", 880, 895], ["IgA", "PROTEIN", 897, 900], ["IgG", "PROTEIN", 902, 905], ["IgM", "PROTEIN", 911, 914], ["C3", "PROTEIN", 935, 937], ["C4", "PROTEIN", 942, 944], ["interleukins", "PROTEIN", 947, 959], ["IL", "PROTEIN", 986, 988], ["TNF", "PROTEIN", 997, 1000], ["immune cells", "CELL_TYPE", 1009, 1021], ["B lymphocytes", "CELL_TYPE", 1023, 1036], ["T lymphocytes", "CELL_TYPE", 1038, 1051], ["CD4", "PROTEIN", 1053, 1056], ["T cells", "CELL_TYPE", 1059, 1066], ["CD8 + T cells", "CELL_TYPE", 1072, 1085], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 213, 221], ["patients", "SPECIES", 272, 280], ["COVID", "TEST", 170, 175], ["COVID", "TEST", 227, 232], ["radiological imaging", "TEST", 333, 353], ["hematological testing", "TEST", 369, 390], ["complete blood picture", "TEST", 401, 423], ["white blood cells", "TEST", 425, 442], ["neutrophil count", "TEST", 444, 460], ["lymphocyte count", "TEST", 462, 478], ["monocyte count", "TEST", 480, 494], ["eosinophils count", "TEST", 496, 513], ["basophils", "TEST", 515, 524], ["red blood cells", "TEST", 526, 541], ["hemoglobin", "TEST", 543, 553], ["hematocrit", "TEST", 555, 565], ["platelet count", "TEST", 571, 585], ["coagulation profile", "TEST", 588, 607], ["prothrombin time", "TEST", 609, 625], ["international normalized ratio", "TEST", 627, 657], ["activated partial thromboplastin time", "PROBLEM", 659, 696], ["thrombin time", "TEST", 698, 711], ["fibrinogen", "TEST", 713, 723], ["D-dimer", "TEST", 729, 736], ["immunological parameters", "TEST", 741, 765], ["inflammatory markers", "TEST", 776, 796], ["ferritin", "TEST", 798, 806], ["erythrocyte sedimentation rate", "TEST", 808, 838], ["procalcitonin", "TEST", 840, 853], ["C-reactive protein", "TEST", 859, 877], ["immunoglobulins", "TEST", 880, 895], ["IgA", "TEST", 897, 900], ["IgG", "TEST", 902, 905], ["IgM", "TEST", 911, 914], ["complement tests (C3 and C4)", "TEST", 917, 945], ["interleukins", "TEST", 947, 959], ["IL", "TEST", 961, 963], ["IL", "TEST", 967, 969], ["IL", "TEST", 973, 975], ["IL", "TEST", 979, 981], ["IL", "TEST", 986, 988], ["TNF", "TEST", 997, 1000], ["immune cells", "TEST", 1009, 1021], ["lymphocytes", "TEST", 1025, 1036], ["T", "TEST", 1038, 1039], ["lymphocytes", "TEST", 1040, 1051], ["CD4", "TEST", 1053, 1056], ["T cells", "TEST", 1059, 1066], ["CD8", "TEST", 1072, 1075], ["each laboratory test", "TEST", 1185, 1205]]], ["The following exclusion criteria were considered: (1) Case reports, reviews, editorial materials, conference abstracts, summaries of discussions, (2) Insufficient reported data information; or (3) In vitro or in vivo studies.Data abstractionFour investigators separately conducted literature screening, data extraction, and literature quality evaluation, and any differences were resolved through another two reviewers.", [["vivo studies", "TEST", 212, 224], ["Data abstraction", "TEST", 225, 241], ["literature screening", "TEST", 281, 301], ["data extraction", "TEST", 303, 318], ["literature quality evaluation", "TEST", 324, 353]]], ["Information extracted from eligible articles in a predesigned form in excel, including the last name of the first author, date and year of publication, journal name, study design, country of the population, sample size, mean age, sex, and quality assessment.Quality assessmentA modified version of the Newcastle-Ottawa scale (NOS) was adopted to evaluate the process in terms of queue selection, comparability of queues, and evaluation of results [12, 13] .", [["quality assessment", "TEST", 239, 257], ["evaluation", "TEST", 425, 435], ["size", "OBSERVATION_MODIFIER", 214, 218]]], ["The quality of the included studies was assessed independently by three reviewers, and disagreements were resolved by the process described above.", [["the included studies", "TEST", 15, 35]]], ["Higher NOS scores showed a higher literature quality.", [["NOS", "GENE_OR_GENE_PRODUCT", 7, 10], ["NOS", "PROTEIN", 7, 10], ["Higher NOS scores", "TEST", 0, 17]]], ["NOS scores of at least six were considered high-quality literature.Quality assessmentto mean and standard deviation (SD) using the following formulas: [Mean = (Q1+median +Q3)/3] and [SD = IQR/1.35], whereas, values reported in the articles as mean and 95%CI were estimated using the following formula [SD = p N \ufffd (Upper limit of CI-Lower limit of CI)/3.92].", [["NOS", "GENE_OR_GENE_PRODUCT", 0, 3], ["NOS", "PROTEIN", 0, 3], ["NOS scores", "TEST", 0, 10], ["standard deviation (SD)", "TREATMENT", 97, 120], ["Mean", "TEST", 152, 156], ["SD", "TEST", 183, 185], ["IQR", "TEST", 188, 191], ["mean", "TEST", 243, 247], ["CI", "TEST", 255, 257], ["SD", "TEST", 302, 304], ["CI", "TEST", 329, 331], ["CI", "TEST", 347, 349]]], ["A continuous random-effect model was applied using the DerSimonian-Laird (inverse variance) method [16, 17] .Quality assessmentNext, in the presence of individual patient data, single-armed observed values were converted to two-armed data to act as each other's control group based on covariate information.", [["patient", "ORGANISM", 163, 170], ["patient", "SPECIES", 163, 170], ["A continuous random-effect model", "TREATMENT", 0, 32], ["the DerSimonian-Laird (inverse variance", "TREATMENT", 51, 90], ["Quality assessment", "TEST", 109, 127], ["individual patient data", "TEST", 152, 175]]], ["Only studies investigating different outcomes were considered as potential matched pairs, and two-arm meta-analysis was applied to compare between mild versus severe COVID-19 infection (based on the results of the chest radiography, clinical examination, and symptoms), ICU admission versus general ward admission, and expired versus survivors.", [["chest", "ANATOMY", 214, 219], ["infection", "DISEASE", 175, 184], ["potential matched pairs", "PROBLEM", 65, 88], ["two-arm meta-analysis", "TREATMENT", 94, 115], ["mild versus severe COVID-19 infection", "PROBLEM", 147, 184], ["the chest radiography", "TEST", 210, 231], ["clinical examination", "TEST", 233, 253], ["symptoms", "PROBLEM", 259, 267], ["mild", "OBSERVATION_MODIFIER", 147, 151], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["infection", "OBSERVATION", 175, 184], ["chest", "ANATOMY", 214, 219]]], ["Meta-analysis for each outcome was processed using a random-effects model since heterogeneity among studies was expected.", [["a random-effects model", "TREATMENT", 51, 73], ["heterogeneity among studies", "PROBLEM", 80, 107]]], ["For pairwise comparison, estimates of SMD served as quantitative measures of the strength of evidence, which were then converted to the odds ratio (OR) with 95%CI for better interpretation by clinical domains.Decision tree to identify predictors for poor outcomesUsing laboratory features for clinical prediction, the decision tree algorithm was employed to identify the key risk factors attributed to severe COVID-19 infection, which include a count of studies \ufffd10.", [["infection", "DISEASE", 418, 427], ["poor outcomes", "PROBLEM", 250, 263], ["severe COVID-19 infection", "PROBLEM", 402, 427], ["a count of studies", "TEST", 443, 461], ["severe", "OBSERVATION_MODIFIER", 402, 408], ["infection", "OBSERVATION", 418, 427]]], ["The accuracy of the model was measured by the Area Under the Receiver Operating Characteristic (ROC) Curve (AUC), which depicts the true positive rate versus the false positive rate at various discrimination thresholds.", [["Curve (AUC)", "TEST", 101, 112], ["the true positive rate", "PROBLEM", 128, 150], ["positive rate", "OBSERVATION", 137, 150], ["false", "OBSERVATION", 162, 167], ["positive rate", "OBSERVATION", 168, 181]]], ["The markers that have the highest AUC were identified, and the sensitivity and specificity of the cut-off threshold level were determined.", [["The markers", "TEST", 0, 11], ["the highest AUC", "TEST", 22, 37], ["the sensitivity", "TEST", 59, 74], ["highest", "OBSERVATION_MODIFIER", 26, 33]]], ["R Studio was employed using the following packages: tidyverse, magrittr, rpart, caret, and pROC.Trial sequential analysis (TSA)The statistical trustworthiness of this meta-analysis assessment was conducted using TSA through combining the cumulative sample sizes of all appropriate records with the threshold of statistical impact to diminish the accidental errors and enhance the intensity of expectations [18] .", [["TSA", "CHEMICAL", 212, 215], ["tidyverse", "TREATMENT", 52, 61], ["magrittr", "TREATMENT", 63, 71], ["rpart", "TREATMENT", 73, 78], ["caret", "TREATMENT", 80, 85], ["pROC", "TREATMENT", 91, 95], ["Trial sequential analysis", "TEST", 96, 121], ["this meta-analysis assessment", "TEST", 162, 191], ["TSA", "TREATMENT", 212, 215], ["the accidental errors", "PROBLEM", 342, 363]]], ["Two side trials with \"type I error (\u03b1)\" along with power set at 5% and 80% were employed.", [["Two side trials", "TREATMENT", 0, 15]]], ["In the case of the \"Z-curve\" traverses the TSA monitoring boundaries, a reasonable degree of impact was accomplished, and no supplementary trials are crucial.", [["TSA", "CHEMICAL", 43, 46]]], ["TSA platform (version 0.9.5.10 beta) was operated in the experiment.Assessment of heterogeneity and publication biasAfter that, the heterogeneity was evaluated using Cochran's Q statistic and quantified by using I 2 statistics, which represents an estimation of the total variation across studies beyond chance.", [["TSA", "CHEMICAL", 0, 3], ["TSA", "CHEMICAL", 0, 3], ["TSA", "SIMPLE_CHEMICAL", 0, 3], ["TSA platform", "TEST", 0, 12], ["heterogeneity and publication bias", "PROBLEM", 82, 116], ["heterogeneity", "OBSERVATION", 82, 95]]], ["Articles were considered to have significant heterogeneity between studies when the p-value less than 0.1 or I 2 greater than 50%.", [["the p-value", "TEST", 80, 91], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["heterogeneity", "OBSERVATION", 45, 58]]], ["Subgroup analysis was performed based on the study sample size (\ufffd50 patients compared to >50 patients) and the origin of patients (Wuhan city versus others).", [["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 121, 129], ["Subgroup analysis", "TEST", 0, 17], ["the study sample size", "TEST", 41, 62], ["size", "OBSERVATION_MODIFIER", 58, 62]]], ["Also, sensitivity analyses and meta-regression with the random-effects model using restricted maximum likelihood algorithm were conducted to explore potential sources of heterogeneity.Assessment of heterogeneity and publication biasFinally, publication bias was assessed using a funnel plot and quantified using Begg's and Mazumdar rank correlation with continuity correction and Egger's linear regression tests.Assessment of heterogeneity and publication biasAsymmetry of the collected studies' distribution by visual inspection or P-value < 0.1 indicated obvious publication bias [19] .", [["sensitivity analyses", "TEST", 6, 26], ["meta-regression", "TEST", 31, 46], ["heterogeneity", "PROBLEM", 170, 183], ["publication bias", "TEST", 216, 232], ["publication bias", "TEST", 241, 257], ["a funnel plot", "TEST", 277, 290], ["Begg's", "TREATMENT", 312, 318], ["continuity correction", "TREATMENT", 354, 375], ["Egger's linear regression tests", "TEST", 380, 411], ["heterogeneity", "PROBLEM", 426, 439], ["publication bias", "TEST", 444, 460], ["the collected studies", "TEST", 473, 494], ["visual inspection", "TEST", 512, 529], ["P-value", "TEST", 533, 540], ["obvious publication bias", "PROBLEM", 557, 581], ["heterogeneity", "OBSERVATION", 170, 183], ["heterogeneity", "OBSERVATION", 426, 439]]], ["The Duval and Tweedie's trim and fill method's assumption were considered to reduce the bias in pooled estimates [20] .Literature searchA flowchart outlining the systematic review search results is described in Fig 1A.", [["The Duval and Tweedie's trim", "TREATMENT", 0, 28], ["fill method's assumption", "TREATMENT", 33, 57]]], ["Upon reviewing the retrieved articles, a total of 1230 records were excluded for duplication, and 3522 unique records were initially identified.", [["duplication", "PROBLEM", 81, 92]]], ["Following screening of titles and abstracts, several studies were excluded for being case reports (n = 44), review articles (n = 262), irrelevant publications (n = 1355), or editorial materials (n = 1809).", [["several studies", "TEST", 45, 60]]], ["Ultimately, a total of 52 eligible articles were included for the quantitative synthesis of this meta-analysis study, with 52 records represented single-arm analysis [1, 9, , 16 records represented two-arms severity analysis [24, 26, 32, 34, 37, 40, 41, 45, 46, 50, 51, 63, 64, 66, 69, 70] ; meanwhile, 7 and 4 records were utilized for survival [9, 30, 53, 55, 61, 67, 68] and ICU admission [1, 31, 36, 52] analyses, respectively.Literature searchCharacteristics of the included studies.", [["this meta-analysis study", "TEST", 92, 116], ["single-arm analysis", "TEST", 146, 165], ["arms severity analysis", "TEST", 202, 224], ["survival", "TEST", 337, 345], ["analyses", "TEST", 408, 416], ["the included studies", "TEST", 467, 487]]], ["Our review included 52 studies that were pub- Table 1 .", [["52 studies", "TEST", 20, 30]]], ["A total of 6320 patients with SARS-CoV-2 infection were enrolled across the articles.", [["SARS-CoV-2 infection", "DISEASE", 30, 50], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["SARS", "PROBLEM", 30, 34], ["CoV", "PROBLEM", 35, 38], ["2 infection", "PROBLEM", 39, 50], ["infection", "OBSERVATION", 41, 50]]], ["Most records (n = 47) were retrospective case studies, while other study design included two prospective cohort studies, one observational cohort study, one descriptive case series, and one case-control study.", [["retrospective case studies", "TEST", 27, 53], ["two prospective cohort studies", "TEST", 89, 119], ["observational cohort study", "TEST", 125, 151]]], ["Our team stratified 36 different laboratory parameters into seven subclasses, including complete blood picture, coagulation profile, immunological markers, immunoglobulins, complement tests, interleukins, and immune cells, as previously described in the methodology.", [["blood", "ANATOMY", 97, 102], ["immune cells", "ANATOMY", 209, 221], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 156, 171], ["interleukins", "GENE_OR_GENE_PRODUCT", 191, 203], ["immune cells", "CELL", 209, 221], ["immunological markers", "PROTEIN", 133, 154], ["immunoglobulins", "PROTEIN", 156, 171], ["interleukins", "PROTEIN", 191, 203], ["immune cells", "CELL_TYPE", 209, 221], ["complete blood picture", "TEST", 88, 110], ["coagulation profile", "TEST", 112, 131], ["immunological markers", "TEST", 133, 154], ["immunoglobulins", "TEST", 156, 171], ["complement tests", "TEST", 173, 189], ["interleukins", "TEST", 191, 203], ["immune cells", "PROBLEM", 209, 221], ["immune cells", "OBSERVATION", 209, 221]]], ["Regarding quality score assessment, 39 studies achieved a score higher than six out of a maximum of nine (high quality), while the remaining 13 studies earned a score equal or lower than six (low quality), as shown in Table 1 .Pooled estimates of laboratory parameters: Single-arm meta-analysisThe final pooled estimates of single-arm meta-analysis included 52 eligible articles.", [["quality score assessment", "TEST", 10, 34], ["39 studies", "TEST", 36, 46], ["a score", "TEST", 56, 63], ["the remaining 13 studies", "TEST", 127, 151], ["Single-arm meta-analysis", "TEST", 270, 294], ["single-arm meta-analysis", "TREATMENT", 324, 348], ["arm", "ANATOMY", 277, 280], ["arm", "ANATOMY", 331, 334]]], ["The pooled mean of laboratory parameters and 95%CI among SARS-CoV-2 infected patients, including hematological, immunological, and inflammatory variables, is illustrated in Table 2 .", [["hematological", "ANATOMY", 97, 110], ["SARS-CoV-2 infected", "DISEASE", 57, 76], ["SARS-CoV-2", "ORGANISM", 57, 67], ["patients", "ORGANISM", 77, 85], ["CoV-", "SPECIES", 62, 66], ["patients", "SPECIES", 77, 85], ["SARS-CoV", "SPECIES", 57, 65], ["laboratory parameters", "TEST", 19, 40], ["%CI", "TEST", 47, 50], ["SARS", "TEST", 57, 61], ["CoV", "TEST", 62, 65], ["inflammatory variables", "PROBLEM", 131, 153], ["hematological", "ANATOMY", 97, 110], ["inflammatory", "OBSERVATION_MODIFIER", 131, 143]]], ["Our results depicted a wide variability between studies for each laboratory marker.", [["a wide variability", "PROBLEM", 21, 39], ["each laboratory marker", "TEST", 60, 82], ["wide", "OBSERVATION_MODIFIER", 23, 27]]], ["Apart from immunoglobulins, IL-2R, and IL-8, significant heterogeneity was observed.", [["immunoglobulins", "GENE_OR_GENE_PRODUCT", 11, 26], ["IL-2R", "GENE_OR_GENE_PRODUCT", 28, 33], ["IL-8", "GENE_OR_GENE_PRODUCT", 39, 43], ["immunoglobulins", "PROTEIN", 11, 26], ["IL", "PROTEIN", 28, 30], ["IL", "PROTEIN", 39, 41], ["immunoglobulins", "TEST", 11, 26], ["IL", "TEST", 28, 30], ["IL", "TREATMENT", 39, 41], ["significant heterogeneity", "PROBLEM", 45, 70], ["immunoglobulins", "OBSERVATION", 11, 26], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["heterogeneity", "OBSERVATION", 57, 70]]], ["Subgroup analysis by sample size and city of origin and sensitivity analysis failed to reveal the source of variation for each parameter.", [["Subgroup analysis", "TEST", 0, 17], ["sample size", "TEST", 21, 32], ["sensitivity analysis", "TEST", 56, 76], ["size", "OBSERVATION_MODIFIER", 28, 32]]], ["Additionally, meta-regression also rendered insignificant results.Pooled estimates of laboratory parameters according to disease severity: Pairwise meta-analysisTwo-arms meta-analyses were then conducted for three pairwise comparisons; (1) Severe versus mild COVID, (2) ICU admitted patients versus the general ward, and (3) Expired versus survivors (Table 3) .", [["COVID", "DISEASE", 259, 264], ["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291], ["laboratory parameters", "TEST", 86, 107], ["Pairwise meta-analysis", "TEST", 139, 161], ["arms meta-analyses", "TEST", 165, 183], ["Severe versus mild COVID", "PROBLEM", 240, 264], ["mild", "OBSERVATION_MODIFIER", 254, 258]]], ["Laboratory parameters of 16 eligible records were utilized to compare between severe and non-severe patients.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["Laboratory parameters", "TEST", 0, 21], ["severe and non-severe patients", "PROBLEM", 78, 108]]], ["Severe cohorts were more likely to have high blood levels (Table 3A) .Pooled estimates of laboratory parameters according to disease severity: Pairwise meta-analysisSignificant heterogeneity was observed in eight of these parameters, namely WBC (I 2 = 62.9%, p <0.001), neutrophil count (I 2 = 67.6%, p <0.001), lymphocyte count (I 2 = 77.4%, p <0.001), prothrombin time (I 2 = 72%, p = 0.003), D-dimers (I 2 = 55.6%, p = 0.021), procalcitonin (I 2 = 86.1%, p <0.001), IL-6 (I 2 = 84.4%, p <0.001), and IL-10 (I 2 = 82.8%, p = 0.003).", [["blood", "ANATOMY", 45, 50], ["neutrophil", "ANATOMY", 270, 280], ["lymphocyte", "ANATOMY", 312, 322], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["neutrophil", "CELL", 270, 280], ["lymphocyte", "CELL", 312, 322], ["prothrombin", "GENE_OR_GENE_PRODUCT", 354, 365], ["IL-6", "GENE_OR_GENE_PRODUCT", 469, 473], ["IL-10", "GENE_OR_GENE_PRODUCT", 503, 508], ["neutrophil", "CELL_TYPE", 270, 280], ["prothrombin", "PROTEIN", 354, 365], ["procalcitonin", "PROTEIN", 430, 443], ["IL", "PROTEIN", 503, 505], ["Severe cohorts", "PROBLEM", 0, 14], ["high blood levels", "PROBLEM", 40, 57], ["laboratory parameters", "TEST", 90, 111], ["Pairwise meta-analysis", "TEST", 143, 165], ["Significant heterogeneity", "PROBLEM", 165, 190], ["these parameters", "TEST", 216, 232], ["WBC", "TEST", 241, 244], ["I", "TEST", 246, 247], ["p", "TEST", 259, 260], ["neutrophil count", "TEST", 270, 286], ["I", "TEST", 288, 289], ["p", "TEST", 301, 302], ["lymphocyte count", "TEST", 312, 328], ["I", "TEST", 330, 331], ["p", "TEST", 343, 344], ["prothrombin time", "TEST", 354, 370], ["I", "TEST", 372, 373], ["p", "TEST", 383, 384], ["D-dimers", "TEST", 395, 403], ["I", "TEST", 405, 406], ["p", "TEST", 418, 419], ["procalcitonin", "TEST", 430, 443], ["I", "TEST", 445, 446], ["p", "TEST", 458, 459], ["IL", "TEST", 469, 471], ["I", "TEST", 475, 476], ["p", "TEST", 488, 489], ["IL", "TEST", 503, 505], ["p", "TEST", 523, 524], ["Significant", "OBSERVATION_MODIFIER", 165, 176], ["heterogeneity", "OBSERVATION", 177, 190]]], ["(Table 3B) .Pooled estimates of laboratory parameters according to ICU admission: Pairwise meta-analysisRemarkable heterogeneity was obvious in studies of neutrophil count (I 2 = 93.1%, p <0.001), lymphocyte count (I 2 = 68.5%, p = 0.023), and hemoglobin (I 2 = 66.3%, p = 0.08).", [["neutrophil", "ANATOMY", 155, 165], ["lymphocyte", "ANATOMY", 197, 207], ["neutrophil", "CELL", 155, 165], ["lymphocyte", "CELL", 197, 207], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 244, 254], ["hemoglobin", "PROTEIN", 244, 254], ["Pairwise meta-analysis", "TEST", 82, 104], ["neutrophil count", "TEST", 155, 171], ["I", "TEST", 173, 174], ["p", "TEST", 186, 187], ["lymphocyte count", "TEST", 197, 213], ["I", "TEST", 215, 216], ["p", "TEST", 228, 229], ["hemoglobin", "TEST", 244, 254], ["I", "TEST", 256, 257], ["p", "TEST", 269, 270], ["neutrophil count", "OBSERVATION", 155, 171]]], ["These parameters were enclosed in two to four studies; therefore, further tracing for the source of heterogeneity was not applicable.Pooled estimates of laboratory parameters according to mortality: Pairwise meta-analysisOf the included articles, 7 studies contained separate results for laboratory testing in survival versus expired patients.", [["patients", "ORGANISM", 334, 342], ["patients", "SPECIES", 334, 342], ["further tracing", "TEST", 66, 81], ["heterogeneity", "PROBLEM", 100, 113], ["laboratory parameters", "TEST", 153, 174], ["7 studies", "TEST", 247, 256], ["laboratory testing", "TEST", 288, 306]]], ["Considerable heterogeneity was also noted in some of these parameters, namely WBC (I 2 = 78.0%, p <0.001), neutrophilic count (I 2 = 90.9%, p <0.001), lymphocyte count (I 2 = 89.3%, p <0.001), platelet count (I 2 = 59.5%, p = 0.030), ferritin (I 2 = 91.6%, p <0.001), procalcitonin (I 2 = 81.5%, p = 0.005), CRP (I 2 = 87.3%, p <0.001), and IL-6 (I 2 = 75.4%, p = 0.007).", [["neutrophilic", "ANATOMY", 107, 119], ["lymphocyte", "ANATOMY", 151, 161], ["platelet", "ANATOMY", 193, 201], ["neutrophilic", "PATHOLOGICAL_FORMATION", 107, 119], ["lymphocyte", "CELL", 151, 161], ["platelet", "CELL", 193, 201], ["ferritin", "GENE_OR_GENE_PRODUCT", 234, 242], ["CRP", "GENE_OR_GENE_PRODUCT", 308, 311], ["IL-6", "GENE_OR_GENE_PRODUCT", 341, 345], ["ferritin", "PROTEIN", 234, 242], ["procalcitonin", "PROTEIN", 268, 281], ["CRP", "PROTEIN", 308, 311], ["IL", "PROTEIN", 341, 343], ["Considerable heterogeneity", "PROBLEM", 0, 26], ["these parameters", "TEST", 53, 69], ["WBC", "TEST", 78, 81], ["I", "TEST", 83, 84], ["p", "TEST", 96, 97], ["neutrophilic count", "TEST", 107, 125], ["I", "TEST", 127, 128], ["p", "TEST", 140, 141], ["lymphocyte count", "TEST", 151, 167], ["I", "TEST", 169, 170], ["p", "TEST", 182, 183], ["platelet count", "TEST", 193, 207], ["I", "TEST", 209, 210], ["p", "TEST", 222, 223], ["ferritin", "TEST", 234, 242], ["I", "TEST", 244, 245], ["p", "TEST", 257, 258], ["procalcitonin", "TEST", 268, 281], ["I", "TEST", 283, 284], ["p", "TEST", 296, 297], ["CRP", "TEST", 308, 311], ["I", "TEST", 313, 314], ["p", "TEST", 326, 327], ["IL", "TEST", 341, 343], ["p", "TEST", 360, 361], ["heterogeneity", "OBSERVATION", 13, 26]]], ["Given the small number of enrolled studies with discriminated data on patients who survived or died, we failed to identify the source of heterogeneity.Subgroup and sensitivity analysisFor the studies which included a comparison between mild and severe patients, subgroup and sensitivity analyses were performed for five laboratory markers (WBC, neutrophil count, lymphocyte count, procalcitonin, and CRP).", [["WBC", "ANATOMY", 340, 343], ["neutrophil", "ANATOMY", 345, 355], ["lymphocyte", "ANATOMY", 363, 373], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 252, 260], ["WBC", "CELL", 340, 343], ["neutrophil", "CELL", 345, 355], ["lymphocyte", "CELL", 363, 373], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 381, 394], ["CRP", "GENE_OR_GENE_PRODUCT", 400, 403], ["WBC", "PROTEIN", 340, 343], ["procalcitonin", "PROTEIN", 381, 394], ["CRP", "PROTEIN", 400, 403], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 252, 260], ["enrolled studies", "TEST", 26, 42], ["heterogeneity", "PROBLEM", 137, 150], ["Subgroup and sensitivity analysis", "TEST", 151, 184], ["the studies", "TEST", 188, 199], ["mild and severe patients", "PROBLEM", 236, 260], ["subgroup and sensitivity analyses", "TEST", 262, 295], ["five laboratory markers", "TEST", 315, 338], ["WBC", "TEST", 340, 343], ["neutrophil count", "TEST", 345, 361], ["lymphocyte count", "TEST", 363, 379], ["procalcitonin", "TEST", 381, 394], ["CRP", "TEST", 400, 403], ["small", "OBSERVATION_MODIFIER", 10, 15], ["heterogeneity", "OBSERVATION", 137, 150]]], ["First, to identify how each study affects the overall estimate of the rest of the studies, we performed leave-one-out sensitivity analyses.", [["the studies", "TEST", 78, 89], ["sensitivity analyses", "TEST", 118, 138]]], ["In contrast, subgroup analysis revealed homogeneity with certain categorizations.", [["subgroup analysis", "TEST", 13, 30]]], ["For WBCs lab results, heterogeneity was resolved on stratification by the origin of study population [Wuhan population: I 2 = 73.4%, p = 0.002, other cities: I 2 = 0%, p = 0.53] and month of publication [April: I 2 = 74.5%, p = 0.001, February/March: I 2 = 47.5%, p = 0.06].", [["WBCs", "CELL", 4, 8], ["WBCs", "CELL_TYPE", 4, 8], ["WBCs lab", "TEST", 4, 12], ["heterogeneity", "PROBLEM", 22, 35], ["p", "TEST", 133, 134], ["p", "TEST", 168, 169], ["publication", "TEST", 191, 202], ["I", "TEST", 211, 212], ["p", "TEST", 224, 225], ["I", "TEST", 251, 252], ["p", "TEST", 264, 265]]], ["Regarding neutrophilic count, the variance in the results resolved in articles with large sample size >50 patients (I 2 = 46.2%, p = 0.06).", [["neutrophilic", "ANATOMY", 10, 22], ["neutrophilic", "CELL", 10, 22], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["neutrophilic count", "TEST", 10, 28], ["the variance", "TEST", 30, 42], ["large sample size", "TEST", 84, 101], ["p", "TEST", 129, 130], ["neutrophilic count", "OBSERVATION", 10, 28], ["large", "OBSERVATION_MODIFIER", 84, 89], ["size", "OBSERVATION_MODIFIER", 97, 101]]], ["Moreover, the degree of dissimilarities of procalcitonin results found in different studies was ameliorated in April publications (I 2 = 41.5%, p = 0.16) and in those with low sample size (I 2 = 0%, p = 0.80).", [["procalcitonin", "GENE_OR_GENE_PRODUCT", 43, 56], ["procalcitonin", "PROTEIN", 43, 56], ["procalcitonin results", "TEST", 43, 64], ["different studies", "TEST", 74, 91], ["p", "TEST", 144, 145], ["size", "OBSERVATION_MODIFIER", 183, 187]]], ["Similarly, homogeneity was generated in CRP results in articles with low sample size (I 2 = 0%, p = 0.58) ( Table 4 ).Meta-regression analysisConsidering the number of the included studies with severity, ICU admission, and mortality data was rather small, we performed meta-regression analyses for only five parameters (mentioned above) in studies comparing mild and severe disease (Table 4 ).", [["CRP", "GENE_OR_GENE_PRODUCT", 40, 43], ["CRP", "PROTEIN", 40, 43], ["CRP", "TEST", 40, 43], ["Meta-regression analysis", "TEST", 118, 142], ["mortality data", "TEST", 223, 237], ["meta-regression analyses", "TEST", 269, 293], ["mild and severe disease", "PROBLEM", 358, 381], ["low sample", "OBSERVATION_MODIFIER", 69, 79], ["size", "OBSERVATION_MODIFIER", 80, 84], ["mild", "OBSERVATION_MODIFIER", 358, 362], ["severe", "OBSERVATION_MODIFIER", 367, 373], ["disease", "OBSERVATION", 374, 381]]], ["For WBCs, higher difference between mild and severe cohorts was noted in Wuhan studies than other population (coefficient = 0.31, 95%CI = 0.03, 0.58, p = 0.029).", [["WBCs", "ANATOMY", 4, 8], ["WBCs", "CELL", 4, 8], ["WBCs", "CELL_TYPE", 4, 8], ["WBCs", "TEST", 4, 8], ["higher difference between mild and severe cohorts", "PROBLEM", 10, 59], ["Wuhan studies", "TEST", 73, 86], ["coefficient", "TEST", 110, 121], ["CI", "TEST", 133, 135], ["p", "TEST", 150, 151], ["higher", "OBSERVATION_MODIFIER", 10, 16], ["difference", "OBSERVATION_MODIFIER", 17, 27], ["mild", "OBSERVATION_MODIFIER", 36, 40], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["cohorts", "OBSERVATION", 52, 59]]], ["Moreover, articles with larger sample size exhibited a wider variation of neutrophilic count between severe and non-severe cases (coefficient = 0.60, 95%CI = 0.20, 1.01, p = 0.003).", [["neutrophilic", "ANATOMY", 74, 86], ["neutrophilic", "CELL", 74, 86], ["larger sample size", "PROBLEM", 24, 42], ["neutrophilic count", "TEST", 74, 92], ["severe and non-severe cases", "PROBLEM", 101, 128], ["coefficient", "TEST", 130, 141], ["CI", "TEST", 153, 155], ["p", "TEST", 170, 171], ["larger", "OBSERVATION_MODIFIER", 24, 30], ["size", "OBSERVATION_MODIFIER", 38, 42], ["wider", "OBSERVATION_MODIFIER", 55, 60], ["variation", "OBSERVATION_MODIFIER", 61, 70], ["neutrophilic count", "OBSERVATION", 74, 92], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["non-severe", "OBSERVATION_MODIFIER", 112, 122]]], ["For the same marker, later studies published in April also showed higher difference compared to those published in February and March (coefficient = 0.31, 95%CI = 0.06, 0.55, p = 0.014).", [["later studies", "TEST", 21, 34], ["CI", "TEST", 158, 160], ["higher", "OBSERVATION_MODIFIER", 66, 72]]], ["In contrast, more reduction of lymphocytes was observed in April articles than earlier ones (coefficient = -0.57, 95%CI = -0.97, -0.17, p = 0.006).Publication biasPublication bias was performed to the same five parameters with study count \ufffd10 (S1 Fig).", [["lymphocytes", "ANATOMY", 31, 42], ["lymphocytes", "CELL", 31, 42], ["lymphocytes", "CELL_TYPE", 31, 42], ["lymphocytes", "PROBLEM", 31, 42], ["coefficient", "TEST", 93, 104], ["CI", "TEST", 117, 119], ["Publication biasPublication bias", "TEST", 147, 179], ["study count", "TEST", 227, 238], ["more", "OBSERVATION_MODIFIER", 13, 17], ["reduction", "OBSERVATION_MODIFIER", 18, 27], ["lymphocytes", "OBSERVATION", 31, 42]]], ["Visual inspection of the funnel plots suggested symmetrical distribution for all laboratory parameters tested.", [["Visual inspection", "TEST", 0, 17], ["the funnel plots", "TEST", 21, 37], ["all laboratory parameters", "TEST", 77, 102], ["symmetrical distribution", "OBSERVATION", 48, 72]]], ["The Egger test (p > 0.1) confirmed that there was no substantial evidence of publication bias; Egger's regression p values were 0.44, 0.50, 0.68, 0.56, and 0.22 for WBC, neutrophil count, lymphocyte count, procalcitonin, and CRP, respectively.Decision tree and Receiver Operating Characteristic (ROC) curveTo identify predictors for severity, decision tree analysis was applied using multiple laboratory results.", [["WBC", "ANATOMY", 165, 168], ["neutrophil", "ANATOMY", 170, 180], ["lymphocyte", "ANATOMY", 188, 198], ["WBC", "CELL", 165, 168], ["neutrophil", "CELL", 170, 180], ["lymphocyte", "CELL", 188, 198], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 206, 219], ["CRP", "GENE_OR_GENE_PRODUCT", 225, 228], ["procalcitonin", "PROTEIN", 206, 219], ["CRP", "PROTEIN", 225, 228], ["The Egger test", "TEST", 0, 14], ["publication bias", "PROBLEM", 77, 93], ["Egger's regression p values", "TEST", 95, 122], ["WBC", "TEST", 165, 168], ["neutrophil count", "TEST", 170, 186], ["lymphocyte count", "TEST", 188, 204], ["procalcitonin", "TEST", 206, 219], ["CRP", "TEST", 225, 228], ["severity", "PROBLEM", 333, 341], ["no substantial evidence of", "UNCERTAINTY", 50, 76], ["publication bias", "OBSERVATION", 77, 93], ["neutrophil count", "OBSERVATION", 170, 186]]], ["High performance of classification was found with the usage of a single parameter; neutrophilic count identified severe patients with 100% sensitivity and 81% specificity at a cutoff value of >3.74 identified by the specified decision tree model.", [["neutrophilic", "ANATOMY", 83, 95], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["neutrophilic count", "TEST", 83, 101], ["a cutoff value", "TEST", 174, 188], ["severe", "OBSERVATION_MODIFIER", 113, 119]]], ["Further analysis of the area under the curve of input data is shown in Table 5 .Trial sequential analysisAs elaborated by the decision tree algorithm for the role of neutrophilic count on decisionmaking to discriminate between COVID-19 patients with a mild and severe presentation, TSA was employed on that particular laboratory parameter to test for the presence of sufficient studies from which results were drawn.", [["neutrophilic", "ANATOMY", 166, 178], ["TSA", "CHEMICAL", 282, 285], ["TSA", "CHEMICAL", 282, 285], ["neutrophilic", "CELL", 166, 178], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 236, 244], ["Further analysis", "TEST", 0, 16], ["input data", "TEST", 48, 58], ["Trial sequential analysis", "TEST", 80, 105], ["neutrophilic count", "TEST", 166, 184], ["COVID", "TEST", 227, 232], ["a mild and severe presentation", "PROBLEM", 250, 280], ["TSA", "TEST", 282, 285], ["neutrophilic count", "OBSERVATION", 166, 184], ["mild", "OBSERVATION_MODIFIER", 252, 256], ["severe", "OBSERVATION_MODIFIER", 261, 267]]], ["The sample size of studies containing neutrophilic count information and classifying cohorts into mild and severe COVID-19 infection accounted for a total of 1,558 subjects.", [["infection", "DISEASE", 123, 132], ["COVID-19", "SPECIES", 114, 122], ["studies", "TEST", 19, 26], ["neutrophilic count information", "TEST", 38, 68], ["mild and severe COVID-19 infection", "PROBLEM", 98, 132], ["size", "OBSERVATION_MODIFIER", 11, 15], ["neutrophilic count", "OBSERVATION", 38, 56], ["mild", "OBSERVATION_MODIFIER", 98, 102], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["infection", "OBSERVATION", 123, 132]]], ["TSA illustrated crossing of the monitoring boundary by the cumulative Z-curve before reaching the required sample size, suggesting that the cumulative proof was acceptable, and no additional future studies are needed to authenticate the significances (Fig 2) .DiscussionDuring the last few months, the prevalence of COVID-19 infection was increased daily among different countries overall in the world.", [["TSA", "CHEMICAL", 0, 3], ["COVID-19", "CHEMICAL", 316, 324], ["infection", "DISEASE", 325, 334], ["TSA", "CHEMICAL", 0, 3], ["TSA", "SIMPLE_CHEMICAL", 0, 3], ["COVID-19", "ORGANISM", 316, 324], ["COVID-19", "SPECIES", 316, 324], ["TSA", "TREATMENT", 0, 3], ["additional future studies", "TEST", 180, 205], ["COVID-19 infection", "PROBLEM", 316, 334], ["size", "OBSERVATION_MODIFIER", 114, 118], ["infection", "OBSERVATION", 325, 334]]], ["Thus, the need to assess the disease severity and mortality are required to limit the pervasiveness of this pandemic [71] .", [["the disease severity", "PROBLEM", 25, 45]]], ["A diverse of abnormal laboratory parameters including hematological, inflammatory as well as immunological markers thought to be raised throughout COVID-19 outbreak [2, 72] .", [["abnormal laboratory parameters", "PROBLEM", 13, 43], ["inflammatory", "PROBLEM", 69, 81], ["immunological markers", "TEST", 93, 114], ["COVID", "TEST", 147, 152], ["diverse", "OBSERVATION_MODIFIER", 2, 9], ["abnormal", "OBSERVATION_MODIFIER", 13, 21], ["inflammatory", "OBSERVATION_MODIFIER", 69, 81]]], ["In this comprehensive metaanalysis, our team attempted to interpret the distinct questions raised about the various spectrum of laboratory parameters associated with the severity and mortality of COVID-19.", [["laboratory parameters", "TEST", 128, 149], ["the severity", "PROBLEM", 166, 178], ["COVID", "TEST", 196, 201]]], ["At the beginning of this workflow, our team investigated different hematological, inflammatory, and immunological variables of 6320 patients diagnosed with COVID-19.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["different hematological, inflammatory", "PROBLEM", 57, 94], ["COVID", "TEST", 156, 161], ["inflammatory", "OBSERVATION_MODIFIER", 82, 94]]], ["Our findings using random-effect models revealed increased levels of WBCs and neutrophil counts that were significantly associated with higher odds ratio among severe, ICU admission and Expired patients with COVID-19.", [["WBCs", "ANATOMY", 69, 73], ["neutrophil", "ANATOMY", 78, 88], ["WBCs", "CELL", 69, 73], ["neutrophil", "CELL", 78, 88], ["patients", "ORGANISM", 194, 202], ["WBCs", "CELL_TYPE", 69, 73], ["neutrophil", "CELL_TYPE", 78, 88], ["patients", "SPECIES", 194, 202], ["random-effect models", "TEST", 19, 39], ["increased levels of WBCs", "PROBLEM", 49, 73], ["neutrophil counts", "TEST", 78, 95], ["COVID", "TEST", 208, 213], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["neutrophil counts", "OBSERVATION", 78, 95], ["severe", "OBSERVATION_MODIFIER", 160, 166]]], ["On the contrary, the levels of lymphocyte and platelet counts were lowered among severe and expired patients with COVID-19.", [["lymphocyte", "ANATOMY", 31, 41], ["platelet", "ANATOMY", 46, 54], ["COVID-19", "CHEMICAL", 114, 122], ["lymphocyte", "CELL", 31, 41], ["platelet", "CELL", 46, 54], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["the levels of lymphocyte", "TEST", 17, 41], ["platelet counts", "TEST", 46, 61], ["COVID", "TEST", 114, 119], ["lymphocyte", "ANATOMY", 31, 41], ["platelet counts", "OBSERVATION", 46, 61], ["severe", "OBSERVATION_MODIFIER", 81, 87]]], ["Also, we observed depletion in quantities of CD4 + T cells and CD8 + T cells among severe and mortality patients.", [["CD4 + T cells", "ANATOMY", 45, 58], ["CD8 + T cells", "ANATOMY", 63, 76], ["CD4", "GENE_OR_GENE_PRODUCT", 45, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 63, 66], ["patients", "ORGANISM", 104, 112], ["CD4", "PROTEIN", 45, 48], ["T cells", "CELL_TYPE", 51, 58], ["CD8 + T cells", "CELL_TYPE", 63, 76], ["patients", "SPECIES", 104, 112], ["CD4 + T cells", "PROBLEM", 45, 58], ["CD8 + T cells", "PROBLEM", 63, 76], ["depletion", "OBSERVATION", 18, 27], ["severe", "OBSERVATION_MODIFIER", 83, 89]]], ["Nevertheless, in patients with the COVID-19 outbreak, the WBC count can vary [73] .", [["WBC", "ANATOMY", 58, 61], ["patients", "ORGANISM", 17, 25], ["WBC", "CELL", 58, 61], ["patients", "SPECIES", 17, 25], ["the COVID", "TEST", 31, 40], ["the WBC count", "TEST", 54, 67]]], ["Other reports indicated that leukopenia, leukocytosis, and lymphopenia have been reported, although lymphopenia appears most common [74, 75] .", [["leukopenia", "DISEASE", 29, 39], ["leukocytosis", "DISEASE", 41, 53], ["lymphopenia", "DISEASE", 59, 70], ["lymphopenia", "DISEASE", 100, 111], ["leukopenia", "PROBLEM", 29, 39], ["leukocytosis", "PROBLEM", 41, 53], ["lymphopenia", "PROBLEM", 59, 70], ["lymphopenia", "PROBLEM", 100, 111], ["leukopenia", "OBSERVATION", 29, 39], ["leukocytosis", "OBSERVATION", 41, 53], ["lymphopenia", "OBSERVATION", 59, 70], ["lymphopenia", "OBSERVATION", 100, 111]]], ["Another study supported that lymphopenia is an effective and reliable indicator of the severity and hospitalization in COVID-19 patients [76] .", [["lymphopenia", "DISEASE", 29, 40], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["Another study", "TEST", 0, 13], ["lymphopenia", "PROBLEM", 29, 40], ["the severity", "PROBLEM", 83, 95], ["COVID", "TEST", 119, 124], ["lymphopenia", "OBSERVATION", 29, 40]]], ["The additional report suggested that COVID-19 illness might be implicated with CD4 + and CD8 + T cells depletion through acting on lymphocytes, especially T lymphocytes [34] .", [["CD4 + and CD8 + T cells", "ANATOMY", 79, 102], ["lymphocytes", "ANATOMY", 131, 142], ["T lymphocytes", "ANATOMY", 155, 168], ["illness", "DISEASE", 46, 53], ["COVID-19", "ORGANISM", 37, 45], ["CD4", "GENE_OR_GENE_PRODUCT", 79, 82], ["CD8", "GENE_OR_GENE_PRODUCT", 89, 92], ["lymphocytes", "CELL", 131, 142], ["T lymphocytes", "CELL", 155, 168], ["CD4", "PROTEIN", 79, 82], ["CD8", "PROTEIN", 89, 92], ["lymphocytes", "CELL_TYPE", 131, 142], ["T lymphocytes", "CELL_TYPE", 155, 168], ["COVID", "TEST", 37, 42], ["CD4", "TEST", 79, 82], ["CD8", "TEST", 89, 92], ["T cells depletion", "PROBLEM", 95, 112], ["lymphocytes", "TEST", 131, 142], ["cells depletion", "OBSERVATION", 97, 112]]], ["A recent meta-analysis study discovered that the severity among COVID-19 patients might correlate with higher levels of WBCs count and lower levels of lymphocyte, CD4 + T cells, and CD8 + T cells counts [72] .", [["WBCs", "ANATOMY", 120, 124], ["lymphocyte", "ANATOMY", 151, 161], ["CD4 + T cells", "ANATOMY", 163, 176], ["CD8 + T cells", "ANATOMY", 182, 195], ["patients", "ORGANISM", 73, 81], ["WBCs", "CELL", 120, 124], ["lymphocyte", "CELL", 151, 161], ["CD4", "GENE_OR_GENE_PRODUCT", 163, 166], ["CD8", "GENE_OR_GENE_PRODUCT", 182, 185], ["WBCs", "CELL_TYPE", 120, 124], ["lymphocyte, CD4 + T cells", "CELL_TYPE", 151, 176], ["CD8 + T cells", "CELL_TYPE", 182, 195], ["patients", "SPECIES", 73, 81], ["A recent meta-analysis study", "TEST", 0, 28], ["COVID", "TEST", 64, 69], ["WBCs count", "TEST", 120, 130], ["lymphocyte", "TEST", 151, 161], ["CD4", "TEST", 163, 166], ["T cells", "TEST", 169, 176], ["CD8", "TEST", 182, 185], ["T cells counts", "TEST", 188, 202], ["lymphocyte", "ANATOMY", 151, 161]]], ["In this respect, we could speculate that the depletion in the number of lymphocytes count is directly proportional with the severity of COVID-19 infection and the high survival rate of the disease is associated with the ability to renovate lymphocyte cells, particularly T lymphocytes which are crucial for destroying the infected viral particles [77] .", [["lymphocytes", "ANATOMY", 72, 83], ["lymphocyte cells", "ANATOMY", 240, 256], ["T lymphocytes", "ANATOMY", 271, 284], ["infection", "DISEASE", 145, 154], ["lymphocytes", "CELL", 72, 83], ["COVID-19", "GENE_OR_GENE_PRODUCT", 136, 144], ["lymphocyte cells", "CELL", 240, 256], ["T lymphocytes", "CELL", 271, 284], ["lymphocytes", "CELL_TYPE", 72, 83], ["lymphocyte cells", "CELL_TYPE", 240, 256], ["T lymphocytes", "CELL_TYPE", 271, 284], ["COVID-19", "SPECIES", 136, 144], ["the depletion", "PROBLEM", 41, 54], ["lymphocytes count", "TEST", 72, 89], ["COVID-19 infection", "PROBLEM", 136, 154], ["the disease", "PROBLEM", 185, 196], ["lymphocyte cells", "PROBLEM", 240, 256], ["T lymphocytes", "PROBLEM", 271, 284], ["the infected viral particles", "PROBLEM", 318, 346], ["depletion", "OBSERVATION", 45, 54], ["lymphocytes count", "OBSERVATION", 72, 89], ["infection", "OBSERVATION", 145, 154], ["high", "OBSERVATION_MODIFIER", 163, 167], ["survival", "OBSERVATION_MODIFIER", 168, 176], ["disease", "OBSERVATION", 189, 196]]], ["During disease severity, remarkable thrombocytopenia was observed and confirmed by Lippi and his colleagues that revealed a reduction of platelet count among severe and died patients with COVID-19 supporting that thrombocytopenia could consider as an exacerbating indicator during the progression of the disease [78] .", [["platelet", "ANATOMY", 137, 145], ["thrombocytopenia", "DISEASE", 36, 52], ["reduction of platelet count", "DISEASE", 124, 151], ["thrombocytopenia", "DISEASE", 213, 229], ["COVID-19", "CHEMICAL", 188, 196], ["platelet", "CELL", 137, 145], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["disease severity", "PROBLEM", 7, 23], ["remarkable thrombocytopenia", "PROBLEM", 25, 52], ["a reduction of platelet count", "PROBLEM", 122, 151], ["COVID", "TEST", 188, 193], ["thrombocytopenia", "PROBLEM", 213, 229], ["an exacerbating indicator", "PROBLEM", 248, 273], ["the disease", "PROBLEM", 300, 311], ["thrombocytopenia", "OBSERVATION", 36, 52], ["reduction", "OBSERVATION_MODIFIER", 124, 133], ["platelet count", "OBSERVATION", 137, 151], ["thrombocytopenia", "OBSERVATION", 213, 229]]], ["Therefore, our findings could support Shi et al. conclusion that high WBC count with lymphopenia could be considered as a differential diagnostic criterion for COVID-19 [79] .DiscussionConsidering coagulation profile, our team observed a prolonged in most coagulation markers among severe, ICU and expired patients, especially prothrombin time, fibrinogen, Ddimer, but with normal proportions of activated partial thromboplastin time (APTT) that could focus the light on the pathogenesis of COVID-19 infection through interfering with extrinsic coagulation pathway.", [["WBC", "ANATOMY", 70, 73], ["lymphopenia", "DISEASE", 85, 96], ["COVID-19", "CHEMICAL", 491, 499], ["infection", "DISEASE", 500, 509], ["COVID-19", "CHEMICAL", 160, 168], ["COVID-19", "CHEMICAL", 491, 499], ["WBC", "CELL", 70, 73], ["patients", "ORGANISM", 306, 314], ["prothrombin", "GENE_OR_GENE_PRODUCT", 327, 338], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 345, 355], ["Ddimer", "SIMPLE_CHEMICAL", 357, 363], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 414, 428], ["APTT", "GENE_OR_GENE_PRODUCT", 435, 439], ["COVID-19", "GENE_OR_GENE_PRODUCT", 491, 499], ["coagulation markers", "PROTEIN", 256, 275], ["prothrombin", "PROTEIN", 327, 338], ["fibrinogen", "PROTEIN", 345, 355], ["Ddimer", "PROTEIN", 357, 363], ["APTT", "PROTEIN", 435, 439], ["patients", "SPECIES", 306, 314], ["COVID-19", "SPECIES", 491, 499], ["high WBC count", "PROBLEM", 65, 79], ["lymphopenia", "PROBLEM", 85, 96], ["COVID", "TEST", 160, 165], ["coagulation profile", "TEST", 197, 216], ["prothrombin time", "TEST", 327, 343], ["fibrinogen", "TEST", 345, 355], ["Ddimer", "TEST", 357, 363], ["activated partial thromboplastin time", "TREATMENT", 396, 433], ["APTT", "TEST", 435, 439], ["COVID-19 infection", "PROBLEM", 491, 509], ["extrinsic coagulation pathway", "TREATMENT", 535, 564], ["high", "OBSERVATION_MODIFIER", 65, 69], ["WBC count", "OBSERVATION_MODIFIER", 70, 79], ["lymphopenia", "OBSERVATION", 85, 96], ["infection", "OBSERVATION", 500, 509]]], ["A recently published report concluded similar findings in the form of observation of higher levels prothrombin time, D-dimer along fibrin degradation products among non-survival compared with survival patients [80] .DiscussionNumerous studies illustrated the pathogenesis action of COVID-19 with the induction of cytokine storm throughout the progressive phase of the infection [72, 81, 82] .", [["COVID-19", "CHEMICAL", 282, 290], ["infection", "DISEASE", 368, 377], ["COVID-19", "CHEMICAL", 282, 290], ["prothrombin", "GENE_OR_GENE_PRODUCT", 99, 110], ["D-dimer", "SIMPLE_CHEMICAL", 117, 124], ["fibrin", "GENE_OR_GENE_PRODUCT", 131, 137], ["patients", "ORGANISM", 201, 209], ["COVID-19", "CELL", 282, 290], ["prothrombin", "PROTEIN", 99, 110], ["D-dimer", "PROTEIN", 117, 124], ["fibrin degradation products", "PROTEIN", 131, 158], ["cytokine", "PROTEIN", 313, 321], ["patients", "SPECIES", 201, 209], ["higher levels prothrombin time", "PROBLEM", 85, 115], ["D-dimer", "TREATMENT", 117, 124], ["fibrin degradation products", "TREATMENT", 131, 158], ["Numerous studies", "TEST", 226, 242], ["COVID", "TEST", 282, 287], ["cytokine storm", "TREATMENT", 313, 327], ["the infection", "PROBLEM", 364, 377], ["infection", "OBSERVATION", 368, 377]]], ["The generation of cytokine storm within COVID-19 patients required increased levels of IFN-\u03b3 and IL-1\u03b2 that could stimulate the cellular response of T helper type 1 (Th1) which has a crucial function in the acceleration of specific immunity against COVID-19 outbreak [81] .", [["cellular", "ANATOMY", 128, 136], ["COVID-19", "CELL", 40, 48], ["patients", "ORGANISM", 49, 57], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 87, 92], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 97, 102], ["cellular", "CELL", 128, 136], ["T helper type 1", "GENE_OR_GENE_PRODUCT", 149, 164], ["Th1", "GENE_OR_GENE_PRODUCT", 166, 169], ["cytokine", "PROTEIN", 18, 26], ["IFN-\u03b3 and IL-1\u03b2", "PROTEIN", 87, 102], ["Th1", "CELL_TYPE", 166, 169], ["patients", "SPECIES", 49, 57], ["T helper type 1", "SPECIES", 149, 164], ["cytokine storm", "PROBLEM", 18, 32], ["COVID", "TEST", 40, 45], ["IFN", "TREATMENT", 87, 90], ["IL", "TREATMENT", 97, 99], ["COVID", "TEST", 249, 254], ["cytokine storm", "OBSERVATION", 18, 32], ["crucial function", "OBSERVATION", 183, 199]]], ["Due to the elevated levels of IL-2R and IL-6 accompanied by the advancement of COVID-19, several cytokines secreted by T helper type 2 (Th2) cells that could neutralize the inflammatory responses including IL-4 and IL-10 [72, 81] .", [["T helper type 2 (Th2) cells", "ANATOMY", 119, 146], ["IL-2R", "GENE_OR_GENE_PRODUCT", 30, 35], ["IL-6", "GENE_OR_GENE_PRODUCT", 40, 44], ["COVID-19", "GENE_OR_GENE_PRODUCT", 79, 87], ["T helper type 2 (Th2) cells", "CELL", 119, 146], ["IL-4", "GENE_OR_GENE_PRODUCT", 206, 210], ["IL-10", "GENE_OR_GENE_PRODUCT", 215, 220], ["IL-2R", "PROTEIN", 30, 35], ["IL-6", "PROTEIN", 40, 44], ["COVID-19", "PROTEIN", 79, 87], ["cytokines", "PROTEIN", 97, 106], ["T helper type 2 (Th2) cells", "CELL_TYPE", 119, 146], ["IL", "PROTEIN", 206, 208], ["IL", "PROTEIN", 215, 217], ["the elevated levels", "PROBLEM", 7, 26], ["IL", "TEST", 30, 32], ["IL", "TEST", 40, 42], ["COVID", "TEST", 79, 84], ["the inflammatory responses", "TEST", 169, 195], ["IL", "TEST", 206, 208], ["IL", "TEST", 215, 217], ["inflammatory", "OBSERVATION_MODIFIER", 173, 185]]], ["Our findings revealed a significantly associated with elevated levels of anti-inflammatory cytokines involving IL-6 and IL-10 among severe and expired patients with COVID-19.", [["IL-6", "GENE_OR_GENE_PRODUCT", 111, 115], ["IL-10", "GENE_OR_GENE_PRODUCT", 120, 125], ["patients", "ORGANISM", 151, 159], ["anti-inflammatory cytokines", "PROTEIN", 73, 100], ["IL-6", "PROTEIN", 111, 115], ["IL", "PROTEIN", 120, 122], ["patients", "SPECIES", 151, 159], ["Our findings", "TEST", 0, 12], ["elevated levels", "PROBLEM", 54, 69], ["anti-inflammatory cytokines", "TREATMENT", 73, 100], ["IL", "TEST", 111, 113], ["IL", "TEST", 120, 122], ["COVID", "TEST", 165, 170], ["elevated", "OBSERVATION_MODIFIER", 54, 62], ["anti-inflammatory cytokines", "OBSERVATION", 73, 100], ["severe", "OBSERVATION_MODIFIER", 132, 138]]], ["A recent study indicated a similar assumption with these findings and identified elevated levels of IL-6 and IL-10 among non-survived compared with survived patients [9] .", [["IL-6", "GENE_OR_GENE_PRODUCT", 100, 104], ["IL-10", "GENE_OR_GENE_PRODUCT", 109, 114], ["patients", "ORGANISM", 157, 165], ["IL-6", "PROTEIN", 100, 104], ["IL", "PROTEIN", 109, 111], ["patients", "SPECIES", 157, 165], ["A recent study", "TEST", 0, 14], ["elevated levels of IL", "PROBLEM", 81, 102], ["IL", "TEST", 109, 111], ["elevated", "OBSERVATION_MODIFIER", 81, 89]]], ["Another confirmation of this conclusion is confirmed by a newly published metaanalysis report that indicated an exaggerated elevation of IL-6 and IL-10 throughout the severe level of COVID-19 infection [72] .DiscussionConcerning the inflammatory markers associated with the COVID-19 pandemic, this comprehensive meta-analysis study observed higher concentrations of C-reactive protein (CRP) and procalcitonin besides elevated erythrocyte sedimentation rate (ESR) levels among severe and expired patients with COVID-19.", [["erythrocyte", "ANATOMY", 426, 437], ["COVID-19", "CHEMICAL", 183, 191], ["infection", "DISEASE", 192, 201], ["COVID-19", "CHEMICAL", 183, 191], ["COVID-19", "CHEMICAL", 509, 517], ["IL-6", "GENE_OR_GENE_PRODUCT", 137, 141], ["IL-10", "GENE_OR_GENE_PRODUCT", 146, 151], ["COVID-19", "GENE_OR_GENE_PRODUCT", 183, 191], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 366, 384], ["CRP", "GENE_OR_GENE_PRODUCT", 386, 389], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 395, 408], ["erythrocyte", "CELL", 426, 437], ["patients", "ORGANISM", 495, 503], ["IL-6", "PROTEIN", 137, 141], ["IL", "PROTEIN", 146, 148], ["C-reactive protein", "PROTEIN", 366, 384], ["CRP", "PROTEIN", 386, 389], ["procalcitonin", "PROTEIN", 395, 408], ["patients", "SPECIES", 495, 503], ["an exaggerated elevation of IL", "PROBLEM", 109, 139], ["IL", "TEST", 146, 148], ["COVID", "TEST", 183, 188], ["infection", "PROBLEM", 192, 201], ["the inflammatory markers", "PROBLEM", 229, 253], ["the COVID", "TEST", 270, 279], ["this comprehensive meta-analysis study", "TEST", 293, 331], ["C-reactive protein", "TEST", 366, 384], ["CRP", "TEST", 386, 389], ["procalcitonin", "TEST", 395, 408], ["elevated erythrocyte sedimentation rate", "PROBLEM", 417, 456], ["ESR) levels", "TEST", 458, 469], ["COVID", "TEST", 509, 514], ["exaggerated", "OBSERVATION_MODIFIER", 112, 123], ["elevation", "OBSERVATION_MODIFIER", 124, 133], ["inflammatory", "OBSERVATION_MODIFIER", 233, 245], ["elevated erythrocyte sedimentation", "OBSERVATION", 417, 451], ["severe", "OBSERVATION_MODIFIER", 476, 482]]], ["Recently, Henry et al. established a meta-analysis survey and corroborated this finding with a higher significance of CRP and procalcitonin levels [72] .", [["CRP", "GENE_OR_GENE_PRODUCT", 118, 121], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 126, 139], ["CRP", "PROTEIN", 118, 121], ["procalcitonin", "PROTEIN", 126, 139], ["a meta-analysis survey", "TEST", 35, 57], ["CRP", "TEST", 118, 121], ["procalcitonin levels", "TEST", 126, 146]]], ["Other recent reports identified higher levels of CRP among severe patients with COVID-19 infection [76] .", [["COVID-19", "CHEMICAL", 80, 88], ["infection", "DISEASE", 89, 98], ["CRP", "GENE_OR_GENE_PRODUCT", 49, 52], ["patients", "ORGANISM", 66, 74], ["CRP", "PROTEIN", 49, 52], ["patients", "SPECIES", 66, 74], ["CRP", "TEST", 49, 52], ["COVID", "TEST", 80, 85], ["infection", "PROBLEM", 89, 98], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["infection", "OBSERVATION", 89, 98]]], ["An additional meta-analysis survey established based on four recent articles indicated prolonged levels of procalcitonin among severe patients with COVID-19 [83] .", [["COVID-19", "CHEMICAL", 148, 156], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 107, 120], ["patients", "ORGANISM", 134, 142], ["procalcitonin", "PROTEIN", 107, 120], ["patients", "SPECIES", 134, 142], ["An additional meta-analysis survey", "TEST", 0, 34], ["procalcitonin", "TREATMENT", 107, 120], ["COVID", "TEST", 148, 153]]], ["In this respect, we might speculate the potential role of procalcitonin as a prognostic biomarker during the severe status of COVID-19.", [["COVID-19", "CHEMICAL", 126, 134], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 58, 71], ["procalcitonin", "PROTEIN", 58, 71], ["procalcitonin", "TREATMENT", 58, 71], ["a prognostic biomarker", "TEST", 75, 97], ["COVID", "TEST", 126, 131]]], ["Finally, our team revealed increased levels of serum ferritin among non-survived patients compared with survived patients, and this significant outcome was observed in another meta-analysis study among severe and non-survival patients with COVID-19 infection [72] .DiscussionThis comprehensive meta-analysis confronted several limitations that raised throughout the processing of the outcomes.", [["serum", "ANATOMY", 47, 52], ["COVID-19", "CHEMICAL", 240, 248], ["infection", "DISEASE", 249, 258], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["ferritin", "GENE_OR_GENE_PRODUCT", 53, 61], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 226, 234], ["serum ferritin", "PROTEIN", 47, 61], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 226, 234], ["increased levels of serum ferritin", "PROBLEM", 27, 61], ["another meta-analysis study", "TEST", 168, 195], ["COVID-19 infection", "PROBLEM", 240, 258], ["increased", "OBSERVATION_MODIFIER", 27, 36]]], ["First, the insufficient laboratory data concerning the interest of design causing the increasing bias among different covariates.", [["the increasing bias", "PROBLEM", 82, 101], ["increasing", "OBSERVATION_MODIFIER", 86, 96], ["bias", "OBSERVATION", 97, 101]]], ["Second, the variation in the characteristics among different articles concerning the severity and survival of COVID-19.", [["COVID", "TEST", 110, 115], ["variation", "OBSERVATION_MODIFIER", 12, 21]]], ["Third, the small sample sizes of some studies besides most of the concerned articles were established within China, especially Wuhan.", [["some studies", "TEST", 33, 45], ["small", "OBSERVATION_MODIFIER", 11, 16], ["sample", "OBSERVATION_MODIFIER", 17, 23], ["sizes", "OBSERVATION_MODIFIER", 24, 29]]], ["Finally, there was an observed publication bias and heterogeneity in this comprehensive meta-analysis.ConclusionIn conclusion, several laboratory parameters could associate with the severity and mortality of COVID-19 infection and should be screened and measured continuously during the progression of this pandemic.", [["COVID-19", "CHEMICAL", 208, 216], ["infection", "DISEASE", 217, 226], ["COVID-19", "CELL", 208, 216], ["COVID-19", "SPECIES", 208, 216], ["an observed publication bias", "PROBLEM", 19, 47], ["this comprehensive meta-analysis", "TEST", 69, 101], ["the severity", "PROBLEM", 178, 190], ["COVID-19 infection", "PROBLEM", 208, 226], ["this pandemic", "PROBLEM", 302, 315], ["publication bias", "OBSERVATION", 31, 47], ["heterogeneity", "OBSERVATION_MODIFIER", 52, 65], ["infection", "OBSERVATION", 217, 226]]], ["These parameters included WBCs count, lymphocytes, platelet count, prothrombin time, D-dimer, and fibrinogen.", [["WBCs", "ANATOMY", 26, 30], ["lymphocytes", "ANATOMY", 38, 49], ["platelet", "ANATOMY", 51, 59], ["WBCs", "CELL", 26, 30], ["lymphocytes", "CELL", 38, 49], ["platelet", "CELL", 51, 59], ["prothrombin", "GENE_OR_GENE_PRODUCT", 67, 78], ["D-dimer", "GENE_OR_GENE_PRODUCT", 85, 92], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 98, 108], ["WBCs", "CELL_TYPE", 26, 30], ["lymphocytes", "CELL_TYPE", 38, 49], ["prothrombin", "PROTEIN", 67, 78], ["D-dimer", "PROTEIN", 85, 92], ["fibrinogen", "PROTEIN", 98, 108], ["These parameters", "TEST", 0, 16], ["WBCs count", "TEST", 26, 36], ["lymphocytes", "TEST", 38, 49], ["platelet count", "TEST", 51, 65], ["prothrombin time", "TEST", 67, 83], ["D-dimer", "TEST", 85, 92], ["fibrinogen", "TEST", 98, 108], ["lymphocytes", "ANATOMY", 38, 49], ["platelet count", "OBSERVATION", 51, 65]]], ["Also, various interleukins could serve as antiinflammatory markers such as IL-6, and IL-10 and should be evaluated.", [["interleukins", "GENE_OR_GENE_PRODUCT", 14, 26], ["IL-6", "GENE_OR_GENE_PRODUCT", 75, 79], ["IL-10", "GENE_OR_GENE_PRODUCT", 85, 90], ["interleukins", "PROTEIN", 14, 26], ["IL-6", "PROTEIN", 75, 79], ["IL", "PROTEIN", 85, 87], ["various interleukins", "PROBLEM", 6, 26], ["antiinflammatory markers", "TEST", 42, 66], ["IL", "TEST", 75, 77]]], ["The estimation of other inflammatory biomarkers like CRP and procalcitonin could be helpful in the monitor the severity of the disease.ConclusionSupporting information S1 Table.", [["CRP", "GENE_OR_GENE_PRODUCT", 53, 56], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 61, 74], ["CRP", "PROTEIN", 53, 56], ["procalcitonin", "PROTEIN", 61, 74], ["other inflammatory biomarkers", "TEST", 18, 47], ["CRP", "TEST", 53, 56], ["procalcitonin", "TEST", 61, 74], ["the disease", "PROBLEM", 123, 134], ["inflammatory", "OBSERVATION_MODIFIER", 24, 36], ["disease", "OBSERVATION", 127, 134]]], ["The standard error provides a measure of the precision of the effect size as an estimate of the population parameter.", [["size", "OBSERVATION_MODIFIER", 69, 73]]], ["It starts with zero at the top.", [["zero", "OBSERVATION_MODIFIER", 15, 19]]], ["Studies with smaller sample sizes produce less precise estimated effects with a broader base.", [["Studies", "TEST", 0, 7], ["smaller sample sizes", "PROBLEM", 13, 33], ["smaller", "OBSERVATION_MODIFIER", 13, 20], ["sample", "OBSERVATION_MODIFIER", 21, 27], ["sizes", "OBSERVATION_MODIFIER", 28, 33], ["less precise", "OBSERVATION_MODIFIER", 42, 54], ["broader", "OBSERVATION_MODIFIER", 80, 87], ["base", "OBSERVATION_MODIFIER", 88, 92]]], ["The pooled estimated effects would be expected to scatter symmetrically around the total overall estimate of the meta-analysis (represented by the vertical line).", [["scatter", "OBSERVATION_MODIFIER", 50, 57], ["symmetrically", "OBSERVATION_MODIFIER", 58, 71], ["total", "OBSERVATION_MODIFIER", 83, 88], ["vertical line", "OBSERVATION", 147, 160]]], ["Each circle represents a study (black circle).", [["a study", "TEST", 23, 30]]], ["In the case of asymmetry, Duval and Tweedie's trim and fill method predict the missing studies (red circle).", [["asymmetry", "PROBLEM", 15, 24], ["Duval and Tweedie's trim", "TREATMENT", 26, 50], ["asymmetry", "OBSERVATION", 15, 24]]], ["Begg's and Egger's tests were performed.", [["Begg's and Egger's tests", "TEST", 0, 24]]], ["P values <0.1 were set to have a significant bias.", [["P values", "TEST", 0, 8], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["bias", "OBSERVATION", 45, 49]]]], "PMC7268958": [], "PMC7498112": [], "2785fc4d6b3ebd29f3267d262b0f398ae125d476": [["IntroductionA growing wealth of evidence supports immune surveillance and immune tolerance as key players in cancer development and progression.", [["cancer", "ANATOMY", 109, 115], ["cancer", "DISEASE", 109, 115], ["cancer", "CANCER", 109, 115], ["immune surveillance", "TEST", 50, 69], ["immune tolerance", "PROBLEM", 74, 90], ["progression", "OBSERVATION_MODIFIER", 132, 143]]], ["These observations have led to renewed interest in developing strategies that harness endogenous immunity and tilt immune equilibrium in favor of enhanced tumor killing.", [["tumor", "ANATOMY", 155, 160], ["tumor", "DISEASE", 155, 160], ["tumor", "CANCER", 155, 160], ["harness endogenous immunity", "PROBLEM", 78, 105], ["tilt immune equilibrium", "PROBLEM", 110, 133], ["enhanced tumor killing", "PROBLEM", 146, 168], ["enhanced", "OBSERVATION_MODIFIER", 146, 154], ["tumor", "OBSERVATION", 155, 160]]], ["One such strategy has been the exploitation of tumorassociated ligands and their corresponding inhibitory receptors on T cells, collectively known as immune checkpoints.", [["T cells", "ANATOMY", 119, 126], ["T cells", "CELL", 119, 126], ["tumorassociated ligands", "PROTEIN", 47, 70], ["inhibitory receptors", "PROTEIN", 95, 115], ["T cells", "CELL_TYPE", 119, 126], ["tumorassociated ligands", "PROBLEM", 47, 70], ["immune checkpoints", "TREATMENT", 150, 168]]], ["Immune checkpoints associated with the CTLA-4 and PD-1 pathways are critical modulators of immune activation, both acting to dampen the immune response.", [["CTLA-4", "GENE_OR_GENE_PRODUCT", 39, 45], ["PD-1", "GENE_OR_GENE_PRODUCT", 50, 54], ["Immune checkpoints", "TREATMENT", 0, 18], ["the CTLA", "TEST", 35, 43], ["PD", "TEST", 50, 52], ["immune activation", "PROBLEM", 91, 108], ["immune activation", "OBSERVATION", 91, 108]]], ["Mutant cancer cells may effectively \"hijack\" immune checkpoint activation through PD-1 and CTLA-4 pathways, allowing tumor cells to evade normal immune surveillance and escape immune destruction by anti-tumor T lymphocytes.", [["cancer cells", "ANATOMY", 7, 19], ["tumor cells", "ANATOMY", 117, 128], ["anti-tumor T lymphocytes", "ANATOMY", 198, 222], ["cancer", "DISEASE", 7, 13], ["tumor", "DISEASE", 117, 122], ["cancer cells", "CELL", 7, 19], ["PD-1", "GENE_OR_GENE_PRODUCT", 82, 86], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 91, 97], ["tumor cells", "CELL", 117, 128], ["anti-tumor T lymphocytes", "CELL", 198, 222], ["Mutant cancer cells", "CELL_TYPE", 0, 19], ["tumor cells", "CELL_TYPE", 117, 128], ["anti-tumor T lymphocytes", "CELL_TYPE", 198, 222], ["Mutant cancer cells", "PROBLEM", 0, 19], ["PD", "TEST", 82, 84], ["CTLA", "TEST", 91, 95], ["tumor cells", "PROBLEM", 117, 128], ["escape immune destruction", "PROBLEM", 169, 194], ["anti-tumor T lymphocytes", "PROBLEM", 198, 222], ["cancer", "OBSERVATION", 7, 13], ["tumor cells", "OBSERVATION", 117, 128]]], ["Recognition of PD-1 and CTLA-4 pathways as druggable targets in anticancer therapy has led to the successful launching of a new class of drugs, referred to as immune checkpoint inhibitors (ICIs).", [["anticancer", "ANATOMY", 64, 74], ["PD-1", "GENE_OR_GENE_PRODUCT", 15, 19], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 24, 30], ["anticancer", "CANCER", 64, 74], ["PD", "TEST", 15, 17], ["CTLA", "TEST", 24, 28], ["anticancer therapy", "TREATMENT", 64, 82], ["drugs", "TREATMENT", 137, 142], ["immune checkpoint inhibitors", "TREATMENT", 159, 187]]], ["Over the past decade, a rapidly evolving list of ICIs, including the CTLA-4 inhibitor, ipilimumab; the PD-1 inhibitors, nivolumab and pembrolizumab; and the PD-L1 inhibitors, atezolizumab, avelumab, and durvalumab have been FDA-approved in the management of a variety of solid and hematologic malignancies.", [["solid", "ANATOMY", 271, 276], ["hematologic malignancies", "ANATOMY", 281, 305], ["CTLA-4 inhibitor", "CHEMICAL", 69, 85], ["ipilimumab", "CHEMICAL", 87, 97], ["nivolumab", "CHEMICAL", 120, 129], ["pembrolizumab", "CHEMICAL", 134, 147], ["atezolizumab", "CHEMICAL", 175, 187], ["avelumab", "CHEMICAL", 189, 197], ["durvalumab", "CHEMICAL", 203, 213], ["hematologic malignancies", "DISEASE", 281, 305], ["ipilimumab", "CHEMICAL", 87, 97], ["nivolumab", "CHEMICAL", 120, 129], ["pembrolizumab", "CHEMICAL", 134, 147], ["atezolizumab", "CHEMICAL", 175, 187], ["avelumab", "CHEMICAL", 189, 197], ["durvalumab", "CHEMICAL", 203, 213], ["ICIs", "CANCER", 49, 53], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 69, 75], ["ipilimumab", "SIMPLE_CHEMICAL", 87, 97], ["PD-1", "GENE_OR_GENE_PRODUCT", 103, 107], ["nivolumab", "SIMPLE_CHEMICAL", 120, 129], ["pembrolizumab", "SIMPLE_CHEMICAL", 134, 147], ["PD-L1", "GENE_OR_GENE_PRODUCT", 157, 162], ["atezolizumab", "SIMPLE_CHEMICAL", 175, 187], ["avelumab", "SIMPLE_CHEMICAL", 189, 197], ["durvalumab", "SIMPLE_CHEMICAL", 203, 213], ["solid", "CANCER", 271, 276], ["hematologic malignancies", "CANCER", 281, 305], ["ICIs", "TREATMENT", 49, 53], ["the CTLA", "TREATMENT", 65, 73], ["ipilimumab", "TREATMENT", 87, 97], ["the PD", "TREATMENT", 99, 105], ["inhibitors", "TREATMENT", 108, 118], ["nivolumab", "TREATMENT", 120, 129], ["pembrolizumab", "TREATMENT", 134, 147], ["the PD-L1 inhibitors", "TREATMENT", 153, 173], ["atezolizumab", "TREATMENT", 175, 187], ["avelumab", "TREATMENT", 189, 197], ["durvalumab", "TREATMENT", 203, 213], ["solid and hematologic malignancies", "PROBLEM", 271, 305], ["hematologic malignancies", "OBSERVATION", 281, 305]]], ["These agents represent a paradigm shift in which the T cell, rather than the cancer cell, represents the therapeutic target.IntroductionThe use of the body's own immune defense system to fight cancer has ushered in a unique spectrum of immune-related adverse reactions (IrAEs), which can affect virtually every organ system.", [["T cell", "ANATOMY", 53, 59], ["cancer cell", "ANATOMY", 77, 88], ["body", "ANATOMY", 151, 155], ["cancer", "ANATOMY", 193, 199], ["organ", "ANATOMY", 311, 316], ["cancer", "DISEASE", 77, 83], ["cancer", "DISEASE", 193, 199], ["IrAEs", "DISEASE", 270, 275], ["T cell", "CELL", 53, 59], ["cancer cell", "CELL", 77, 88], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["cancer", "CANCER", 193, 199], ["organ", "ORGAN", 311, 316], ["T cell", "CELL_TYPE", 53, 59], ["cancer cell", "CELL_TYPE", 77, 88], ["a paradigm shift", "PROBLEM", 23, 39], ["the T cell", "PROBLEM", 49, 59], ["the cancer cell", "PROBLEM", 73, 88], ["fight cancer", "PROBLEM", 187, 199], ["immune-related adverse reactions", "PROBLEM", 236, 268], ["paradigm shift", "OBSERVATION", 25, 39], ["cancer cell", "OBSERVATION", 77, 88]]], ["Lung-related IrAEs are, fortunately, less common than toxicities to other organ systems; however, toxicity to the lung represents a potentially lethal form of IrAEs and one of the most frequent causes of drug discontinuation.", [["Lung", "ANATOMY", 0, 4], ["organ", "ANATOMY", 74, 79], ["lung", "ANATOMY", 114, 118], ["IrAEs", "DISEASE", 13, 18], ["toxicities", "DISEASE", 54, 64], ["toxicity", "DISEASE", 98, 106], ["IrAEs", "DISEASE", 159, 164], ["Lung", "ORGAN", 0, 4], ["organ", "ORGAN", 74, 79], ["lung", "ORGAN", 114, 118], ["IrAEs", "PROBLEM", 13, 18], ["toxicities to other organ systems", "PROBLEM", 54, 87], ["toxicity to the lung", "PROBLEM", 98, 118], ["IrAEs", "PROBLEM", 159, 164], ["drug discontinuation", "TREATMENT", 204, 224], ["IrAEs", "OBSERVATION", 13, 18], ["lung", "ANATOMY", 114, 118]]], ["Pneumonitis is often reported [1] [2] [3] [4] [5] [6] [7] [8] [9] , although pleural [10] , vascular [11, 12] , airway, and sarcoid-like reactions associated with mediastinal lymphadenopathy have also been described [13] [14] [15] [16] .IrAEs: pneumonitisStratification schemes that characterize pneumonitis severity are based on clinical symptoms in accordance with the common terminology criteria for adverse events (CTCAE).", [["pleural", "ANATOMY", 77, 84], ["vascular", "ANATOMY", 92, 100], ["airway", "ANATOMY", 112, 118], ["mediastinal lymphadenopathy", "ANATOMY", 163, 190], ["Pneumonitis", "DISEASE", 0, 11], ["sarcoid-like reactions", "DISEASE", 124, 146], ["mediastinal lymphadenopathy", "DISEASE", 163, 190], ["pneumonitis", "DISEASE", 244, 255], ["pneumonitis", "DISEASE", 296, 307], ["CTCAE", "DISEASE", 419, 424], ["[1] [2] [3] [4] [5] [6] [7] [8]", "CHEMICAL", 30, 61], ["[1] [2] [3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 30, 65], ["vascular [11, 12]", "SIMPLE_CHEMICAL", 92, 109], ["airway", "MULTI-TISSUE_STRUCTURE", 112, 118], ["[13] [14] [15] [16]", "SIMPLE_CHEMICAL", 216, 235], ["Pneumonitis", "PROBLEM", 0, 11], ["airway, and sarcoid-like reactions", "PROBLEM", 112, 146], ["mediastinal lymphadenopathy", "PROBLEM", 163, 190], ["pneumonitisStratification schemes", "PROBLEM", 244, 277], ["pneumonitis severity", "PROBLEM", 296, 316], ["clinical symptoms", "PROBLEM", 330, 347], ["adverse events", "PROBLEM", 403, 417], ["pleural", "ANATOMY", 77, 84], ["vascular", "ANATOMY", 92, 100], ["airway", "ANATOMY", 112, 118], ["sarcoid", "OBSERVATION", 124, 131], ["mediastinal", "ANATOMY", 163, 174], ["lymphadenopathy", "OBSERVATION", 175, 190], ["pneumonitis", "OBSERVATION", 244, 255], ["pneumonitis", "OBSERVATION", 296, 307]]], ["Hence, grade 1 pneumonitis represents radiographic changes without associated symptoms.", [["pneumonitis", "DISEASE", 15, 26], ["grade 1 pneumonitis", "PROBLEM", 7, 26], ["radiographic changes", "PROBLEM", 38, 58], ["associated symptoms", "PROBLEM", 67, 86], ["grade 1", "OBSERVATION_MODIFIER", 7, 14], ["pneumonitis", "OBSERVATION", 15, 26]]], ["Patients with grade 2 pneumonitis have mild dyspnea and/or cough.", [["pneumonitis", "DISEASE", 22, 33], ["dyspnea", "DISEASE", 44, 51], ["cough", "DISEASE", 59, 64], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["grade 2 pneumonitis", "PROBLEM", 14, 33], ["mild dyspnea", "PROBLEM", 39, 51], ["cough", "PROBLEM", 59, 64], ["grade 2", "OBSERVATION_MODIFIER", 14, 21], ["pneumonitis", "OBSERVATION", 22, 33], ["mild", "OBSERVATION_MODIFIER", 39, 43], ["dyspnea", "OBSERVATION", 44, 51], ["cough", "OBSERVATION", 59, 64]]], ["High-grade pneumonitis is indicated by severe or medically significant symptoms that are not immediately life threatening (grade 3) and life-threatening symptoms that require urgent medical attention (grade 4).IrAEs: pneumonitisRates of pneumonitis appear to be conditioned by the ICI drug class, as well as the histologic type of tumor being treated.", [["tumor", "ANATOMY", 331, 336], ["pneumonitis", "DISEASE", 11, 22], ["pneumonitis", "DISEASE", 237, 248], ["ICI", "CHEMICAL", 281, 284], ["tumor", "DISEASE", 331, 336], ["ICI", "CHEMICAL", 281, 284], ["IrAEs", "SIMPLE_CHEMICAL", 210, 215], ["ICI", "SIMPLE_CHEMICAL", 281, 284], ["tumor", "CANCER", 331, 336], ["High-grade pneumonitis", "PROBLEM", 0, 22], ["severe or medically significant symptoms", "PROBLEM", 39, 79], ["life-threatening symptoms", "PROBLEM", 136, 161], ["urgent medical attention", "TREATMENT", 175, 199], ["pneumonitisRates", "PROBLEM", 217, 233], ["pneumonitis", "PROBLEM", 237, 248], ["tumor", "PROBLEM", 331, 336], ["-grade", "OBSERVATION_MODIFIER", 4, 10], ["pneumonitis", "OBSERVATION", 11, 22], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["pneumonitis", "OBSERVATION", 237, 248], ["tumor", "OBSERVATION", 331, 336]]], ["PD-1 and PD-L1 inhibitor therapies confer a higher incidence of any grade pneumonitis (2.7-5%), as well as highgrade pneumonitis (0.8-2.0%), compared to CTLA-4 blocking agents (1.3% all grade, 0.3% high grade) when either approach is given as monotherapy [6, [17] [18] [19] [20] [21] .", [["pneumonitis", "DISEASE", 74, 85], ["pneumonitis", "DISEASE", 117, 128], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["PD-L1", "GENE_OR_GENE_PRODUCT", 9, 14], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 153, 159], ["[17] [18] [19] [20", "SIMPLE_CHEMICAL", 259, 277], ["PD", "TEST", 0, 2], ["PD-L1 inhibitor therapies", "TREATMENT", 9, 34], ["any grade pneumonitis", "PROBLEM", 64, 85], ["highgrade pneumonitis", "PROBLEM", 107, 128], ["CTLA", "TEST", 153, 157], ["4 blocking agents", "TREATMENT", 158, 175], ["monotherapy", "TREATMENT", 243, 254], ["pneumonitis", "OBSERVATION", 74, 85], ["pneumonitis", "OBSERVATION", 117, 128]]], ["Rates of pneumonitis are significantly increased with PD-1 or PD-L1 plus CTLA-4 inhibitor combinations, approaching 10% in some studies [6, 17, [22] [23] [24] [25] [26] and Fig. 1 .", [["pneumonitis", "DISEASE", 9, 20], ["PD-1", "GENE_OR_GENE_PRODUCT", 54, 58], ["PD-L1", "GENE_OR_GENE_PRODUCT", 62, 67], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 73, 79], ["pneumonitis", "PROBLEM", 9, 20], ["PD", "TEST", 54, 56], ["PD", "TEST", 62, 64], ["CTLA", "TEST", 73, 77], ["some studies", "TEST", 123, 135], ["pneumonitis", "OBSERVATION", 9, 20], ["significantly", "OBSERVATION_MODIFIER", 25, 38], ["increased", "OBSERVATION_MODIFIER", 39, 48]]], ["Pneumonitis following combination therapy is often more severe, with slower recovery periods than with monotherapy [6, 23] .", [["Pneumonitis", "DISEASE", 0, 11], ["Pneumonitis", "PROBLEM", 0, 11], ["combination therapy", "TREATMENT", 22, 41], ["monotherapy", "TREATMENT", 103, 114], ["more severe", "OBSERVATION_MODIFIER", 51, 62]]], ["Details regarding the role of CTLA-4 inhibitors in augmenting the rate and severity of pneumonitis when given in combination with PD-1/PD-L1 blocking agents have not been fully elucidated; however, clinicians should be aware of the significantly higher incidence of pneumonitis during combination therapy and patients should be closely monitored for associated signs and symptoms.", [["pneumonitis", "DISEASE", 87, 98], ["pneumonitis", "DISEASE", 266, 277], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 30, 36], ["PD-1", "GENE_OR_GENE_PRODUCT", 130, 134], ["PD-L1", "GENE_OR_GENE_PRODUCT", 135, 140], ["patients", "ORGANISM", 309, 317], ["patients", "SPECIES", 309, 317], ["CTLA-4 inhibitors", "TREATMENT", 30, 47], ["pneumonitis", "PROBLEM", 87, 98], ["PD", "TREATMENT", 130, 132], ["PD-L1 blocking agents", "TREATMENT", 135, 156], ["pneumonitis", "PROBLEM", 266, 277], ["combination therapy", "TREATMENT", 285, 304], ["associated signs and symptoms", "PROBLEM", 350, 379], ["pneumonitis", "OBSERVATION", 87, 98], ["pneumonitis", "OBSERVATION", 266, 277]]], ["In contrast to conventional chemotherapies and target therapies, ICI therapy may elicit durable effects and toxicities well beyond discontinuation of the drug, due to the induction of immunologic memory [27] .", [["ICI", "CHEMICAL", 65, 68], ["toxicities", "DISEASE", 108, 118], ["ICI", "CHEMICAL", 65, 68], ["ICI", "SIMPLE_CHEMICAL", 65, 68], ["conventional chemotherapies", "TREATMENT", 15, 42], ["target therapies", "TREATMENT", 47, 63], ["ICI therapy", "TREATMENT", 65, 76], ["toxicities", "PROBLEM", 108, 118], ["the drug", "TREATMENT", 150, 158]]], ["As a result, increased rates of pneumonitis following sequential PD-1/PD-L1 or CTLA-4 monotherapies appear similar to pneumonitis rates when ICI combinations are given concomitantly (Fig. 1) .IrAEs: pneumonitisIrAE profiles across different ICI classes appear to be driven by variations in ICI class-specific immune cell activation.", [["immune cell", "ANATOMY", 309, 320], ["pneumonitis", "DISEASE", 32, 43], ["pneumonitis", "DISEASE", 118, 129], ["ICI", "CHEMICAL", 141, 144], ["ICI", "CHEMICAL", 241, 244], ["ICI", "CHEMICAL", 290, 293], ["ICI", "CHEMICAL", 141, 144], ["ICI", "CHEMICAL", 290, 293], ["PD-1", "GENE_OR_GENE_PRODUCT", 65, 69], ["PD-L1", "GENE_OR_GENE_PRODUCT", 70, 75], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 79, 85], ["ICI", "SIMPLE_CHEMICAL", 141, 144], ["IrAEs", "SIMPLE_CHEMICAL", 192, 197], ["ICI", "SIMPLE_CHEMICAL", 290, 293], ["immune cell", "CELL", 309, 320], ["pneumonitis", "PROBLEM", 32, 43], ["sequential PD", "TEST", 54, 67], ["PD", "PROBLEM", 70, 72], ["CTLA", "TEST", 79, 83], ["4 monotherapies", "TREATMENT", 84, 99], ["pneumonitis rates", "PROBLEM", 118, 135], ["ICI combinations", "TREATMENT", 141, 157], ["pneumonitisIrAE profiles", "PROBLEM", 199, 223], ["different ICI classes", "TREATMENT", 231, 252], ["variations in ICI class", "PROBLEM", 276, 299], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["pneumonitis", "OBSERVATION", 32, 43], ["L1", "ANATOMY", 73, 75], ["pneumonitis", "OBSERVATION", 118, 129], ["immune cell activation", "OBSERVATION", 309, 331]]], ["For example, the greater risk of pneumonitis with agents targeting the PD-1/PD-L1 axis may be due to activation of lung macrophages [28, 29] .", [["lung macrophages", "ANATOMY", 115, 131], ["pneumonitis", "DISEASE", 33, 44], ["PD-1", "GENE_OR_GENE_PRODUCT", 71, 75], ["PD-L1", "GENE_OR_GENE_PRODUCT", 76, 81], ["lung macrophages", "CELL", 115, 131], ["lung macrophages", "CELL_TYPE", 115, 131], ["pneumonitis", "PROBLEM", 33, 44], ["agents", "TREATMENT", 50, 56], ["the PD", "TEST", 67, 73], ["activation of lung macrophages", "PROBLEM", 101, 131], ["greater", "OBSERVATION_MODIFIER", 17, 24], ["pneumonitis", "OBSERVATION", 33, 44], ["L1 axis", "ANATOMY", 79, 86], ["may be due to", "UNCERTAINTY", 87, 100], ["lung", "ANATOMY", 115, 119], ["macrophages", "OBSERVATION", 120, 131]]], ["Notable differences in the prevalence of pneumonitis have also been suggested within the PD-1/PD-L1 agent class, with higher rates of all grade, as well as high grade, pneumonitis reported in association with drugs that block the PD-1 axis compared to PD-L1 antagonists [22, 30] .", [["pneumonitis", "DISEASE", 41, 52], ["pneumonitis", "DISEASE", 168, 179], ["PD-1", "GENE_OR_GENE_PRODUCT", 89, 93], ["PD-L1", "GENE_OR_GENE_PRODUCT", 94, 99], ["PD-1", "GENE_OR_GENE_PRODUCT", 230, 234], ["PD-L1 antagonists", "GENE_OR_GENE_PRODUCT", 252, 269], ["pneumonitis", "PROBLEM", 41, 52], ["the PD", "TEST", 85, 91], ["high grade, pneumonitis", "PROBLEM", 156, 179], ["drugs", "TREATMENT", 209, 214], ["PD-L1 antagonists", "TREATMENT", 252, 269], ["pneumonitis", "OBSERVATION", 41, 52], ["higher", "OBSERVATION_MODIFIER", 118, 124], ["rates", "OBSERVATION_MODIFIER", 125, 130], ["all grade", "OBSERVATION_MODIFIER", 134, 143], ["high grade", "OBSERVATION_MODIFIER", 156, 166], ["pneumonitis", "OBSERVATION", 168, 179]]], ["However, other studies have not corroborated these observations [17] .", [["other studies", "TEST", 9, 22]]], ["Unlike CTLA-4-related pneumotoxicity, which appears to be dose-related, no associations between the appearance and severity of pneumonitis and the dose of PD-1/PD-L1 axis blocking agents have been reported [31, 32] .IrAEs: pneumonitisThe influence of tumor histology in the development of ICI-related pneumonitis has been increasingly recognized, with the highest incidence among patients with lung and renal cell cancers compared to other tumor types, such as melanoma [5, 6, 25] .", [["tumor", "ANATOMY", 251, 256], ["lung", "ANATOMY", 394, 398], ["renal cell cancers", "ANATOMY", 403, 421], ["tumor", "ANATOMY", 440, 445], ["melanoma", "ANATOMY", 461, 469], ["CTLA-4", "CHEMICAL", 7, 13], ["pneumotoxicity", "DISEASE", 22, 36], ["pneumonitis", "DISEASE", 127, 138], ["pneumonitis", "DISEASE", 223, 234], ["tumor", "DISEASE", 251, 256], ["ICI", "CHEMICAL", 289, 292], ["pneumonitis", "DISEASE", 301, 312], ["lung and renal cell cancers", "DISEASE", 394, 421], ["tumor", "DISEASE", 440, 445], ["melanoma", "DISEASE", 461, 469], ["ICI", "CHEMICAL", 289, 292], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 7, 13], ["PD-1", "GENE_OR_GENE_PRODUCT", 155, 159], ["PD-L1", "GENE_OR_GENE_PRODUCT", 160, 165], ["tumor", "CANCER", 251, 256], ["ICI", "SIMPLE_CHEMICAL", 289, 292], ["patients", "ORGANISM", 380, 388], ["lung", "ORGAN", 394, 398], ["renal cell cancers", "CANCER", 403, 421], ["tumor", "CANCER", 440, 445], ["melanoma", "CANCER", 461, 469], ["patients", "SPECIES", 380, 388], ["CTLA", "TEST", 7, 11], ["related pneumotoxicity", "PROBLEM", 14, 36], ["pneumonitis", "PROBLEM", 127, 138], ["PD-1/PD-L1 axis blocking agents", "TREATMENT", 155, 186], ["pneumonitis", "PROBLEM", 223, 234], ["tumor histology", "PROBLEM", 251, 266], ["ICI", "PROBLEM", 289, 292], ["related pneumonitis", "PROBLEM", 293, 312], ["lung and renal cell cancers", "PROBLEM", 394, 421], ["other tumor types", "PROBLEM", 434, 451], ["melanoma", "PROBLEM", 461, 469], ["pneumonitis", "OBSERVATION", 127, 138], ["pneumonitis", "OBSERVATION", 223, 234], ["tumor", "OBSERVATION", 251, 256], ["pneumonitis", "OBSERVATION", 301, 312], ["lung", "ANATOMY", 394, 398], ["renal", "ANATOMY", 403, 408], ["cell cancers", "OBSERVATION", 409, 421], ["tumor", "OBSERVATION", 440, 445], ["melanoma", "OBSERVATION", 461, 469]]], ["The driving forces for variations in the prevalence of pneumonitis among different tumor types are not fully understood.", [["tumor", "ANATOMY", 83, 88], ["pneumonitis", "DISEASE", 55, 66], ["tumor", "DISEASE", 83, 88], ["tumor", "CANCER", 83, 88], ["pneumonitis", "PROBLEM", 55, 66], ["pneumonitis", "OBSERVATION", 55, 66], ["tumor", "OBSERVATION", 83, 88]]], ["Existing tumor burden in the lung, prior lung irradiation, and co-morbidities, such as COPD among lung cancer patients, may limit the lung's tolerance to additional injury and explain the higher rates of pneumonitis in this group of patients [33, 34] .", [["tumor", "ANATOMY", 9, 14], ["lung", "ANATOMY", 29, 33], ["lung", "ANATOMY", 41, 45], ["lung cancer", "ANATOMY", 98, 109], ["lung", "ANATOMY", 134, 138], ["tumor", "DISEASE", 9, 14], ["COPD", "DISEASE", 87, 91], ["lung cancer", "DISEASE", 98, 109], ["pneumonitis", "DISEASE", 204, 215], ["tumor", "CANCER", 9, 14], ["lung", "ORGAN", 29, 33], ["lung", "ORGAN", 41, 45], ["lung cancer", "CANCER", 98, 109], ["patients", "ORGANISM", 110, 118], ["lung", "ORGAN", 134, 138], ["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 233, 241], ["Existing tumor burden in the lung", "PROBLEM", 0, 33], ["prior lung irradiation", "TREATMENT", 35, 57], ["co-morbidities", "PROBLEM", 63, 77], ["COPD", "PROBLEM", 87, 91], ["lung cancer", "PROBLEM", 98, 109], ["the lung's tolerance", "PROBLEM", 130, 150], ["additional injury", "PROBLEM", 154, 171], ["pneumonitis", "PROBLEM", 204, 215], ["tumor", "OBSERVATION", 9, 14], ["lung", "ANATOMY", 29, 33], ["lung", "ANATOMY", 41, 45], ["irradiation", "OBSERVATION", 46, 57], ["COPD", "OBSERVATION", 87, 91], ["lung", "ANATOMY", 98, 102], ["cancer", "OBSERVATION", 103, 109], ["lung", "ANATOMY", 134, 138], ["pneumonitis", "OBSERVATION", 204, 215]]], ["However, these co-morbid conditions may not be applicable for PD-1-treated patients with renal cancer, where the rates of pneumonitis are also high.", [["renal cancer", "ANATOMY", 89, 101], ["PD", "DISEASE", 62, 64], ["renal cancer", "DISEASE", 89, 101], ["pneumonitis", "DISEASE", 122, 133], ["PD-1", "GENE_OR_GENE_PRODUCT", 62, 66], ["patients", "ORGANISM", 75, 83], ["renal cancer", "CANCER", 89, 101], ["patients", "SPECIES", 75, 83], ["these co-morbid conditions", "PROBLEM", 9, 35], ["PD", "TEST", 62, 64], ["renal cancer", "PROBLEM", 89, 101], ["pneumonitis", "PROBLEM", 122, 133], ["renal", "ANATOMY", 89, 94], ["cancer", "OBSERVATION", 95, 101], ["pneumonitis", "OBSERVATION", 122, 133], ["high", "OBSERVATION_MODIFIER", 143, 147]]], ["Neo-antigen formation, the adaptive immune response, immune infiltrates, and the tumor microenvironment are all influenced by tumor histology and may offer additional explanations for the diversity of toxicity risk across different tumor types.", [["immune infiltrates", "ANATOMY", 53, 71], ["tumor", "ANATOMY", 81, 86], ["tumor", "ANATOMY", 126, 131], ["tumor", "ANATOMY", 232, 237], ["tumor", "DISEASE", 81, 86], ["tumor", "DISEASE", 126, 131], ["toxicity", "DISEASE", 201, 209], ["tumor", "DISEASE", 232, 237], ["Neo-antigen", "GENE_OR_GENE_PRODUCT", 0, 11], ["tumor", "CANCER", 81, 86], ["tumor", "CANCER", 126, 131], ["tumor", "CANCER", 232, 237], ["Neo-antigen formation", "PROBLEM", 0, 21], ["immune infiltrates", "PROBLEM", 53, 71], ["the tumor microenvironment", "PROBLEM", 77, 103], ["tumor histology", "TEST", 126, 141], ["toxicity risk across different tumor types", "PROBLEM", 201, 243], ["tumor", "OBSERVATION", 81, 86], ["different", "OBSERVATION_MODIFIER", 222, 231], ["tumor", "OBSERVATION", 232, 237]]], ["Pre-existing fibrotic lung disease and a history of current or prior tobacco use have been implicated in the development of ICI-related pneumotoxicity, although details of these associations have yet to be defined clearly (Fig. 2) [17, 35] .IrAEs: pneumonitisOther risk factors of uncertain significance include preexisting autoimmune disorders, chronic viral syndromes, solid organ, or hematopoietic stem cell transplantation, as patients with these disorders were excluded from early clinical trials.", [["fibrotic lung", "ANATOMY", 13, 26], ["solid organ", "ANATOMY", 371, 382], ["hematopoietic stem cell", "ANATOMY", 387, 410], ["fibrotic lung disease", "DISEASE", 13, 34], ["ICI", "CHEMICAL", 124, 127], ["pneumotoxicity", "DISEASE", 136, 150], ["autoimmune disorders", "DISEASE", 324, 344], ["chronic viral syndromes", "DISEASE", 346, 369], ["ICI", "CHEMICAL", 124, 127], ["lung", "ORGAN", 22, 26], ["tobacco", "ORGANISM", 69, 76], ["ICI", "SIMPLE_CHEMICAL", 124, 127], ["organ", "ORGAN", 377, 382], ["hematopoietic stem cell", "CELL", 387, 410], ["patients", "ORGANISM", 431, 439], ["patients", "SPECIES", 431, 439], ["tobacco", "SPECIES", 69, 76], ["Pre-existing fibrotic lung disease", "PROBLEM", 0, 34], ["ICI-related pneumotoxicity", "PROBLEM", 124, 150], ["pneumonitisOther risk factors", "PROBLEM", 248, 277], ["preexisting autoimmune disorders", "PROBLEM", 312, 344], ["chronic viral syndromes", "PROBLEM", 346, 369], ["solid organ", "PROBLEM", 371, 382], ["hematopoietic stem cell transplantation", "TREATMENT", 387, 426], ["these disorders", "PROBLEM", 445, 460], ["fibrotic", "OBSERVATION_MODIFIER", 13, 21], ["lung", "ANATOMY", 22, 26], ["disease", "OBSERVATION", 27, 34], ["autoimmune", "OBSERVATION", 324, 334], ["chronic", "OBSERVATION_MODIFIER", 346, 353], ["viral syndromes", "OBSERVATION", 354, 369], ["solid organ", "ANATOMY", 371, 382], ["hematopoietic stem cell transplantation", "OBSERVATION", 387, 426]]], ["Nonetheless, evidence from several small retrospective studies suggests that patients with pre-existing autoimmune disorders may be safely treated with ICI therapies.", [["autoimmune disorders", "DISEASE", 104, 124], ["ICI", "CHEMICAL", 152, 155], ["ICI", "CHEMICAL", 152, 155], ["patients", "ORGANISM", 77, 85], ["ICI", "SIMPLE_CHEMICAL", 152, 155], ["patients", "SPECIES", 77, 85], ["several small retrospective studies", "TEST", 27, 62], ["pre-existing autoimmune disorders", "PROBLEM", 91, 124], ["ICI therapies", "TREATMENT", 152, 165], ["several", "OBSERVATION_MODIFIER", 27, 34], ["small", "OBSERVATION_MODIFIER", 35, 40], ["autoimmune", "OBSERVATION", 104, 114]]], ["Severe and/or fatal pneumonitis in this setting has been reported rarely, thus underscoring the need for vigilance in carefully selecting and monitoring these patients [36] [37] [38] .", [["pneumonitis", "DISEASE", 20, 31], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["Severe and/or fatal pneumonitis", "PROBLEM", 0, 31], ["fatal", "OBSERVATION_MODIFIER", 14, 19], ["pneumonitis", "OBSERVATION", 20, 31]]], ["Fatal IrAEs associated with severe graft versus host disease following hematopoietic stem cell transplantation in patients with hematologic malignancies who had been previously exposed to ICI therapies have raised concerns regarding the use of ICIs in this setting [39, 40] .", [["graft", "ANATOMY", 35, 40], ["hematopoietic stem cell", "ANATOMY", 71, 94], ["hematologic malignancies", "ANATOMY", 128, 152], ["IrAEs", "DISEASE", 6, 11], ["graft versus host disease", "DISEASE", 35, 60], ["hematologic malignancies", "DISEASE", 128, 152], ["ICI", "CHEMICAL", 188, 191], ["ICI", "CHEMICAL", 188, 191], ["graft", "TISSUE", 35, 40], ["hematopoietic stem cell", "CELL", 71, 94], ["patients", "ORGANISM", 114, 122], ["hematologic malignancies", "CANCER", 128, 152], ["ICI", "SIMPLE_CHEMICAL", 188, 191], ["patients", "SPECIES", 114, 122], ["Fatal IrAEs", "PROBLEM", 0, 11], ["severe graft versus host disease", "PROBLEM", 28, 60], ["hematopoietic stem cell transplantation", "TREATMENT", 71, 110], ["hematologic malignancies", "PROBLEM", 128, 152], ["ICI therapies", "TREATMENT", 188, 201], ["ICIs", "TREATMENT", 244, 248], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["graft versus host disease", "OBSERVATION", 35, 60], ["hematopoietic stem cell transplantation", "OBSERVATION", 71, 110]]], ["These observations are concerning, particularly in the light of emerging evidence that supports the use of PD-1 inhibitors in the treatment of hematologic malignancies [41] [42] [43] .", [["hematologic malignancies", "ANATOMY", 143, 167], ["hematologic malignancies", "DISEASE", 143, 167], ["PD-1", "GENE_OR_GENE_PRODUCT", 107, 111], ["hematologic malignancies", "CANCER", 143, 167], ["PD-1 inhibitors", "TREATMENT", 107, 122], ["hematologic malignancies", "PROBLEM", 143, 167]]], ["Several small case reports have also suggested that ICI therapy may be safe in selected patients with chronic viral illnesses, such as human immunodeficiency virus infection or hepatitis C [44, 45] .", [["ICI", "CHEMICAL", 52, 55], ["chronic viral illnesses", "DISEASE", 102, 125], ["human immunodeficiency virus infection", "DISEASE", 135, 173], ["hepatitis C", "DISEASE", 177, 188], ["ICI", "CHEMICAL", 52, 55], ["ICI", "SIMPLE_CHEMICAL", 52, 55], ["patients", "ORGANISM", 88, 96], ["human immunodeficiency virus", "ORGANISM", 135, 163], ["hepatitis C", "ORGANISM", 177, 188], ["patients", "SPECIES", 88, 96], ["human immunodeficiency virus", "SPECIES", 135, 163], ["human immunodeficiency virus", "SPECIES", 135, 163], ["ICI therapy", "TREATMENT", 52, 63], ["chronic viral illnesses", "PROBLEM", 102, 125], ["human immunodeficiency virus infection", "PROBLEM", 135, 173], ["hepatitis C", "PROBLEM", 177, 188], ["small", "OBSERVATION_MODIFIER", 8, 13]]], ["However, further prospective investigations are needed and the importance of multidisciplinary collaborations involving the oncologist, pulmonologist, liver, and infectious disease specialists cannot be over-emphasized.", [["liver", "ANATOMY", 151, 156], ["liver, and infectious disease", "DISEASE", 151, 180], ["liver", "ORGAN", 151, 156], ["further prospective investigations", "TEST", 9, 43], ["liver", "ANATOMY", 151, 156]]], ["In several retrospective studies, ICI blockade in patients with pre-existing autoimmune disease elicited new IrAEs, transient flare-ups of preexisting autoimmune disease, or both.", [["ICI", "CHEMICAL", 34, 37], ["autoimmune disease", "DISEASE", 77, 95], ["IrAEs", "DISEASE", 109, 114], ["autoimmune disease", "DISEASE", 151, 169], ["ICI", "CHEMICAL", 34, 37], ["ICI", "SIMPLE_CHEMICAL", 34, 37], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["several retrospective studies", "TEST", 3, 32], ["ICI blockade", "TREATMENT", 34, 46], ["pre-existing autoimmune disease", "PROBLEM", 64, 95], ["new IrAEs", "PROBLEM", 105, 114], ["transient flare", "PROBLEM", 116, 131], ["preexisting autoimmune disease", "PROBLEM", 139, 169], ["autoimmune disease", "OBSERVATION", 77, 95], ["new", "OBSERVATION_MODIFIER", 105, 108], ["transient", "OBSERVATION_MODIFIER", 116, 125], ["flare", "OBSERVATION_MODIFIER", 126, 131], ["autoimmune disease", "OBSERVATION", 151, 169]]], ["New IrAEs and disease exacerbations were mild in most cases, although rare cases of severe and fatal pneumonitis have been reported [36] [37] [38] 46] .IrAEs: pneumonitisImmune-related pneumonitis (Ir-pneumonitis) refers to a non-infective inflammatory response that localizes to the interstitium and alveoli and results in a diverse spectrum of CT findings and histopathologic patterns.", [["interstitium", "ANATOMY", 284, 296], ["alveoli", "ANATOMY", 301, 308], ["pneumonitis", "DISEASE", 101, 112], ["IrAEs", "CHEMICAL", 152, 157], ["pneumonitis", "DISEASE", 159, 170], ["pneumonitis", "DISEASE", 185, 196], ["Ir-pneumonitis", "DISEASE", 198, 212], ["interstitium", "TISSUE", 284, 296], ["alveoli", "MULTI-TISSUE_STRUCTURE", 301, 308], ["New IrAEs", "PROBLEM", 0, 9], ["disease exacerbations", "PROBLEM", 14, 35], ["severe and fatal pneumonitis", "PROBLEM", 84, 112], ["pneumonitis", "PROBLEM", 159, 170], ["pneumonitis", "PROBLEM", 185, 196], ["Ir-pneumonitis", "PROBLEM", 198, 212], ["a non-infective inflammatory response", "PROBLEM", 224, 261], ["CT findings", "TEST", 346, 357], ["histopathologic patterns", "TEST", 362, 386], ["IrAEs", "OBSERVATION", 4, 9], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["fatal", "OBSERVATION_MODIFIER", 95, 100], ["pneumonitis", "OBSERVATION", 101, 112], ["pneumonitis", "OBSERVATION", 159, 170], ["pneumonitis", "OBSERVATION", 185, 196], ["non-infective", "OBSERVATION_MODIFIER", 226, 239], ["inflammatory", "OBSERVATION", 240, 252], ["interstitium", "ANATOMY", 284, 296], ["alveoli", "ANATOMY", 301, 308]]], ["These changes are collectively referred to as interstitial lung disease (ILD).", [["interstitial lung", "ANATOMY", 46, 63], ["interstitial lung disease", "DISEASE", 46, 71], ["ILD", "DISEASE", 73, 76], ["interstitial lung", "CANCER", 46, 63], ["interstitial lung disease (ILD)", "PROBLEM", 46, 77], ["interstitial", "ANATOMY_MODIFIER", 46, 58], ["lung", "ANATOMY", 59, 63], ["disease", "OBSERVATION", 64, 71]]], ["Three a b c d e f Fig. 1 Accelerated lung injury following sequential ICI therapy.", [["lung", "ANATOMY", 37, 41], ["lung injury", "DISEASE", 37, 48], ["ICI", "CHEMICAL", 70, 73], ["ICI", "CHEMICAL", 70, 73], ["lung", "ORGAN", 37, 41], ["ICI", "SIMPLE_CHEMICAL", 70, 73], ["a b c d e f Fig", "TREATMENT", 6, 21], ["Accelerated lung injury", "PROBLEM", 25, 48], ["sequential ICI therapy", "TREATMENT", 59, 81], ["Accelerated", "OBSERVATION_MODIFIER", 25, 36], ["lung", "ANATOMY", 37, 41], ["injury", "OBSERVATION", 42, 48], ["ICI therapy", "OBSERVATION", 70, 81]]], ["A 60year-old man with metastatic urothelial carcinoma was treated with Pembrolizumab after failing standard chemotherapy.", [["metastatic urothelial carcinoma", "ANATOMY", 22, 53], ["urothelial carcinoma", "DISEASE", 33, 53], ["Pembrolizumab", "CHEMICAL", 71, 84], ["Pembrolizumab", "CHEMICAL", 71, 84], ["man", "ORGANISM", 13, 16], ["metastatic urothelial carcinoma", "CANCER", 22, 53], ["Pembrolizumab", "SIMPLE_CHEMICAL", 71, 84], ["man", "SPECIES", 13, 16], ["metastatic urothelial carcinoma", "PROBLEM", 22, 53], ["Pembrolizumab", "TREATMENT", 71, 84], ["failing standard chemotherapy", "TREATMENT", 91, 120], ["metastatic", "OBSERVATION_MODIFIER", 22, 32], ["urothelial", "ANATOMY", 33, 43], ["carcinoma", "OBSERVATION", 44, 53]]], ["Pembrolizumab was interrupted after cycle 2 due to increased shortness of breath.", [["Pembrolizumab", "CHEMICAL", 0, 13], ["shortness of breath", "DISEASE", 61, 80], ["Pembrolizumab", "CHEMICAL", 0, 13], ["Pembrolizumab", "SIMPLE_CHEMICAL", 0, 13], ["Pembrolizumab", "TREATMENT", 0, 13], ["increased shortness of breath", "PROBLEM", 51, 80], ["increased", "OBSERVATION_MODIFIER", 51, 60]]], ["Baseline CT imaging showed bilateral subpleural reticulations over the upper and lower lobes, consistent with his known history of idiopathic pulmonary fibrosis (a, b).", [["subpleural reticulations", "ANATOMY", 37, 61], ["upper", "ANATOMY", 71, 76], ["lower lobes", "ANATOMY", 81, 92], ["pulmonary", "ANATOMY", 142, 151], ["idiopathic pulmonary fibrosis", "DISEASE", 131, 160], ["subpleural reticulations", "PATHOLOGICAL_FORMATION", 37, 61], ["upper", "ORGANISM_SUBDIVISION", 71, 76], ["lower lobes", "ORGANISM_SUBDIVISION", 81, 92], ["pulmonary", "ORGAN", 142, 151], ["Baseline CT imaging", "TEST", 0, 19], ["bilateral subpleural reticulations over the upper and lower lobes", "PROBLEM", 27, 92], ["idiopathic pulmonary fibrosis", "PROBLEM", 131, 160], ["bilateral", "ANATOMY_MODIFIER", 27, 36], ["subpleural", "ANATOMY_MODIFIER", 37, 47], ["reticulations", "OBSERVATION", 48, 61], ["upper", "ANATOMY_MODIFIER", 71, 76], ["lower lobes", "ANATOMY", 81, 92], ["consistent with", "UNCERTAINTY", 94, 109], ["idiopathic", "OBSERVATION_MODIFIER", 131, 141], ["pulmonary", "ANATOMY", 142, 151], ["fibrosis", "OBSERVATION", 152, 160]]], ["Repeat CT imaging after cycle 2 of Pembrolizumab showed marked increase in diffuse upper and lower lobe and bilateral ground glass opacities (c, d).", [["diffuse upper", "ANATOMY", 75, 88], ["lower lobe", "ANATOMY", 93, 103], ["Pembrolizumab", "CHEMICAL", 35, 48], ["Pembrolizumab", "CHEMICAL", 35, 48], ["Pembrolizumab", "SIMPLE_CHEMICAL", 35, 48], ["upper", "ORGANISM_SUBDIVISION", 83, 88], ["Repeat CT imaging", "TEST", 0, 17], ["cycle", "TEST", 24, 29], ["Pembrolizumab", "TEST", 35, 48], ["marked increase in diffuse upper and lower lobe and bilateral ground glass opacities", "PROBLEM", 56, 140], ["marked", "OBSERVATION_MODIFIER", 56, 62], ["increase", "OBSERVATION_MODIFIER", 63, 71], ["diffuse", "OBSERVATION_MODIFIER", 75, 82], ["upper", "ANATOMY_MODIFIER", 83, 88], ["lower lobe", "ANATOMY", 93, 103], ["bilateral", "ANATOMY_MODIFIER", 108, 117], ["ground glass opacities", "OBSERVATION", 118, 140]]], ["Symptoms and ground glass findings on CT nearly completely resolved with drug withdrawal and systemic corticosteroids.", [["Symptoms", "PROBLEM", 0, 8], ["ground glass findings", "PROBLEM", 13, 34], ["CT", "TEST", 38, 40], ["drug withdrawal", "PROBLEM", 73, 88], ["systemic corticosteroids", "TREATMENT", 93, 117], ["ground glass", "OBSERVATION", 13, 25], ["corticosteroids", "OBSERVATION", 102, 117]]], ["The PD-L1 inhibitor, durvalumab, given as monotherapy, was subsequently initiated.", [["durvalumab", "CHEMICAL", 21, 31], ["durvalumab", "CHEMICAL", 21, 31], ["PD-L1", "GENE_OR_GENE_PRODUCT", 4, 9], ["durvalumab", "SIMPLE_CHEMICAL", 21, 31], ["The PD-L1 inhibitor", "TREATMENT", 0, 19], ["durvalumab", "TREATMENT", 21, 31], ["monotherapy", "TREATMENT", 42, 53], ["L1", "ANATOMY", 7, 9]]], ["Three weeks after cycle 1 of durvalumab, severe and progressive symptoms of dyspnea, dry cough and hypoxia developed, resulting in admission and intubation for hypoxemic respiratory failure.", [["respiratory", "ANATOMY", 170, 181], ["durvalumab", "CHEMICAL", 29, 39], ["dyspnea", "DISEASE", 76, 83], ["dry cough", "DISEASE", 85, 94], ["hypoxia", "DISEASE", 99, 106], ["hypoxemic respiratory failure", "DISEASE", 160, 189], ["durvalumab", "CHEMICAL", 29, 39], ["durvalumab", "SIMPLE_CHEMICAL", 29, 39], ["durvalumab", "TREATMENT", 29, 39], ["severe and progressive symptoms", "PROBLEM", 41, 72], ["dyspnea", "PROBLEM", 76, 83], ["dry cough", "PROBLEM", 85, 94], ["hypoxia", "PROBLEM", 99, 106], ["intubation", "TREATMENT", 145, 155], ["hypoxemic respiratory failure", "PROBLEM", 160, 189], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["progressive", "OBSERVATION_MODIFIER", 52, 63], ["dyspnea", "OBSERVATION", 76, 83], ["dry", "OBSERVATION_MODIFIER", 85, 88], ["cough", "OBSERVATION", 89, 94], ["hypoxia", "OBSERVATION", 99, 106], ["hypoxemic", "OBSERVATION_MODIFIER", 160, 169], ["respiratory failure", "OBSERVATION", 170, 189]]], ["All cultures were negative and no malignant cells were seen on BAL fluid.", [["cultures", "ANATOMY", 4, 12], ["malignant cells", "ANATOMY", 34, 49], ["BAL fluid", "ANATOMY", 63, 72], ["malignant cells", "CELL", 34, 49], ["BAL fluid", "ORGANISM_SUBSTANCE", 63, 72], ["malignant cells", "CELL_TYPE", 34, 49], ["All cultures", "TEST", 0, 12], ["malignant cells", "PROBLEM", 34, 49], ["BAL fluid", "TEST", 63, 72], ["no", "UNCERTAINTY", 31, 33], ["malignant cells", "OBSERVATION", 34, 49]]], ["The patient continued to deteriorate despite high-dose steroids, antibiotics, and aggressive supportive care and later expired.", [["steroids", "CHEMICAL", 55, 63], ["steroids", "CHEMICAL", 55, 63], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["high-dose steroids", "TREATMENT", 45, 63], ["antibiotics", "TREATMENT", 65, 76], ["aggressive supportive care", "TREATMENT", 82, 108]]], ["An autopsy report confirmed diffuse alveolar damage with pulmonary fibrosis felt to be related to ICI therapy distinct lung injury patterns predominate: nonspecific interstitial pneumonitis (NSIP), organizing pneumonia (OP), and diffuse alveolar damage (DAD).", [["alveolar", "ANATOMY", 36, 44], ["pulmonary", "ANATOMY", 57, 66], ["lung", "ANATOMY", 119, 123], ["interstitial", "ANATOMY", 165, 177], ["alveolar", "ANATOMY", 237, 245], ["alveolar damage", "DISEASE", 36, 51], ["pulmonary fibrosis", "DISEASE", 57, 75], ["ICI", "CHEMICAL", 98, 101], ["lung injury", "DISEASE", 119, 130], ["interstitial pneumonitis", "DISEASE", 165, 189], ["NSIP", "DISEASE", 191, 195], ["pneumonia", "DISEASE", 209, 218], ["OP", "DISEASE", 220, 222], ["alveolar damage", "DISEASE", 237, 252], ["DAD", "DISEASE", 254, 257], ["ICI", "CHEMICAL", 98, 101], ["alveolar", "TISSUE", 36, 44], ["pulmonary", "ORGAN", 57, 66], ["ICI", "SIMPLE_CHEMICAL", 98, 101], ["lung", "ORGAN", 119, 123], ["alveolar", "MULTI-TISSUE_STRUCTURE", 237, 245], ["An autopsy", "TEST", 0, 10], ["diffuse alveolar damage", "PROBLEM", 28, 51], ["pulmonary fibrosis", "PROBLEM", 57, 75], ["ICI therapy", "TREATMENT", 98, 109], ["distinct lung injury patterns", "PROBLEM", 110, 139], ["nonspecific interstitial pneumonitis", "PROBLEM", 153, 189], ["NSIP)", "PROBLEM", 191, 196], ["organizing pneumonia (OP)", "PROBLEM", 198, 223], ["diffuse alveolar damage", "PROBLEM", 229, 252], ["diffuse", "OBSERVATION_MODIFIER", 28, 35], ["alveolar", "ANATOMY_MODIFIER", 36, 44], ["damage", "OBSERVATION", 45, 51], ["pulmonary", "ANATOMY", 57, 66], ["fibrosis", "OBSERVATION", 67, 75], ["felt to be related to", "UNCERTAINTY", 76, 97], ["ICI therapy", "OBSERVATION", 98, 109], ["lung", "ANATOMY", 119, 123], ["injury", "OBSERVATION", 124, 130], ["nonspecific", "OBSERVATION_MODIFIER", 153, 164], ["interstitial", "ANATOMY_MODIFIER", 165, 177], ["pneumonitis", "OBSERVATION", 178, 189], ["NSIP", "OBSERVATION", 191, 195], ["organizing", "OBSERVATION_MODIFIER", 198, 208], ["pneumonia", "OBSERVATION", 209, 218], ["diffuse", "OBSERVATION_MODIFIER", 229, 236], ["alveolar", "ANATOMY_MODIFIER", 237, 245], ["damage", "OBSERVATION", 246, 252]]], ["Other reported findings include diffuse alveolar hemorrhage (DAH), hypersensitivity pneumonitis (HP), acute interstitial pneumonitis (AIP), acute respiratory distress syndrome (ARDS), pulmonary fibrosis (PF), and sarcoid-like reactions with lymphadenopathy [47] .IrAEs: pneumonitisCT imaging is the preferred imaging modality due to its higher sensitivity and specificity in the detection of interstitial lung disease [48, 49] .", [["alveolar", "ANATOMY", 40, 48], ["interstitial", "ANATOMY", 108, 120], ["respiratory", "ANATOMY", 146, 157], ["pulmonary", "ANATOMY", 184, 193], ["interstitial lung", "ANATOMY", 392, 409], ["alveolar hemorrhage", "DISEASE", 40, 59], ["DAH", "DISEASE", 61, 64], ["hypersensitivity pneumonitis", "DISEASE", 67, 95], ["HP", "DISEASE", 97, 99], ["interstitial pneumonitis", "DISEASE", 108, 132], ["AIP", "DISEASE", 134, 137], ["acute respiratory distress syndrome", "DISEASE", 140, 175], ["ARDS", "DISEASE", 177, 181], ["pulmonary fibrosis", "DISEASE", 184, 202], ["PF", "DISEASE", 204, 206], ["sarcoid-like reactions", "DISEASE", 213, 235], ["lymphadenopathy", "DISEASE", 241, 256], ["interstitial lung disease", "DISEASE", 392, 417], ["alveolar", "MULTI-TISSUE_STRUCTURE", 40, 48], ["pulmonary", "ORGAN", 184, 193], ["IrAEs", "SIMPLE_CHEMICAL", 263, 268], ["interstitial", "CANCER", 392, 404], ["lung", "ORGAN", 405, 409], ["diffuse alveolar hemorrhage", "PROBLEM", 32, 59], ["DAH)", "PROBLEM", 61, 65], ["hypersensitivity pneumonitis (HP)", "PROBLEM", 67, 100], ["acute interstitial pneumonitis", "PROBLEM", 102, 132], ["AIP)", "PROBLEM", 134, 138], ["acute respiratory distress syndrome", "PROBLEM", 140, 175], ["ARDS)", "PROBLEM", 177, 182], ["pulmonary fibrosis (PF)", "PROBLEM", 184, 207], ["sarcoid", "PROBLEM", 213, 220], ["like reactions", "PROBLEM", 221, 235], ["lymphadenopathy", "PROBLEM", 241, 256], ["pneumonitisCT imaging", "TEST", 270, 291], ["imaging modality", "TEST", 309, 325], ["interstitial lung disease", "PROBLEM", 392, 417], ["diffuse", "OBSERVATION_MODIFIER", 32, 39], ["alveolar", "ANATOMY_MODIFIER", 40, 48], ["hemorrhage", "OBSERVATION", 49, 59], ["DAH", "OBSERVATION", 61, 64], ["hypersensitivity", "OBSERVATION_MODIFIER", 67, 83], ["pneumonitis", "OBSERVATION", 84, 95], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["interstitial", "ANATOMY_MODIFIER", 108, 120], ["pneumonitis", "OBSERVATION", 121, 132], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory distress syndrome", "OBSERVATION", 146, 175], ["ARDS", "OBSERVATION", 177, 181], ["pulmonary", "ANATOMY", 184, 193], ["fibrosis", "OBSERVATION", 194, 202], ["sarcoid", "OBSERVATION", 213, 220], ["lymphadenopathy", "OBSERVATION", 241, 256], ["interstitial", "ANATOMY_MODIFIER", 392, 404], ["lung", "ANATOMY", 405, 409], ["disease", "OBSERVATION", 410, 417]]], ["Ground glass opacities, consolidations, and reticular markings with sub-pleural and bibasilar predominance are common radiographic features of many lung injury patterns.", [["reticular", "ANATOMY", 44, 53], ["pleural", "ANATOMY", 72, 79], ["lung", "ANATOMY", 148, 152], ["lung injury", "DISEASE", 148, 159], ["pleural", "MULTI-TISSUE_STRUCTURE", 72, 79], ["lung", "ORGAN", 148, 152], ["Ground glass opacities", "PROBLEM", 0, 22], ["consolidations", "PROBLEM", 24, 38], ["reticular markings", "PROBLEM", 44, 62], ["sub-pleural and bibasilar predominance", "PROBLEM", 68, 106], ["many lung injury patterns", "PROBLEM", 143, 168], ["glass opacities", "OBSERVATION", 7, 22], ["consolidations", "OBSERVATION", 24, 38], ["reticular", "ANATOMY_MODIFIER", 44, 53], ["markings", "OBSERVATION", 54, 62], ["sub", "OBSERVATION_MODIFIER", 68, 71], ["pleural", "ANATOMY", 72, 79], ["bibasilar", "ANATOMY_MODIFIER", 84, 93], ["predominance", "OBSERVATION", 94, 106], ["many", "OBSERVATION_MODIFIER", 143, 147], ["lung", "ANATOMY", 148, 152], ["injury", "OBSERVATION", 153, 159]]], ["Various imaging characteristics may suggest different lung injury patterns.", [["lung", "ANATOMY", 54, 58], ["lung injury", "DISEASE", 54, 65], ["lung", "ORGAN", 54, 58], ["Various imaging", "TEST", 0, 15], ["different lung injury patterns", "PROBLEM", 44, 74], ["may suggest", "UNCERTAINTY", 32, 43], ["different", "OBSERVATION_MODIFIER", 44, 53], ["lung", "ANATOMY", 54, 58], ["injury", "OBSERVATION", 59, 65]]], ["For example, ground glass and consolidative opacities that localize predominantly to the lung periphery with the reverse halo sign are classic findings of OP (Fig. 3) .", [["lung periphery", "ANATOMY", 89, 103], ["OP", "CHEMICAL", 155, 157], ["lung periphery", "MULTI-TISSUE_STRUCTURE", 89, 103], ["ground glass and consolidative opacities", "PROBLEM", 13, 53], ["the reverse halo sign", "PROBLEM", 109, 130], ["ground glass", "OBSERVATION", 13, 25], ["consolidative", "OBSERVATION_MODIFIER", 30, 43], ["opacities", "OBSERVATION", 44, 53], ["predominantly", "OBSERVATION_MODIFIER", 68, 81], ["lung", "ANATOMY", 89, 93], ["periphery", "ANATOMY_MODIFIER", 94, 103], ["reverse halo", "OBSERVATION", 113, 125]]], ["Ground glass opacities, reticular infiltrates, and traction bronchiectasis with sub-pleural sparing characterizes NSIP.", [["reticular infiltrates", "ANATOMY", 24, 45], ["pleural", "ANATOMY", 84, 91], ["bronchiectasis", "DISEASE", 60, 74], ["NSIP", "DISEASE", 114, 118], ["Ground glass opacities", "PROBLEM", 0, 22], ["reticular infiltrates", "PROBLEM", 24, 45], ["traction bronchiectasis", "PROBLEM", 51, 74], ["sub-pleural sparing", "PROBLEM", 80, 99], ["NSIP", "PROBLEM", 114, 118], ["glass opacities", "OBSERVATION", 7, 22], ["reticular", "OBSERVATION_MODIFIER", 24, 33], ["infiltrates", "OBSERVATION", 34, 45], ["traction", "OBSERVATION_MODIFIER", 51, 59], ["bronchiectasis", "OBSERVATION", 60, 74], ["sub", "OBSERVATION_MODIFIER", 80, 83], ["pleural", "ANATOMY", 84, 91], ["sparing", "OBSERVATION", 92, 99], ["NSIP", "OBSERVATION", 114, 118]]], ["The typical radiographic findings of DAD/ARDS include alveolar inflammation and edema with deposition of collagen as the disease progresses.", [["alveolar", "ANATOMY", 54, 62], ["edema", "ANATOMY", 80, 85], ["DAD", "DISEASE", 37, 40], ["ARDS", "DISEASE", 41, 45], ["alveolar inflammation", "DISEASE", 54, 75], ["edema", "DISEASE", 80, 85], ["alveolar", "TISSUE", 54, 62], ["edema", "PATHOLOGICAL_FORMATION", 80, 85], ["collagen", "GENE_OR_GENE_PRODUCT", 105, 113], ["collagen", "PROTEIN", 105, 113], ["DAD", "PROBLEM", 37, 40], ["ARDS", "PROBLEM", 41, 45], ["alveolar inflammation", "PROBLEM", 54, 75], ["edema", "PROBLEM", 80, 85], ["deposition of collagen", "TREATMENT", 91, 113], ["ARDS", "OBSERVATION", 41, 45], ["alveolar", "ANATOMY_MODIFIER", 54, 62], ["inflammation", "OBSERVATION", 63, 75], ["edema", "OBSERVATION", 80, 85], ["deposition", "OBSERVATION_MODIFIER", 91, 101], ["collagen", "OBSERVATION_MODIFIER", 105, 113], ["disease", "OBSERVATION", 121, 128]]], ["However, the classic features of each major pattern of lung injury are not pathognomonic for ICI-related pneumonitis [17] .", [["lung", "ANATOMY", 55, 59], ["lung injury", "DISEASE", 55, 66], ["ICI", "CHEMICAL", 93, 96], ["pneumonitis", "DISEASE", 105, 116], ["ICI", "CHEMICAL", 93, 96], ["lung", "ORGAN", 55, 59], ["lung injury", "PROBLEM", 55, 66], ["ICI", "PROBLEM", 93, 96], ["pneumonitis", "PROBLEM", 105, 116], ["lung", "ANATOMY", 55, 59], ["injury", "OBSERVATION", 60, 66], ["pneumonitis", "OBSERVATION", 105, 116]]], ["Moreover, imaging findings are not sufficiently sensitive to distinguish ICI-related pneumonitis from other causes of pneumonitis.IrAEs: pneumonitisClinical presentations are highly variable and may range from asymptomatic changes on chest imaging studies, to cough, mild dyspnea, and tachypnea, or to severe dyspnea, which rapidly progresses to fulminant respiratory failure.", [["chest", "ANATOMY", 234, 239], ["respiratory", "ANATOMY", 356, 367], ["ICI", "CHEMICAL", 73, 76], ["pneumonitis", "DISEASE", 85, 96], ["pneumonitis", "DISEASE", 118, 129], ["IrAEs", "DISEASE", 130, 135], ["pneumonitis", "DISEASE", 137, 148], ["cough", "DISEASE", 260, 265], ["dyspnea", "DISEASE", 272, 279], ["tachypnea", "DISEASE", 285, 294], ["dyspnea", "DISEASE", 309, 316], ["respiratory failure", "DISEASE", 356, 375], ["ICI", "CHEMICAL", 73, 76], ["ICI", "SIMPLE_CHEMICAL", 73, 76], ["imaging findings", "TEST", 10, 26], ["ICI", "PROBLEM", 73, 76], ["pneumonitis", "PROBLEM", 85, 96], ["pneumonitis", "PROBLEM", 118, 129], ["pneumonitis", "PROBLEM", 137, 148], ["asymptomatic changes", "PROBLEM", 210, 230], ["chest imaging studies", "TEST", 234, 255], ["cough", "PROBLEM", 260, 265], ["mild dyspnea", "PROBLEM", 267, 279], ["tachypnea", "PROBLEM", 285, 294], ["severe dyspnea", "PROBLEM", 302, 316], ["fulminant respiratory failure", "PROBLEM", 346, 375], ["pneumonitis", "OBSERVATION", 85, 96], ["pneumonitis", "OBSERVATION", 118, 129], ["pneumonitis", "OBSERVATION", 137, 148], ["chest", "ANATOMY", 234, 239], ["mild", "OBSERVATION_MODIFIER", 267, 271], ["dyspnea", "OBSERVATION", 272, 279], ["tachypnea", "OBSERVATION", 285, 294], ["severe", "OBSERVATION_MODIFIER", 302, 308], ["dyspnea", "OBSERVATION", 309, 316], ["fulminant", "OBSERVATION_MODIFIER", 346, 355], ["respiratory failure", "OBSERVATION", 356, 375]]], ["Low-grade fevers and chest pain are less commonly described.", [["chest", "ANATOMY", 21, 26], ["fevers", "DISEASE", 10, 16], ["chest pain", "DISEASE", 21, 31], ["chest", "ORGANISM_SUBDIVISION", 21, 26], ["Low-grade fevers", "PROBLEM", 0, 16], ["chest pain", "PROBLEM", 21, 31], ["-grade", "OBSERVATION_MODIFIER", 3, 9], ["fevers", "OBSERVATION", 10, 16], ["chest", "ANATOMY", 21, 26], ["pain", "OBSERVATION", 27, 31], ["less commonly", "OBSERVATION_MODIFIER", 36, 49]]], ["These signs and symptoms are often mistaken for disease progression, infection, or lymphangitic carcinomatosis.", [["lymphangitic carcinomatosis", "ANATOMY", 83, 110], ["infection", "DISEASE", 69, 78], ["lymphangitic carcinomatosis", "DISEASE", 83, 110], ["lymphangitic carcinomatosis", "CANCER", 83, 110], ["These signs", "TEST", 0, 11], ["symptoms", "PROBLEM", 16, 24], ["disease progression", "PROBLEM", 48, 67], ["infection", "PROBLEM", 69, 78], ["lymphangitic carcinomatosis", "PROBLEM", 83, 110], ["infection", "OBSERVATION", 69, 78], ["lymphangitic carcinomatosis", "OBSERVATION", 83, 110]]], ["Clinicians should, therefore, maintain a high index of suspicion among ICI-treated patients who present with pulmonary symptoms or abnormalities on lung imaging studies.IrAEs: pneumonitisThe time of onset of pneumonitis is broad (2.5-21 months).", [["pulmonary", "ANATOMY", 109, 118], ["lung", "ANATOMY", 148, 152], ["ICI", "CHEMICAL", 71, 74], ["pneumonitis", "DISEASE", 176, 187], ["pneumonitis", "DISEASE", 208, 219], ["ICI", "CHEMICAL", 71, 74], ["ICI", "SIMPLE_CHEMICAL", 71, 74], ["patients", "ORGANISM", 83, 91], ["pulmonary", "ORGAN", 109, 118], ["lung", "ORGAN", 148, 152], ["patients", "SPECIES", 83, 91], ["pulmonary symptoms", "PROBLEM", 109, 127], ["abnormalities", "PROBLEM", 131, 144], ["lung imaging studies", "TEST", 148, 168], ["pneumonitis", "PROBLEM", 176, 187], ["pneumonitis", "PROBLEM", 208, 219], ["pulmonary", "ANATOMY", 109, 118], ["lung", "ANATOMY", 148, 152], ["pneumonitis", "OBSERVATION", 176, 187], ["pneumonitis", "OBSERVATION", 208, 219], ["broad", "OBSERVATION_MODIFIER", 223, 228]]], ["On average, signs and symptoms occur 4.6 months after exposure to ICI monotherapy, but may develop considerably earlier (average 2.5 months) following ICI combination therapy.", [["ICI", "CHEMICAL", 66, 69], ["ICI", "CHEMICAL", 151, 154], ["ICI", "CHEMICAL", 66, 69], ["ICI", "CHEMICAL", 151, 154], ["ICI", "SIMPLE_CHEMICAL", 66, 69], ["ICI", "SIMPLE_CHEMICAL", 151, 154], ["signs and symptoms", "PROBLEM", 12, 30], ["ICI monotherapy", "TREATMENT", 66, 81], ["ICI combination therapy", "TREATMENT", 151, 174]]], ["Triggers for delayed pneumonitis, occurring greater than 6 months after initiation of therapy, are unknown.", [["pneumonitis", "DISEASE", 21, 32], ["delayed pneumonitis", "PROBLEM", 13, 32], ["therapy", "TREATMENT", 86, 93], ["pneumonitis", "OBSERVATION", 21, 32]]], ["Nonetheless, prolonged treatment does not appear to result in an increased cumulative incidence of pneumonitis or other IrAEs.", [["pneumonitis", "DISEASE", 99, 110], ["IrAEs", "DISEASE", 120, 125], ["prolonged treatment", "TREATMENT", 13, 32], ["an increased cumulative incidence of pneumonitis", "PROBLEM", 62, 110], ["other IrAEs", "PROBLEM", 114, 125], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["cumulative", "OBSERVATION_MODIFIER", 75, 85], ["pneumonitis", "OBSERVATION", 99, 110]]], ["NSCLC and drug re-challenge after resolution of a prior pneumonitis event have also been associated with earlier symptom onset (median 2.7 months) [17, 25, 35, 50] .IrAEs: pneumonitisThe diagnosis of ICI-related pneumonitis is established based on a compatible history and findings on CT, coupled with the exclusion of competing diagnoses, such as infection, lymphangitic spread of tumor, alveolar hemorrhage, or vasculitis (Table 1) .", [["NSCLC", "ANATOMY", 0, 5], ["lymphangitic", "ANATOMY", 359, 371], ["tumor", "ANATOMY", 382, 387], ["alveolar", "ANATOMY", 389, 397], ["NSCLC", "DISEASE", 0, 5], ["pneumonitis", "DISEASE", 56, 67], ["pneumonitis", "DISEASE", 172, 183], ["ICI", "CHEMICAL", 200, 203], ["pneumonitis", "DISEASE", 212, 223], ["infection", "DISEASE", 348, 357], ["tumor", "DISEASE", 382, 387], ["alveolar hemorrhage", "DISEASE", 389, 408], ["vasculitis", "DISEASE", 413, 423], ["ICI", "CHEMICAL", 200, 203], ["NSCLC", "CANCER", 0, 5], ["ICI", "SIMPLE_CHEMICAL", 200, 203], ["tumor", "CANCER", 382, 387], ["alveolar", "MULTI-TISSUE_STRUCTURE", 389, 397], ["NSCLC", "PROBLEM", 0, 5], ["drug re-challenge", "TREATMENT", 10, 27], ["a prior pneumonitis", "PROBLEM", 48, 67], ["pneumonitis", "PROBLEM", 172, 183], ["ICI", "PROBLEM", 200, 203], ["related pneumonitis", "PROBLEM", 204, 223], ["CT", "TEST", 285, 287], ["infection", "PROBLEM", 348, 357], ["lymphangitic spread of tumor", "PROBLEM", 359, 387], ["alveolar hemorrhage", "PROBLEM", 389, 408], ["vasculitis", "PROBLEM", 413, 423], ["pneumonitis", "OBSERVATION", 56, 67], ["pneumonitis", "OBSERVATION", 172, 183], ["pneumonitis", "OBSERVATION", 212, 223], ["infection", "OBSERVATION", 348, 357], ["lymphangitic", "OBSERVATION_MODIFIER", 359, 371], ["tumor", "OBSERVATION", 382, 387], ["alveolar", "ANATOMY", 389, 397], ["hemorrhage", "OBSERVATION", 398, 408], ["vasculitis", "OBSERVATION", 413, 423]]], ["Fiberoptic bronchoscopy with bronchoscopic alveolar lavage (BAL) is an important tool in the diagnostic work-up and should be performed early in the course of evaluation on all patients with unexplained symptomatic (grade 2 Fig. 2 Ipilimumab-related accelerated lung injury in a patient with preexisting pulmonary fibrosis.", [["alveolar lavage", "ANATOMY", 43, 58], ["BAL", "ANATOMY", 60, 63], ["lung", "ANATOMY", 262, 266], ["pulmonary", "ANATOMY", 304, 313], ["Ipilimumab", "CHEMICAL", 231, 241], ["lung injury", "DISEASE", 262, 273], ["pulmonary fibrosis", "DISEASE", 304, 322], ["Ipilimumab", "CHEMICAL", 231, 241], ["patients", "ORGANISM", 177, 185], ["Ipilimumab", "SIMPLE_CHEMICAL", 231, 241], ["lung", "ORGAN", 262, 266], ["patient", "ORGANISM", 279, 286], ["pulmonary", "ORGAN", 304, 313], ["patients", "SPECIES", 177, 185], ["patient", "SPECIES", 279, 286], ["Fiberoptic bronchoscopy", "TEST", 0, 23], ["bronchoscopic alveolar lavage", "TEST", 29, 58], ["evaluation", "TEST", 159, 169], ["unexplained symptomatic (grade 2 Fig", "PROBLEM", 191, 227], ["Ipilimumab", "TREATMENT", 231, 241], ["accelerated lung injury", "PROBLEM", 250, 273], ["preexisting pulmonary fibrosis", "PROBLEM", 292, 322], ["alveolar", "ANATOMY", 43, 51], ["lavage", "OBSERVATION", 52, 58], ["Ipilimumab", "OBSERVATION", 231, 241], ["accelerated", "OBSERVATION_MODIFIER", 250, 261], ["lung", "ANATOMY", 262, 266], ["injury", "OBSERVATION", 267, 273], ["pulmonary", "ANATOMY", 304, 313], ["fibrosis", "OBSERVATION", 314, 322]]], ["Severe cough and dyspnea developed 3 weeks after initiation of ipilimumab monotherapy for metastatic prostate cancer.", [["metastatic prostate cancer", "ANATOMY", 90, 116], ["cough", "DISEASE", 7, 12], ["dyspnea", "DISEASE", 17, 24], ["ipilimumab", "CHEMICAL", 63, 73], ["prostate cancer", "DISEASE", 101, 116], ["ipilimumab", "SIMPLE_CHEMICAL", 63, 73], ["prostate cancer", "CANCER", 101, 116], ["Severe cough", "PROBLEM", 0, 12], ["dyspnea", "PROBLEM", 17, 24], ["ipilimumab monotherapy", "TREATMENT", 63, 85], ["metastatic prostate cancer", "PROBLEM", 90, 116], ["cough", "OBSERVATION", 7, 12], ["dyspnea", "OBSERVATION", 17, 24], ["metastatic", "OBSERVATION_MODIFIER", 90, 100], ["prostate", "ANATOMY", 101, 109], ["cancer", "OBSERVATION", 110, 116]]], ["At baseline (a, b), CT imaging showed mild fibrotic changes, consistent with the patient's known history of idiopathic pulmonary fibrosis.", [["pulmonary", "ANATOMY", 119, 128], ["idiopathic pulmonary fibrosis", "DISEASE", 108, 137], ["patient", "ORGANISM", 81, 88], ["pulmonary", "ORGAN", 119, 128], ["patient", "SPECIES", 81, 88], ["CT imaging", "TEST", 20, 30], ["mild fibrotic changes", "PROBLEM", 38, 59], ["idiopathic pulmonary fibrosis", "PROBLEM", 108, 137], ["mild", "OBSERVATION_MODIFIER", 38, 42], ["fibrotic", "OBSERVATION", 43, 51], ["consistent with", "UNCERTAINTY", 61, 76], ["idiopathic", "OBSERVATION_MODIFIER", 108, 118], ["pulmonary", "ANATOMY", 119, 128], ["fibrosis", "OBSERVATION", 129, 137]]], ["The chest CT on admission showed significant progression of pulmonary fibrosis (c, d) in the upper and lower lobes, which progressed despite withdrawal of the agent and initiation of highdose steroids.", [["chest", "ANATOMY", 4, 9], ["pulmonary", "ANATOMY", 60, 69], ["upper", "ANATOMY", 93, 98], ["lower lobes", "ANATOMY", 103, 114], ["pulmonary fibrosis", "DISEASE", 60, 78], ["steroids", "CHEMICAL", 192, 200], ["highdose steroids", "CHEMICAL", 183, 200], ["pulmonary", "ORGAN", 60, 69], ["upper", "ORGANISM_SUBDIVISION", 93, 98], ["lower lobes", "ORGANISM_SUBDIVISION", 103, 114], ["highdose steroids", "SIMPLE_CHEMICAL", 183, 200], ["The chest CT", "TEST", 0, 12], ["pulmonary fibrosis", "PROBLEM", 60, 78], ["the agent", "TREATMENT", 155, 164], ["highdose steroids", "TREATMENT", 183, 200], ["chest", "ANATOMY", 4, 9], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["progression", "OBSERVATION_MODIFIER", 45, 56], ["pulmonary", "ANATOMY", 60, 69], ["fibrosis", "OBSERVATION", 70, 78], ["upper", "ANATOMY_MODIFIER", 93, 98], ["lower lobes", "ANATOMY", 103, 114]]], ["BAL fluids were culture negative.", [["BAL fluids", "ANATOMY", 0, 10], ["BAL fluids", "ORGANISM_SUBSTANCE", 0, 10], ["BAL fluids", "TEST", 0, 10], ["culture", "TEST", 16, 23]]], ["Lung biopsies demonstrated interstitial inflammation and fibrosis, consistent with NSIP, which was thought to be due to Ipilimumab therapy or higher) pulmonary infiltrates to rule out alternative diagnoses.", [["Lung", "ANATOMY", 0, 4], ["interstitial", "ANATOMY", 27, 39], ["pulmonary", "ANATOMY", 150, 159], ["interstitial inflammation", "DISEASE", 27, 52], ["fibrosis", "DISEASE", 57, 65], ["NSIP", "DISEASE", 83, 87], ["Ipilimumab", "CHEMICAL", 120, 130], ["Ipilimumab", "CHEMICAL", 120, 130], ["Lung biopsies", "MULTI-TISSUE_STRUCTURE", 0, 13], ["Ipilimumab", "SIMPLE_CHEMICAL", 120, 130], ["pulmonary", "ORGAN", 150, 159], ["Lung biopsies", "TEST", 0, 13], ["interstitial inflammation", "PROBLEM", 27, 52], ["fibrosis", "PROBLEM", 57, 65], ["NSIP", "PROBLEM", 83, 87], ["Ipilimumab therapy", "TREATMENT", 120, 138], ["higher) pulmonary infiltrates", "PROBLEM", 142, 171], ["biopsies", "OBSERVATION", 5, 13], ["interstitial", "ANATOMY_MODIFIER", 27, 39], ["inflammation", "OBSERVATION", 40, 52], ["fibrosis", "OBSERVATION", 57, 65], ["consistent with", "UNCERTAINTY", 67, 82], ["NSIP", "OBSERVATION", 83, 87], ["thought to be due to", "UNCERTAINTY", 99, 119], ["Ipilimumab therapy", "OBSERVATION", 120, 138], ["pulmonary", "ANATOMY", 150, 159], ["infiltrates", "OBSERVATION", 160, 171]]], ["Systemic corticosteroids are the cornerstone of therapy in patients with pneumonitis grades 2 or higher and, thus, bronchoscopy to exclude an infectious etiology before initiation of steroid therapy is recommended.", [["pneumonitis", "DISEASE", 73, 84], ["steroid", "CHEMICAL", 183, 190], ["corticosteroids", "CHEMICAL", 9, 24], ["steroid", "CHEMICAL", 183, 190], ["patients", "ORGANISM", 59, 67], ["steroid", "SIMPLE_CHEMICAL", 183, 190], ["patients", "SPECIES", 59, 67], ["Systemic corticosteroids", "TREATMENT", 0, 24], ["therapy", "TREATMENT", 48, 55], ["pneumonitis grades 2", "PROBLEM", 73, 93], ["bronchoscopy", "TEST", 115, 127], ["steroid therapy", "TREATMENT", 183, 198], ["corticosteroids", "OBSERVATION", 9, 24], ["pneumonitis", "OBSERVATION", 73, 84], ["higher", "OBSERVATION_MODIFIER", 97, 103], ["infectious", "OBSERVATION", 142, 152]]], ["Patients with suspected pneumonitis grades 2 or higher are Culture and PCR analysis of BAL fluid should be performed to evaluate for infectious causes of pneumonia; however, negative cultures may not definitively exclude infection.", [["BAL fluid", "ANATOMY", 87, 96], ["pneumonitis", "DISEASE", 24, 35], ["pneumonia", "DISEASE", 154, 163], ["infection", "DISEASE", 221, 230], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["suspected pneumonitis grades 2", "PROBLEM", 14, 44], ["Culture", "TEST", 59, 66], ["PCR analysis", "TEST", 71, 83], ["BAL fluid", "TEST", 87, 96], ["infectious causes", "PROBLEM", 133, 150], ["pneumonia", "PROBLEM", 154, 163], ["cultures", "TEST", 183, 191], ["infection", "PROBLEM", 221, 230], ["pneumonitis", "OBSERVATION", 24, 35], ["pneumonia", "OBSERVATION", 154, 163], ["may not definitively exclude", "UNCERTAINTY", 192, 220], ["infection", "OBSERVATION", 221, 230]]], ["Cellular analysis of bronchoscopically obtained lavage fluid may offer important clues to the diagnoses.", [["lavage fluid", "ANATOMY", 48, 60], ["lavage", "ORGANISM_SUBSTANCE", 48, 54], ["Cellular analysis", "TEST", 0, 17], ["lavage fluid", "TEST", 48, 60]]], ["For example, lymphocytosis, elevated eosinophils, and predominance of CD8-positive lymphocytosis are frequent findings on BAL fluid.", [["eosinophils", "ANATOMY", 37, 48], ["BAL fluid", "ANATOMY", 122, 131], ["lymphocytosis", "DISEASE", 13, 26], ["lymphocytosis", "DISEASE", 83, 96], ["eosinophils", "CELL", 37, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["BAL fluid", "ORGANISM_SUBSTANCE", 122, 131], ["eosinophils", "CELL_TYPE", 37, 48], ["CD8", "PROTEIN", 70, 73], ["lymphocytosis", "PROBLEM", 13, 26], ["elevated eosinophils", "PROBLEM", 28, 48], ["CD8", "TEST", 70, 73], ["positive lymphocytosis", "PROBLEM", 74, 96], ["BAL fluid", "TEST", 122, 131], ["lymphocytosis", "OBSERVATION", 13, 26], ["elevated eosinophils", "OBSERVATION", 28, 48], ["predominance", "OBSERVATION_MODIFIER", 54, 66], ["positive", "OBSERVATION_MODIFIER", 74, 82], ["lymphocytosis", "OBSERVATION", 83, 96], ["frequent", "OBSERVATION_MODIFIER", 101, 109], ["BAL fluid", "OBSERVATION", 122, 131]]], ["However, similar findings may be observed with viral pneumonias, such as those caused by CMV, thus limiting the utility of cellular analysis in differentiating pneumonitis from infection.", [["cellular", "ANATOMY", 123, 131], ["viral pneumonias", "DISEASE", 47, 63], ["pneumonitis", "DISEASE", 160, 171], ["infection", "DISEASE", 177, 186], ["CMV", "ORGANISM", 89, 92], ["cellular", "CELL", 123, 131], ["CMV", "SPECIES", 89, 92], ["viral pneumonias", "PROBLEM", 47, 63], ["CMV", "PROBLEM", 89, 92], ["cellular analysis", "TEST", 123, 140], ["pneumonitis", "PROBLEM", 160, 171], ["infection", "PROBLEM", 177, 186], ["may be observed", "UNCERTAINTY", 26, 41], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["pneumonias", "OBSERVATION", 53, 63], ["CMV", "OBSERVATION", 89, 92], ["pneumonitis", "OBSERVATION", 160, 171], ["infection", "OBSERVATION", 177, 186]]], ["Transbronchial and surgically obtained lung biopsies may offer additional information, particularly in the setting of unexplained lymphadenopathy or suspicious lesions suggestive of underlying tumor progression.", [["Transbronchial", "ANATOMY", 0, 14], ["lung biopsies", "ANATOMY", 39, 52], ["lesions", "ANATOMY", 160, 167], ["tumor", "ANATOMY", 193, 198], ["lymphadenopathy", "DISEASE", 130, 145], ["tumor", "DISEASE", 193, 198], ["lung biopsies", "MULTI-TISSUE_STRUCTURE", 39, 52], ["lesions", "PATHOLOGICAL_FORMATION", 160, 167], ["tumor", "CANCER", 193, 198], ["Transbronchial and surgically obtained lung biopsies", "TEST", 0, 52], ["unexplained lymphadenopathy", "PROBLEM", 118, 145], ["suspicious lesions", "PROBLEM", 149, 167], ["underlying tumor progression", "PROBLEM", 182, 210], ["lung", "ANATOMY", 39, 43], ["biopsies", "OBSERVATION", 44, 52], ["unexplained", "OBSERVATION_MODIFIER", 118, 129], ["lymphadenopathy", "OBSERVATION", 130, 145], ["suspicious", "OBSERVATION_MODIFIER", 149, 159], ["lesions", "OBSERVATION", 160, 167], ["suggestive of", "UNCERTAINTY", 168, 181], ["tumor", "OBSERVATION", 193, 198]]], ["Impairment of diffusing capacity may be one of the earliest signals of lung injury and may precede clinical and radiographic findings.", [["lung", "ANATOMY", 71, 75], ["lung injury", "DISEASE", 71, 82], ["lung", "ORGAN", 71, 75], ["Impairment of diffusing capacity", "PROBLEM", 0, 32], ["lung injury", "PROBLEM", 71, 82], ["diffusing capacity", "OBSERVATION", 14, 32], ["lung", "ANATOMY", 71, 75], ["injury", "OBSERVATION", 76, 82]]], ["Thus, pulmonary function tests (PFTs) with measurement of spirometry, lung volumes, and diffusion capacity for carbon monoxide should be performed during the initial evaluation.", [["pulmonary", "ANATOMY", 6, 15], ["lung", "ANATOMY", 70, 74], ["carbon monoxide", "CHEMICAL", 111, 126], ["carbon monoxide", "CHEMICAL", 111, 126], ["pulmonary", "ORGAN", 6, 15], ["lung", "ORGAN", 70, 74], ["carbon monoxide", "SIMPLE_CHEMICAL", 111, 126], ["pulmonary function tests", "TEST", 6, 30], ["PFTs", "TEST", 32, 36], ["measurement of spirometry", "TEST", 43, 68], ["lung volumes", "TEST", 70, 82], ["diffusion capacity", "TEST", 88, 106], ["carbon monoxide", "TEST", 111, 126], ["the initial evaluation", "TEST", 154, 176], ["pulmonary", "ANATOMY", 6, 15], ["lung", "ANATOMY", 70, 74], ["volumes", "ANATOMY_MODIFIER", 75, 82]]], ["Serial PFTs along with 6-min walk tests (6MWT) over the course of treatment may help to guide therapy.TreatmentTreatment approaches to ICI-related pneumonitis have not been standardized or validated in any prospective trials and are largely based on observational reports, clinical experience, and consensus opinion.", [["ICI", "CHEMICAL", 135, 138], ["pneumonitis", "DISEASE", 147, 158], ["ICI", "CHEMICAL", 135, 138], ["ICI", "SIMPLE_CHEMICAL", 135, 138], ["Serial PFTs", "TEST", 0, 11], ["walk tests", "TEST", 29, 39], ["treatment", "TREATMENT", 66, 75], ["therapy", "TREATMENT", 94, 101], ["TreatmentTreatment", "TREATMENT", 102, 120], ["ICI", "TREATMENT", 135, 138], ["pneumonitis", "PROBLEM", 147, 158], ["pneumonitis", "OBSERVATION", 147, 158]]], ["These strategies are largely guided by pneumonitis grades based on CTCACE criteria.", [["pneumonitis", "DISEASE", 39, 50], ["pneumonitis grades", "PROBLEM", 39, 57], ["pneumonitis", "OBSERVATION", 39, 50]]], ["Withholding ICI therapy is recommended for all patients with suspected ICI-related pneumonitis, while the diagnostic work-up and treatment is underway.", [["ICI", "CHEMICAL", 12, 15], ["ICI", "CHEMICAL", 71, 74], ["pneumonitis", "DISEASE", 83, 94], ["ICI", "CHEMICAL", 12, 15], ["ICI", "CHEMICAL", 71, 74], ["ICI", "SIMPLE_CHEMICAL", 12, 15], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["ICI therapy", "TREATMENT", 12, 23], ["related pneumonitis", "PROBLEM", 75, 94], ["treatment", "TREATMENT", 129, 138], ["pneumonitis", "OBSERVATION", 83, 94]]], ["Patients with grade 1 pneumonitis may be monitored as outpatients.", [["pneumonitis", "DISEASE", 22, 33], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["grade 1 pneumonitis", "PROBLEM", 14, 33], ["grade 1", "OBSERVATION_MODIFIER", 14, 21], ["pneumonitis", "OBSERVATION", 22, 33]]], ["Chest CT imaging is recommended prior to the subsequent scheduled dose of ICI (within 3-4 weeks).", [["ICI", "CHEMICAL", 74, 77], ["ICI", "CHEMICAL", 74, 77], ["ICI", "SIMPLE_CHEMICAL", 74, 77], ["Chest CT imaging", "TEST", 0, 16], ["ICI", "TREATMENT", 74, 77]]], ["If infiltrates have resolved, ICI therapy may be cautiously resumed with close follow-up.", [["ICI", "CHEMICAL", 30, 33], ["ICI", "CHEMICAL", 30, 33], ["ICI", "SIMPLE_CHEMICAL", 30, 33], ["infiltrates", "PROBLEM", 3, 14], ["ICI therapy", "TREATMENT", 30, 41], ["infiltrates", "OBSERVATION", 3, 14]]], ["The addition of steroid therapy is recommended for pneumonitis grades 2 or higher.", [["steroid", "CHEMICAL", 16, 23], ["pneumonitis", "DISEASE", 51, 62], ["steroid", "CHEMICAL", 16, 23], ["steroid", "SIMPLE_CHEMICAL", 16, 23], ["steroid therapy", "TREATMENT", 16, 31], ["pneumonitis grades", "PROBLEM", 51, 69], ["steroid therapy", "OBSERVATION", 16, 31], ["higher", "OBSERVATION_MODIFIER", 75, 81]]], ["Patients with grade 2 pneumonitis can typically be treated as outpatients with oral prednisone, dosed at 1 mg/kg of ideal body weight/day.", [["oral", "ANATOMY", 79, 83], ["body", "ANATOMY", 122, 126], ["pneumonitis", "DISEASE", 22, 33], ["prednisone", "CHEMICAL", 84, 94], ["prednisone", "CHEMICAL", 84, 94], ["Patients", "ORGANISM", 0, 8], ["oral", "ORGANISM_SUBDIVISION", 79, 83], ["prednisone", "SIMPLE_CHEMICAL", 84, 94], ["body", "ORGANISM_SUBDIVISION", 122, 126], ["Patients", "SPECIES", 0, 8], ["grade 2 pneumonitis", "PROBLEM", 14, 33], ["oral prednisone", "TREATMENT", 79, 94], ["grade 2", "OBSERVATION_MODIFIER", 14, 21], ["pneumonitis", "OBSERVATION", 22, 33]]], ["Drug re-challenge following resolution of infiltrates in carefully selected patients with grade 2 pneumonitis is also reasonable, with follow-up.", [["pneumonitis", "DISEASE", 98, 109], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Drug re-challenge", "TREATMENT", 0, 17], ["infiltrates", "PROBLEM", 42, 53], ["grade 2 pneumonitis", "PROBLEM", 90, 109], ["infiltrates", "OBSERVATION", 42, 53], ["grade 2", "OBSERVATION_MODIFIER", 90, 97], ["pneumonitis", "OBSERVATION", 98, 109]]], ["In-patient management and permanent withdrawal of ICI therapy is recommended for all patients with grade 3-4 pneumonitis and patients with earlier-stage pneumonitis who demonstrate progression of toxicity despite drug cessation.", [["ICI", "CHEMICAL", 50, 53], ["pneumonitis", "DISEASE", 109, 120], ["pneumonitis", "DISEASE", 153, 164], ["toxicity", "DISEASE", 196, 204], ["ICI", "CHEMICAL", 50, 53], ["patient", "ORGANISM", 3, 10], ["ICI", "SIMPLE_CHEMICAL", 50, 53], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 125, 133], ["patient", "SPECIES", 3, 10], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 125, 133], ["In-patient management", "TREATMENT", 0, 21], ["permanent withdrawal of ICI therapy", "TREATMENT", 26, 61], ["grade 3-4 pneumonitis", "PROBLEM", 99, 120], ["earlier-stage pneumonitis", "PROBLEM", 139, 164], ["progression of toxicity", "PROBLEM", 181, 204], ["drug cessation", "TREATMENT", 213, 227], ["pneumonitis", "OBSERVATION", 109, 120], ["stage", "OBSERVATION_MODIFIER", 147, 152], ["pneumonitis", "OBSERVATION", 153, 164], ["progression", "OBSERVATION_MODIFIER", 181, 192], ["toxicity", "OBSERVATION", 196, 204]]], ["Systemic steroids for this group of patients are typically initiated at 2 mg/kg of ideal body weight/day.", [["body", "ANATOMY", 89, 93], ["steroids", "CHEMICAL", 9, 17], ["steroids", "CHEMICAL", 9, 17], ["patients", "ORGANISM", 36, 44], ["body", "ORGANISM_SUBDIVISION", 89, 93], ["patients", "SPECIES", 36, 44], ["Systemic steroids", "TREATMENT", 0, 17], ["steroids", "OBSERVATION", 9, 17]]], ["As a general guide, we recommend continuing the initial dose of steroids over the ensuing 1-2 weeks, or until symptoms have returned to grade 1 (asymptomatic CT abnormalities), at which time, steroids may be slowly tapered.", [["steroids", "CHEMICAL", 64, 72], ["steroids", "CHEMICAL", 192, 200], ["steroids", "CHEMICAL", 64, 72], ["steroids", "CHEMICAL", 192, 200], ["steroids", "SIMPLE_CHEMICAL", 64, 72], ["steroids", "SIMPLE_CHEMICAL", 192, 200], ["steroids", "TREATMENT", 64, 72], ["symptoms", "PROBLEM", 110, 118], ["grade 1 (asymptomatic CT abnormalities", "PROBLEM", 136, 174], ["steroids", "TREATMENT", 192, 200]]], ["Pneumonitis flares may be more recalcitrant to therapy and have been reported following rapid steroid tapers.", [["Pneumonitis", "DISEASE", 0, 11], ["steroid", "CHEMICAL", 94, 101], ["steroid", "CHEMICAL", 94, 101], ["Pneumonitis flares", "PROBLEM", 0, 18], ["therapy", "TREATMENT", 47, 54], ["rapid steroid tapers", "TREATMENT", 88, 108], ["more recalcitrant", "OBSERVATION_MODIFIER", 26, 43]]], ["We, therefore, recommend a steroid tapering schedule over a minimum 4-6 weeks that is tailored to the severity of the pneumonitis event and response to initial therapy.", [["steroid", "CHEMICAL", 27, 34], ["pneumonitis", "DISEASE", 118, 129], ["steroid", "CHEMICAL", 27, 34], ["steroid", "SIMPLE_CHEMICAL", 27, 34], ["a steroid tapering schedule", "TREATMENT", 25, 52], ["the pneumonitis event", "PROBLEM", 114, 135], ["initial therapy", "TREATMENT", 152, 167], ["pneumonitis", "OBSERVATION", 118, 129]]], ["Fig. 3 Organizing pneumonia following dual ipilimumab/nivolumab therapy.", [["pneumonia", "DISEASE", 18, 27], ["ipilimumab", "CHEMICAL", 43, 53], ["nivolumab", "CHEMICAL", 54, 63], ["ipilimumab", "CHEMICAL", 43, 53], ["nivolumab", "CHEMICAL", 54, 63], ["ipilimumab", "SIMPLE_CHEMICAL", 43, 53], ["nivolumab", "SIMPLE_CHEMICAL", 54, 63], ["pneumonia", "PROBLEM", 18, 27], ["dual ipilimumab/nivolumab therapy", "TREATMENT", 38, 71], ["Organizing", "OBSERVATION_MODIFIER", 7, 17], ["pneumonia", "OBSERVATION", 18, 27]]], ["Progressive dyspnea and dry cough developed 3 weeks following cycle 3 of azacitadine plus nivolumab and ipilimumab for myelodysplastic syndrome.", [["dyspnea", "DISEASE", 12, 19], ["dry cough", "DISEASE", 24, 33], ["azacitadine", "CHEMICAL", 73, 84], ["nivolumab", "CHEMICAL", 90, 99], ["ipilimumab", "CHEMICAL", 104, 114], ["myelodysplastic syndrome", "DISEASE", 119, 143], ["azacitadine", "CHEMICAL", 73, 84], ["nivolumab", "CHEMICAL", 90, 99], ["ipilimumab", "CHEMICAL", 104, 114], ["azacitadine", "SIMPLE_CHEMICAL", 73, 84], ["nivolumab", "SIMPLE_CHEMICAL", 90, 99], ["ipilimumab", "SIMPLE_CHEMICAL", 104, 114], ["Progressive dyspnea", "PROBLEM", 0, 19], ["dry cough", "PROBLEM", 24, 33], ["azacitadine", "TREATMENT", 73, 84], ["nivolumab", "TREATMENT", 90, 99], ["ipilimumab", "TREATMENT", 104, 114], ["myelodysplastic syndrome", "PROBLEM", 119, 143], ["dyspnea", "OBSERVATION", 12, 19], ["dry", "OBSERVATION_MODIFIER", 24, 27], ["cough", "OBSERVATION", 28, 33], ["myelodysplastic syndrome", "OBSERVATION", 119, 143]]], ["A chest CT demonstrated multifocal consolidative and ground glass opacities involving the right upper lobe (a) and bilateral lower lobes (b).", [["chest", "ANATOMY", 2, 7], ["consolidative", "ANATOMY", 35, 48], ["right upper lobe", "ANATOMY", 90, 106], ["lower lobes", "ANATOMY", 125, 136], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 96, 106], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 125, 136], ["A chest CT", "TEST", 0, 10], ["multifocal consolidative and ground glass opacities involving the right upper lobe (a) and bilateral lower lobes", "PROBLEM", 24, 136], ["chest", "ANATOMY", 2, 7], ["multifocal", "OBSERVATION_MODIFIER", 24, 34], ["consolidative", "OBSERVATION", 35, 48], ["ground glass opacities", "OBSERVATION", 53, 75], ["right upper lobe", "ANATOMY", 90, 106], ["bilateral", "ANATOMY_MODIFIER", 115, 124], ["lower lobes", "ANATOMY", 125, 136]]], ["Bronchoalveolar lavage fluid was culture negative.", [["Bronchoalveolar lavage fluid", "ANATOMY", 0, 28], ["Bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 0, 28], ["Bronchoalveolar lavage fluid", "TEST", 0, 28], ["culture", "TEST", 33, 40], ["lavage fluid", "OBSERVATION", 16, 28]]], ["Prominent intraluminal plugs of inflammatory debris within the small airways were seen on lung biopsy, consistent with organizing pneumonia caused by combined Nivolumab/Ipilimumab therapy Prophylaxis against Pneumocystis Jeroveci pneumonia (PJP) in HIV-negative patients requiring prolonged, highdose steroid therapy remains a clinical challenge, as the dose of steroids that delimits \"high dose\" and the duration of steroids that defines \"prolonged\" have not been clearly established [51] [52] [53] [54] [55] [56] .", [["intraluminal", "ANATOMY", 10, 22], ["small airways", "ANATOMY", 63, 76], ["lung biopsy", "ANATOMY", 90, 101], ["pneumonia", "DISEASE", 130, 139], ["Nivolumab", "CHEMICAL", 159, 168], ["Ipilimumab", "CHEMICAL", 169, 179], ["Pneumocystis Jeroveci pneumonia", "DISEASE", 208, 239], ["PJP", "DISEASE", 241, 244], ["HIV-negative", "DISEASE", 249, 261], ["steroid", "CHEMICAL", 301, 308], ["steroids", "CHEMICAL", 362, 370], ["steroids", "CHEMICAL", 417, 425], ["Nivolumab", "CHEMICAL", 159, 168], ["Ipilimumab", "CHEMICAL", 169, 179], ["steroid", "CHEMICAL", 301, 308], ["steroids", "CHEMICAL", 362, 370], ["steroids", "CHEMICAL", 417, 425], ["[51] [52] [53] [54] [55]", "CHEMICAL", 485, 509], ["intraluminal plugs", "PATHOLOGICAL_FORMATION", 10, 28], ["airways", "MULTI-TISSUE_STRUCTURE", 69, 76], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 90, 101], ["Nivolumab", "SIMPLE_CHEMICAL", 159, 168], ["Ipilimumab", "SIMPLE_CHEMICAL", 169, 179], ["Pneumocystis Jeroveci", "ORGANISM", 208, 229], ["HIV", "ORGANISM", 249, 252], ["patients", "ORGANISM", 262, 270], ["highdose steroid", "SIMPLE_CHEMICAL", 292, 308], ["steroids", "SIMPLE_CHEMICAL", 362, 370], ["steroids", "SIMPLE_CHEMICAL", 417, 425], ["[51] [52] [53] [54] [55] [56]", "SIMPLE_CHEMICAL", 485, 514], ["Pneumocystis Jeroveci", "SPECIES", 208, 229], ["HIV", "SPECIES", 249, 252], ["patients", "SPECIES", 262, 270], ["Pneumocystis Jeroveci", "SPECIES", 208, 229], ["HIV", "SPECIES", 249, 252], ["Prominent intraluminal plugs of inflammatory debris", "PROBLEM", 0, 51], ["the small airways", "PROBLEM", 59, 76], ["lung biopsy", "TEST", 90, 101], ["organizing pneumonia", "PROBLEM", 119, 139], ["Nivolumab/Ipilimumab therapy", "TREATMENT", 159, 187], ["Prophylaxis", "TREATMENT", 188, 199], ["Pneumocystis Jeroveci pneumonia", "PROBLEM", 208, 239], ["highdose steroid therapy", "TREATMENT", 292, 316], ["steroids", "TREATMENT", 362, 370], ["steroids", "TREATMENT", 417, 425], ["intraluminal", "ANATOMY_MODIFIER", 10, 22], ["plugs", "OBSERVATION", 23, 28], ["inflammatory", "OBSERVATION_MODIFIER", 32, 44], ["debris", "OBSERVATION", 45, 51], ["small", "OBSERVATION_MODIFIER", 63, 68], ["airways", "ANATOMY", 69, 76], ["lung", "ANATOMY", 90, 94], ["biopsy", "OBSERVATION", 95, 101], ["consistent with", "UNCERTAINTY", 103, 118], ["organizing", "OBSERVATION_MODIFIER", 119, 129], ["pneumonia", "OBSERVATION", 130, 139], ["Ipilimumab therapy", "OBSERVATION", 169, 187]]], ["Adding to this conundrum is the fact that the predilection for PJP may vary among this patient population, rendering some patients, such as those with hematologic malignancies and those who have undergone stem cell and solid organ transplantation, more susceptible to PJP at relatively lower doses of steroids [54] .", [["hematologic malignancies", "ANATOMY", 151, 175], ["stem cell", "ANATOMY", 205, 214], ["solid organ", "ANATOMY", 219, 230], ["PJP", "DISEASE", 63, 66], ["hematologic malignancies", "DISEASE", 151, 175], ["PJP", "DISEASE", 268, 271], ["steroids", "CHEMICAL", 301, 309], ["steroids", "CHEMICAL", 301, 309], ["patient", "ORGANISM", 87, 94], ["patients", "ORGANISM", 122, 130], ["hematologic malignancies", "CANCER", 151, 175], ["stem cell", "CELL", 205, 214], ["organ", "ORGAN", 225, 230], ["patient", "SPECIES", 87, 94], ["patients", "SPECIES", 122, 130], ["PJP", "PROBLEM", 63, 66], ["hematologic malignancies", "PROBLEM", 151, 175], ["stem cell", "TREATMENT", 205, 214], ["solid organ transplantation", "TREATMENT", 219, 246], ["PJP", "TREATMENT", 268, 271], ["steroids", "TREATMENT", 301, 309], ["stem cell", "OBSERVATION", 205, 214], ["solid organ transplantation", "OBSERVATION", 219, 246]]], ["We, therefore, recommend PJP prophylaxis in our cancer patient population throughout the duration of systemic corticosteriod therapy.", [["cancer", "ANATOMY", 48, 54], ["PJP", "CHEMICAL", 25, 28], ["cancer", "DISEASE", 48, 54], ["corticosteriod", "CHEMICAL", 110, 124], ["PJP", "CHEMICAL", 25, 28], ["PJP", "SIMPLE_CHEMICAL", 25, 28], ["cancer", "CANCER", 48, 54], ["patient", "ORGANISM", 55, 62], ["corticosteriod", "SIMPLE_CHEMICAL", 110, 124], ["patient", "SPECIES", 55, 62], ["PJP prophylaxis", "TREATMENT", 25, 40], ["our cancer patient population", "TREATMENT", 44, 73], ["systemic corticosteriod therapy", "TREATMENT", 101, 132]]], ["The addition of TNF-\u03b1 blocking agents may increase the susceptibility to serious infections, including tuberculosis [57, 58] .", [["infections", "DISEASE", 81, 91], ["tuberculosis", "DISEASE", 103, 115], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 16, 21], ["TNF", "PROTEIN", 16, 19], ["TNF-\u03b1 blocking agents", "TREATMENT", 16, 37], ["serious infections", "PROBLEM", 73, 91], ["tuberculosis", "PROBLEM", 103, 115], ["serious", "OBSERVATION_MODIFIER", 73, 80], ["infections", "OBSERVATION", 81, 91]]], ["Accordingly, baseline testing for tuberculosis should be performed on all patients before initiating TNF-\u03b1 inhibiting agents.", [["tuberculosis", "DISEASE", 34, 46], ["patients", "ORGANISM", 74, 82], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 101, 106], ["TNF", "PROTEIN", 101, 104], ["patients", "SPECIES", 74, 82], ["baseline testing", "TEST", 13, 29], ["tuberculosis", "PROBLEM", 34, 46], ["TNF", "TREATMENT", 101, 104], ["inhibiting agents", "TREATMENT", 107, 124]]], ["The need for gastrointestinal prophylaxis may also be appropriate in some patients undergoing prolonged steroid therapy.TreatmentClinical improvement is generally observed within the first 48-72 h of treatment, beyond which pneumonitis is considered steroid refractory.", [["gastrointestinal", "ANATOMY", 13, 29], ["steroid", "CHEMICAL", 104, 111], ["pneumonitis", "DISEASE", 224, 235], ["steroid", "CHEMICAL", 250, 257], ["steroid", "CHEMICAL", 104, 111], ["steroid", "CHEMICAL", 250, 257], ["gastrointestinal", "ORGAN", 13, 29], ["patients", "ORGANISM", 74, 82], ["steroid", "SIMPLE_CHEMICAL", 104, 111], ["patients", "SPECIES", 74, 82], ["gastrointestinal prophylaxis", "TREATMENT", 13, 41], ["prolonged steroid therapy", "TREATMENT", 94, 119], ["treatment", "TREATMENT", 200, 209], ["pneumonitis", "PROBLEM", 224, 235], ["steroid refractory", "PROBLEM", 250, 268], ["gastrointestinal", "ANATOMY", 13, 29], ["prophylaxis", "OBSERVATION", 30, 41], ["steroid therapy", "OBSERVATION", 104, 119], ["pneumonitis", "OBSERVATION", 224, 235], ["steroid refractory", "OBSERVATION", 250, 268]]], ["In patients with high grade and/or steroid refractory disease, additional immunosuppressive therapy with azathioprine, mycophenolate mofetil, cyclophosphamide, and/or tocilizumab may be considered.", [["steroid", "CHEMICAL", 35, 42], ["azathioprine", "CHEMICAL", 105, 117], ["mycophenolate mofetil", "CHEMICAL", 119, 140], ["cyclophosphamide", "CHEMICAL", 142, 158], ["tocilizumab", "CHEMICAL", 167, 178], ["steroid", "CHEMICAL", 35, 42], ["azathioprine", "CHEMICAL", 105, 117], ["mycophenolate mofetil", "CHEMICAL", 119, 140], ["cyclophosphamide", "CHEMICAL", 142, 158], ["patients", "ORGANISM", 3, 11], ["azathioprine", "SIMPLE_CHEMICAL", 105, 117], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 119, 140], ["cyclophosphamide", "SIMPLE_CHEMICAL", 142, 158], ["tocilizumab", "SIMPLE_CHEMICAL", 167, 178], ["patients", "SPECIES", 3, 11], ["high grade and/or steroid refractory disease", "PROBLEM", 17, 61], ["additional immunosuppressive therapy", "TREATMENT", 63, 99], ["azathioprine", "TREATMENT", 105, 117], ["mycophenolate mofetil", "TREATMENT", 119, 140], ["cyclophosphamide", "TREATMENT", 142, 158], ["tocilizumab", "TREATMENT", 167, 178], ["high grade", "OBSERVATION_MODIFIER", 17, 27], ["steroid refractory disease", "OBSERVATION", 35, 61]]], ["However, the clinical impact of augmented immunosuppressive therapies and optimal dose, duration, and timing of these agents have not been studied [9, 59] .", [["augmented immunosuppressive therapies", "TREATMENT", 32, 69], ["these agents", "TREATMENT", 112, 124]]], ["Evidence favoring the use of intravenous immunoglobulin (IVIG) in the management of steroid refractory high-grade pneumonitis has also emerged in recent literature [60] .", [["intravenous", "ANATOMY", 29, 40], ["steroid", "CHEMICAL", 84, 91], ["pneumonitis", "DISEASE", 114, 125], ["steroid", "CHEMICAL", 84, 91], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 29, 55], ["IVIG", "SIMPLE_CHEMICAL", 57, 61], ["high-grade", "PATHOLOGICAL_FORMATION", 103, 113], ["intravenous immunoglobulin", "PROTEIN", 29, 55], ["intravenous immunoglobulin (IVIG)", "TREATMENT", 29, 62], ["steroid refractory high-grade pneumonitis", "PROBLEM", 84, 125], ["-grade", "OBSERVATION_MODIFIER", 107, 113], ["pneumonitis", "OBSERVATION", 114, 125]]], ["These studies require validation in larger prospective trials.TreatmentThe use of immunosuppressive therapies in the management of ICI-related toxicities has prompted concerns regarding the potential for systemic corticosteroids to interfere with the therapeutic efficacy of immune checkpoint blockade.", [["ICI", "CHEMICAL", 131, 134], ["toxicities", "DISEASE", 143, 153], ["ICI", "CHEMICAL", 131, 134], ["ICI", "SIMPLE_CHEMICAL", 131, 134], ["These studies", "TEST", 0, 13], ["larger prospective trials", "TREATMENT", 36, 61], ["immunosuppressive therapies", "TREATMENT", 82, 109], ["ICI", "PROBLEM", 131, 134], ["related toxicities", "PROBLEM", 135, 153], ["systemic corticosteroids", "TREATMENT", 204, 228], ["immune checkpoint blockade", "TREATMENT", 275, 301], ["immune checkpoint blockade", "OBSERVATION", 275, 301]]], ["In two separate studies, overall cancer treatment outcomes among patients receiving prolonged immunosuppression for anti-CTLA-4 induced IrAEs were not statistically different compared to patients not requiring immunosuppressive therapies [61, 62] .TreatmentTwenty-five to thirty-three percent of patients may experience recurrent pneumonitis with drug re-challenge after initial resolution of signs and symptoms.", [["cancer", "ANATOMY", 33, 39], ["cancer", "DISEASE", 33, 39], ["anti-CTLA-4", "CHEMICAL", 116, 127], ["IrAEs", "DISEASE", 136, 141], ["pneumonitis", "DISEASE", 330, 341], ["cancer", "CANCER", 33, 39], ["patients", "ORGANISM", 65, 73], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 116, 127], ["IrAEs", "SIMPLE_CHEMICAL", 136, 141], ["patients", "ORGANISM", 187, 195], ["patients", "ORGANISM", 296, 304], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 187, 195], ["patients", "SPECIES", 296, 304], ["overall cancer treatment", "TREATMENT", 25, 49], ["prolonged immunosuppression", "TREATMENT", 84, 111], ["anti-CTLA", "TREATMENT", 116, 125], ["4 induced IrAEs", "PROBLEM", 126, 141], ["immunosuppressive therapies", "TREATMENT", 210, 237], ["recurrent pneumonitis", "PROBLEM", 320, 341], ["drug re-challenge", "TREATMENT", 347, 364], ["signs and symptoms", "PROBLEM", 393, 411], ["cancer", "OBSERVATION", 33, 39], ["recurrent", "OBSERVATION_MODIFIER", 320, 329], ["pneumonitis", "OBSERVATION", 330, 341]]], ["Resumption of the same ICI agent after resolution of the initial IrAE unprovoked pneumonitis, occurring despite drug discontinuation has also been reported.", [["ICI", "CHEMICAL", 23, 26], ["pneumonitis", "DISEASE", 81, 92], ["ICI", "CHEMICAL", 23, 26], ["ICI", "SIMPLE_CHEMICAL", 23, 26], ["the same ICI agent", "TREATMENT", 14, 32], ["the initial IrAE unprovoked pneumonitis", "PROBLEM", 53, 92], ["drug discontinuation", "TREATMENT", 112, 132], ["unprovoked", "OBSERVATION_MODIFIER", 70, 80], ["pneumonitis", "OBSERVATION", 81, 92]]], ["Rapid steroid tapers (less than 5 weeks) may increase the risk of recurrent events, which tend to be earlier in onset than the first event and more severe [17, [63] [64] [65] .", [["steroid", "CHEMICAL", 6, 13], ["steroid", "CHEMICAL", 6, 13], ["Rapid steroid tapers", "TREATMENT", 0, 20], ["recurrent events", "PROBLEM", 66, 82], ["steroid tapers", "OBSERVATION", 6, 20]]], ["Life-threatening toxicities, particularly those involving the lungs, heart, or central nervous system, are considered absolute contraindications to drug re-challenge.TreatmentFatal ICI-related pneumonitis is, fortunately, rare (0.3%) and varies significantly between treatment regimens.", [["lungs", "ANATOMY", 62, 67], ["heart", "ANATOMY", 69, 74], ["central nervous system", "ANATOMY", 79, 101], ["toxicities", "DISEASE", 17, 27], ["ICI", "CHEMICAL", 181, 184], ["pneumonitis", "DISEASE", 193, 204], ["ICI", "CHEMICAL", 181, 184], ["lungs", "ORGAN", 62, 67], ["heart", "ORGAN", 69, 74], ["central nervous system", "ANATOMICAL_SYSTEM", 79, 101], ["Life-threatening toxicities", "PROBLEM", 0, 27], ["heart, or central nervous system", "PROBLEM", 69, 101], ["drug re-challenge", "TREATMENT", 148, 165], ["TreatmentFatal ICI", "TREATMENT", 166, 184], ["pneumonitis", "PROBLEM", 193, 204], ["treatment regimens", "TREATMENT", 267, 285], ["toxicities", "OBSERVATION", 17, 27], ["lungs", "ANATOMY", 62, 67], ["heart", "ANATOMY", 69, 74], ["central nervous", "ANATOMY", 79, 94], ["pneumonitis", "OBSERVATION", 193, 204]]], ["In a recent large multicenter retrospective review of ICI-associated fatalities, neurologic and cardiac events associated with CTLA-4 toxic effects accounted for nearly half of all deaths.", [["neurologic", "ANATOMY", 81, 91], ["cardiac", "ANATOMY", 96, 103], ["ICI", "CHEMICAL", 54, 57], ["fatalities", "DISEASE", 69, 79], ["neurologic and cardiac events", "DISEASE", 81, 110], ["deaths", "DISEASE", 181, 187], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 127, 133], ["neurologic and cardiac events", "PROBLEM", 81, 110], ["CTLA", "TEST", 127, 131], ["4 toxic effects", "PROBLEM", 132, 147], ["large", "OBSERVATION_MODIFIER", 12, 17], ["cardiac", "ANATOMY", 96, 103]]], ["By contrast, the majority of patients who succumbed to pneumonitis had been treated with PD-1/PD-L1 blockers or PD-1/ CTLA-4 combinations [66] .IrAE: sarcoid-like reactionsSarcoid-like reactions are uncommon IrAEs, which have been observed among 5-7% of patients following both CTLA-4 and PD-1 blockers.", [["pneumonitis", "DISEASE", 55, 66], ["IrAE", "CHEMICAL", 144, 148], ["Sarcoid-like reactions", "DISEASE", 172, 194], ["IrAEs", "DISEASE", 208, 213], ["patients", "ORGANISM", 29, 37], ["PD-1", "GENE_OR_GENE_PRODUCT", 89, 93], ["PD-L1", "GENE_OR_GENE_PRODUCT", 94, 99], ["PD-1", "GENE_OR_GENE_PRODUCT", 112, 116], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 118, 124], ["IrAE", "SIMPLE_CHEMICAL", 144, 148], ["IrAEs", "PATHOLOGICAL_FORMATION", 208, 213], ["patients", "ORGANISM", 254, 262], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 278, 284], ["PD-1 blockers", "GENE_OR_GENE_PRODUCT", 289, 302], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 254, 262], ["pneumonitis", "PROBLEM", 55, 66], ["PD", "TREATMENT", 89, 91], ["PD", "TREATMENT", 94, 96], ["L1 blockers", "TREATMENT", 97, 108], ["PD", "TREATMENT", 112, 114], ["sarcoid", "PROBLEM", 150, 157], ["like reactions", "PROBLEM", 158, 172], ["Sarcoid", "PROBLEM", 172, 179], ["like reactions", "PROBLEM", 180, 194], ["uncommon IrAEs", "PROBLEM", 199, 213], ["CTLA", "TEST", 278, 282], ["PD-1 blockers", "TREATMENT", 289, 302], ["pneumonitis", "OBSERVATION", 55, 66], ["sarcoid", "OBSERVATION", 150, 157], ["Sarcoid", "OBSERVATION", 172, 179]]], ["De novo sarcoid-like reactions as well as exacerbation of pre-existing disease have been reported in association with both classes of ICI therapies [15, 47, 67, 68] .", [["sarcoid", "ANATOMY", 8, 15], ["sarcoid-like reactions", "DISEASE", 8, 30], ["ICI", "CHEMICAL", 134, 137], ["ICI", "CHEMICAL", 134, 137], ["ICI", "SIMPLE_CHEMICAL", 134, 137], ["De novo sarcoid", "PROBLEM", 0, 15], ["like reactions", "PROBLEM", 16, 30], ["pre-existing disease", "PROBLEM", 58, 78], ["ICI therapies", "TREATMENT", 134, 147], ["sarcoid", "OBSERVATION", 8, 15], ["disease", "OBSERVATION", 71, 78]]], ["Enlarged mediastinal lymph nodes may occur in isolation or in association with bilateral upper-or middle-lobe predominant consolidations or ground glass opacities (Fig. 4) .", [["mediastinal lymph nodes", "ANATOMY", 9, 32], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 21, 32], ["Enlarged mediastinal lymph nodes", "PROBLEM", 0, 32], ["bilateral upper-or middle-lobe predominant consolidations", "PROBLEM", 79, 136], ["ground glass opacities", "PROBLEM", 140, 162], ["mediastinal", "ANATOMY", 9, 20], ["lymph nodes", "OBSERVATION", 21, 32], ["bilateral", "ANATOMY_MODIFIER", 79, 88], ["upper", "ANATOMY_MODIFIER", 89, 94], ["middle-lobe", "ANATOMY", 98, 109], ["consolidations", "OBSERVATION", 122, 136], ["ground glass opacities", "OBSERVATION", 140, 162]]], ["Concomitant sarcoid-like reactions involving the skin and kidneys have also been reported.", [["sarcoid", "ANATOMY", 12, 19], ["skin", "ANATOMY", 49, 53], ["kidneys", "ANATOMY", 58, 65], ["sarcoid-like reactions involving the skin and kidneys", "DISEASE", 12, 65], ["skin", "ORGAN", 49, 53], ["kidneys", "ORGAN", 58, 65], ["Concomitant sarcoid", "PROBLEM", 0, 19], ["like reactions involving the skin and kidneys", "PROBLEM", 20, 65], ["sarcoid", "OBSERVATION", 12, 19], ["skin", "ANATOMY", 49, 53], ["kidneys", "ANATOMY", 58, 65]]], ["Biopsies of enlarged lymph nodes or the lung parenchyma are required to exclude competing diagnoses such as cancer progression.", [["Biopsies", "ANATOMY", 0, 8], ["lymph nodes", "ANATOMY", 21, 32], ["lung parenchyma", "ANATOMY", 40, 55], ["cancer", "ANATOMY", 108, 114], ["cancer", "DISEASE", 108, 114], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 21, 32], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 40, 55], ["cancer", "CANCER", 108, 114], ["Biopsies", "TEST", 0, 8], ["enlarged lymph nodes or the lung parenchyma", "PROBLEM", 12, 55], ["cancer progression", "PROBLEM", 108, 126], ["enlarged", "OBSERVATION_MODIFIER", 12, 20], ["lymph nodes", "OBSERVATION", 21, 32], ["lung", "ANATOMY", 40, 44], ["parenchyma", "ANATOMY_MODIFIER", 45, 55], ["cancer", "OBSERVATION", 108, 114]]], ["Elevated CD4:CD8 ratios and overexpression of TH17 on BAL fluid with biopsy evidence of non-caseating granulomas are suggestive of sarcoidosis [69, 70] .", [["BAL fluid", "ANATOMY", 54, 63], ["granulomas", "ANATOMY", 102, 112], ["granulomas", "DISEASE", 102, 112], ["sarcoidosis", "DISEASE", 131, 142], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["TH17", "GENE_OR_GENE_PRODUCT", 46, 50], ["BAL fluid", "ORGANISM_SUBSTANCE", 54, 63], ["granulomas", "CANCER", 102, 112], ["CD4", "PROTEIN", 9, 12], ["CD8", "PROTEIN", 13, 16], ["TH17", "PROTEIN", 46, 50], ["Elevated CD4", "PROBLEM", 0, 12], ["CD8 ratios", "TEST", 13, 23], ["overexpression of TH17", "PROBLEM", 28, 50], ["BAL fluid", "TEST", 54, 63], ["biopsy", "TEST", 69, 75], ["non-caseating granulomas", "PROBLEM", 88, 112], ["sarcoidosis", "PROBLEM", 131, 142], ["CD4", "OBSERVATION", 9, 12], ["overexpression", "OBSERVATION_MODIFIER", 28, 42], ["TH17", "ANATOMY", 46, 50], ["BAL", "ANATOMY", 54, 57], ["fluid", "OBSERVATION", 58, 63], ["non-caseating", "OBSERVATION_MODIFIER", 88, 101], ["granulomas", "OBSERVATION", 102, 112], ["suggestive of", "UNCERTAINTY", 117, 130], ["sarcoidosis", "OBSERVATION", 131, 142]]], ["Interruption of ICI therapy and initiation of systemic steroids typically results in complete resolution of signs and symptoms, with a median time to clinical resolution of 3.1 months [68] .", [["ICI", "CHEMICAL", 16, 19], ["steroids", "CHEMICAL", 55, 63], ["ICI", "CHEMICAL", 16, 19], ["steroids", "CHEMICAL", 55, 63], ["ICI", "SIMPLE_CHEMICAL", 16, 19], ["ICI therapy", "TREATMENT", 16, 27], ["systemic steroids", "TREATMENT", 46, 63], ["signs", "PROBLEM", 108, 113], ["symptoms", "PROBLEM", 118, 126], ["ICI therapy", "OBSERVATION", 16, 27]]], ["ICI therapy in the setting of SARs-CoV-2Pleural effusionsThe conundrum of ICI therapy in the setting of SARs-CoV-2 (COVID-19) infection is problematic on many levels, with no current evidence-based guidelines.", [["ICI", "CHEMICAL", 0, 3], ["effusions", "DISEASE", 48, 57], ["ICI", "CHEMICAL", 74, 77], ["SARs-CoV-2 (COVID-19", "CHEMICAL", 104, 124], ["infection", "DISEASE", 126, 135], ["ICI", "CHEMICAL", 0, 3], ["ICI", "CHEMICAL", 74, 77], ["ICI", "SIMPLE_CHEMICAL", 0, 3], ["ICI", "SIMPLE_CHEMICAL", 74, 77], ["SARs-CoV-2", "ORGANISM", 104, 114], ["COVID-19", "ORGANISM", 116, 124], ["ICI therapy", "TREATMENT", 0, 11], ["SARs", "PROBLEM", 30, 34], ["CoV", "PROBLEM", 35, 38], ["2Pleural effusions", "PROBLEM", 39, 57], ["ICI therapy", "TREATMENT", 74, 85], ["SARs", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["COVID", "TEST", 116, 121], ["infection", "PROBLEM", 126, 135], ["SARs", "OBSERVATION", 30, 34], ["CoV", "ANATOMY", 35, 38], ["2Pleural", "ANATOMY", 39, 47], ["effusions", "OBSERVATION", 48, 57], ["ICI therapy", "OBSERVATION", 74, 85], ["infection", "OBSERVATION", 126, 135]]], ["Potential interactions between this viral illness and ICI-induced immune augmentation has created bidirectional concerns regarding the influence of these agents in exacerbating the clinical course of the viral illness and the potential impact of SARs-CoV-2 in exacerbating ICI-related adverse events.", [["viral illness", "DISEASE", 36, 49], ["ICI", "CHEMICAL", 54, 57], ["viral illness", "DISEASE", 204, 217], ["ICI", "CHEMICAL", 273, 276], ["ICI", "CHEMICAL", 54, 57], ["ICI", "CHEMICAL", 273, 276], ["ICI", "SIMPLE_CHEMICAL", 54, 57], ["CoV-2", "ORGANISM", 251, 256], ["ICI", "SIMPLE_CHEMICAL", 273, 276], ["this viral illness", "PROBLEM", 31, 49], ["ICI-induced immune augmentation", "TREATMENT", 54, 85], ["these agents", "TREATMENT", 148, 160], ["the viral illness", "PROBLEM", 200, 217], ["SARs", "PROBLEM", 246, 250], ["CoV", "TEST", 251, 254], ["exacerbating ICI", "PROBLEM", 260, 276], ["adverse events", "PROBLEM", 285, 299], ["viral illness", "OBSERVATION", 204, 217]]], ["A particular emphasis has been placed on in IrAE-pneumonitis, which may closely mimic SARs-CoV-2-related pneumonia.", [["pneumonitis", "DISEASE", 49, 60], ["pneumonia", "DISEASE", 105, 114], ["CoV-2", "ORGANISM", 91, 96], ["pneumonitis", "PROBLEM", 49, 60], ["pneumonia", "PROBLEM", 105, 114], ["pneumonitis", "OBSERVATION", 49, 60], ["pneumonia", "OBSERVATION", 105, 114]]], ["Assumptions that coinfection with SARs-CoV-2 during ICI therapy may lead to severe complications have generated concerns regarding adaptations in treatment, albeit without any reliable scientific evidence.", [["coinfection", "DISEASE", 17, 28], ["ICI", "CHEMICAL", 52, 55], ["ICI", "CHEMICAL", 52, 55], ["CoV-2", "ORGANISM", 39, 44], ["ICI", "SIMPLE_CHEMICAL", 52, 55], ["coinfection", "PROBLEM", 17, 28], ["SARs", "PROBLEM", 34, 38], ["CoV", "TEST", 39, 42], ["ICI therapy", "TREATMENT", 52, 63], ["severe complications", "PROBLEM", 76, 96], ["treatment", "TREATMENT", 146, 155], ["coinfection", "OBSERVATION", 17, 28]]], ["In fact, in the TERAVOLT study which investigated the impact of severe SARs-CoV-2 infection on patients with thoracic cancers, the type of systemic therapy including immunotherapy did not confer an increase in mortality.", [["thoracic cancers", "ANATOMY", 109, 125], ["infection", "DISEASE", 82, 91], ["thoracic cancers", "DISEASE", 109, 125], ["CoV-2", "ORGANISM", 76, 81], ["patients", "ORGANISM", 95, 103], ["thoracic cancers", "CANCER", 109, 125], ["patients", "SPECIES", 95, 103], ["the TERAVOLT study", "TEST", 12, 30], ["severe SARs", "PROBLEM", 64, 75], ["CoV-2 infection", "PROBLEM", 76, 91], ["thoracic cancers", "PROBLEM", 109, 125], ["systemic therapy", "TREATMENT", 139, 155], ["immunotherapy", "TREATMENT", 166, 179], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["SARs", "OBSERVATION", 71, 75], ["infection", "OBSERVATION", 82, 91], ["thoracic", "ANATOMY", 109, 117], ["cancers", "OBSERVATION", 118, 125], ["increase", "OBSERVATION_MODIFIER", 198, 206]]], ["However, the study was not sufficiently powered in subgroup analysis to render definitive statements regarding the safety of ICI therapy in this setting [76] .", [["ICI", "CHEMICAL", 125, 128], ["ICI", "CHEMICAL", 125, 128], ["ICI", "SIMPLE_CHEMICAL", 125, 128], ["the study", "TEST", 9, 18], ["subgroup analysis", "TEST", 51, 68], ["ICI therapy", "TREATMENT", 125, 136]]], ["Concerns surrounding ICI therapies in patients with concurrent SARs-CoV-2 infection persist.", [["ICI", "CHEMICAL", 21, 24], ["infection", "DISEASE", 74, 83], ["ICI", "CHEMICAL", 21, 24], ["ICI", "SIMPLE_CHEMICAL", 21, 24], ["patients", "ORGANISM", 38, 46], ["CoV-2", "ORGANISM", 68, 73], ["patients", "SPECIES", 38, 46], ["ICI therapies", "TREATMENT", 21, 34], ["concurrent SARs", "PROBLEM", 52, 67], ["CoV-2 infection", "PROBLEM", 68, 83], ["infection", "OBSERVATION", 74, 83]]], ["The need to screen patients for SARs-CoV-2 prior to initiation of ICI therapy is highly debated, as infection status is typically unknown at the time that treatment decisions relating to the initiation of ICI and other cancer therapies are being made.", [["cancer", "ANATOMY", 219, 225], ["ICI", "CHEMICAL", 66, 69], ["infection", "DISEASE", 100, 109], ["ICI", "CHEMICAL", 205, 208], ["cancer", "DISEASE", 219, 225], ["ICI", "CHEMICAL", 66, 69], ["ICI", "CHEMICAL", 205, 208], ["patients", "ORGANISM", 19, 27], ["SARs-CoV-2", "ORGANISM", 32, 42], ["ICI", "SIMPLE_CHEMICAL", 66, 69], ["ICI", "SIMPLE_CHEMICAL", 205, 208], ["cancer", "CANCER", 219, 225], ["patients", "SPECIES", 19, 27], ["SARs", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["ICI therapy", "TREATMENT", 66, 77], ["infection status", "PROBLEM", 100, 116], ["ICI", "TREATMENT", 205, 208], ["other cancer therapies", "TREATMENT", 213, 235], ["cancer", "OBSERVATION", 219, 225]]], ["Questions regarding what to do with ICI therapies that are ongoing at the time of SARs-CoV-2 diagnosis are even more challenging [77, 78] .Pleural effusionsGeneral guidelines based on expert opinion in the management of patients with grade I pneumonitis and concurrent SARs-CoV-2 include withholding therapy, adjustments to less frequent ICI dosing schedules, and cautiously continuing ICI therapy with very close monitoring [79] .", [["Pleural effusions", "ANATOMY", 139, 156], ["ICI", "CHEMICAL", 36, 39], ["Pleural effusions", "DISEASE", 139, 156], ["pneumonitis", "DISEASE", 242, 253], ["ICI", "CHEMICAL", 338, 341], ["ICI", "CHEMICAL", 386, 389], ["ICI", "CHEMICAL", 36, 39], ["ICI", "CHEMICAL", 338, 341], ["ICI", "CHEMICAL", 386, 389], ["ICI", "SIMPLE_CHEMICAL", 36, 39], ["Pleural effusions", "PATHOLOGICAL_FORMATION", 139, 156], ["patients", "ORGANISM", 220, 228], ["ICI", "SIMPLE_CHEMICAL", 338, 341], ["ICI", "SIMPLE_CHEMICAL", 386, 389], ["patients", "SPECIES", 220, 228], ["ICI therapies", "TREATMENT", 36, 49], ["Pleural effusions", "PROBLEM", 139, 156], ["the management", "TREATMENT", 202, 216], ["grade I pneumonitis", "PROBLEM", 234, 253], ["concurrent SARs", "PROBLEM", 258, 273], ["withholding therapy", "TREATMENT", 288, 307], ["less frequent ICI dosing schedules", "TREATMENT", 324, 358], ["cautiously continuing ICI therapy", "TREATMENT", 364, 397], ["effusions", "OBSERVATION", 147, 156], ["pneumonitis", "OBSERVATION", 242, 253]]], ["Patients who develop respiratory symptoms or new pulmonary infiltrates suggestive of SARs-CoV-2 during ICI therapy should be immediately tested for the virus.", [["respiratory", "ANATOMY", 21, 32], ["pulmonary", "ANATOMY", 49, 58], ["respiratory symptoms", "DISEASE", 21, 41], ["ICI", "CHEMICAL", 103, 106], ["ICI", "CHEMICAL", 103, 106], ["Patients", "ORGANISM", 0, 8], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 49, 70], ["CoV-2", "GENE_OR_GENE_PRODUCT", 90, 95], ["ICI", "SIMPLE_CHEMICAL", 103, 106], ["Patients", "SPECIES", 0, 8], ["respiratory symptoms", "PROBLEM", 21, 41], ["new pulmonary infiltrates", "PROBLEM", 45, 70], ["SARs", "PROBLEM", 85, 89], ["CoV", "PROBLEM", 90, 93], ["ICI therapy", "TREATMENT", 103, 114], ["the virus", "PROBLEM", 148, 157], ["respiratory", "ANATOMY", 21, 32], ["new", "OBSERVATION_MODIFIER", 45, 48], ["pulmonary", "ANATOMY", 49, 58], ["infiltrates", "OBSERVATION", 59, 70], ["SARs", "OBSERVATION", 85, 89]]], ["Significant controversies arise for IR-pneumonitis grades 2 and higher, due in part to the attendant use of steroids in these patients.", [["pneumonitis", "DISEASE", 39, 50], ["steroids", "CHEMICAL", 108, 116], ["steroids", "CHEMICAL", 108, 116], ["steroids", "SIMPLE_CHEMICAL", 108, 116], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["pneumonitis grades 2", "PROBLEM", 39, 59], ["steroids", "TREATMENT", 108, 116], ["pneumonitis", "OBSERVATION", 39, 50], ["higher", "OBSERVATION_MODIFIER", 64, 70]]], ["Corticosteroids represent cornerstone treatment in advanced-grade ICI-related pneumonitis, but may exacerbate respiratory sequelae of SARs-CoV-2, particularly those patients with mild disease that do not require oxygen supplementation [76, 78] .", [["respiratory", "ANATOMY", 110, 121], ["ICI", "CHEMICAL", 66, 69], ["pneumonitis", "DISEASE", 78, 89], ["oxygen", "CHEMICAL", 212, 218], ["ICI", "CHEMICAL", 66, 69], ["oxygen", "CHEMICAL", 212, 218], ["patients", "ORGANISM", 165, 173], ["oxygen", "SIMPLE_CHEMICAL", 212, 218], ["patients", "SPECIES", 165, 173], ["Corticosteroids", "TREATMENT", 0, 15], ["cornerstone treatment", "TREATMENT", 26, 47], ["advanced-grade ICI", "PROBLEM", 51, 69], ["related pneumonitis", "PROBLEM", 70, 89], ["respiratory sequelae of SARs", "PROBLEM", 110, 138], ["mild disease", "PROBLEM", 179, 191], ["oxygen supplementation", "TREATMENT", 212, 234], ["grade ICI", "OBSERVATION_MODIFIER", 60, 69], ["pneumonitis", "OBSERVATION", 78, 89], ["mild", "OBSERVATION_MODIFIER", 179, 183], ["disease", "OBSERVATION", 184, 191]]], ["Thus, confirmation of SARs-CoV-2 with PCR testing is recommended before proceeding with corticosteroid therapy for IR-pneumonitis [78] .", [["pneumonitis", "DISEASE", 118, 129], ["SARs-CoV-2", "GENE_OR_GENE_PRODUCT", 22, 32], ["corticosteroid", "SIMPLE_CHEMICAL", 88, 102], ["SARs", "TEST", 22, 26], ["CoV", "TEST", 27, 30], ["PCR testing", "TEST", 38, 49], ["corticosteroid therapy", "TREATMENT", 88, 110], ["pneumonitis", "PROBLEM", 118, 129], ["pneumonitis", "OBSERVATION", 118, 129]]], ["Bronchoscopic evaluation as part of the work-up for IR-pneumonitis in symptomatic patients with confirmed SARs-CoV-2 may facilitate viral transmission through aerosolization of respiratory droplets.", [["Bronchoscopic", "ANATOMY", 0, 13], ["respiratory droplets", "ANATOMY", 177, 197], ["pneumonitis", "DISEASE", 55, 66], ["patients", "ORGANISM", 82, 90], ["CoV-2", "GENE_OR_GENE_PRODUCT", 111, 116], ["patients", "SPECIES", 82, 90], ["Bronchoscopic evaluation", "TEST", 0, 24], ["pneumonitis", "PROBLEM", 55, 66], ["SARs", "PROBLEM", 106, 110], ["CoV", "TEST", 111, 114], ["viral transmission", "TREATMENT", 132, 150], ["respiratory droplets", "PROBLEM", 177, 197], ["pneumonitis", "OBSERVATION", 55, 66], ["respiratory droplets", "OBSERVATION", 177, 197]]], ["We, therefore, avoid bronchoscopy in this setting, except in selected or exceptional cases.Pleural effusionsDespite concerns regarding the potential negative impact of steroids on viral illness, corticosteroids remain the therapy of choice for patients with high-grade IR-pneumonitis.", [["Pleural effusions", "ANATOMY", 91, 108], ["Pleural effusions", "DISEASE", 91, 108], ["steroids", "CHEMICAL", 168, 176], ["viral illness", "DISEASE", 180, 193], ["pneumonitis", "DISEASE", 272, 283], ["steroids", "CHEMICAL", 168, 176], ["corticosteroids", "CHEMICAL", 195, 210], ["Pleural effusions", "PATHOLOGICAL_FORMATION", 91, 108], ["steroids", "SIMPLE_CHEMICAL", 168, 176], ["corticosteroids", "SIMPLE_CHEMICAL", 195, 210], ["patients", "ORGANISM", 244, 252], ["high-grade", "PATHOLOGICAL_FORMATION", 258, 268], ["patients", "SPECIES", 244, 252], ["bronchoscopy", "TEST", 21, 33], ["Pleural effusions", "PROBLEM", 91, 108], ["steroids", "TREATMENT", 168, 176], ["viral illness", "PROBLEM", 180, 193], ["corticosteroids", "TREATMENT", 195, 210], ["the therapy", "TREATMENT", 218, 229], ["high-grade IR-pneumonitis", "PROBLEM", 258, 283], ["effusions", "OBSERVATION", 99, 108], ["pneumonitis", "OBSERVATION", 272, 283]]], ["Additional immunosuppressive therapeutic options, such as anti-IL-6 which has shown therapeutic efficacy in some patients with SARs-CoV-2, may be an effective treatment strategy in steroid-refractory pneumonitis.", [["anti-IL-6", "CHEMICAL", 58, 67], ["steroid", "CHEMICAL", 181, 188], ["pneumonitis", "DISEASE", 200, 211], ["steroid", "CHEMICAL", 181, 188], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 58, 67], ["patients", "ORGANISM", 113, 121], ["CoV-2", "ORGANISM", 132, 137], ["steroid", "SIMPLE_CHEMICAL", 181, 188], ["patients", "SPECIES", 113, 121], ["Additional immunosuppressive therapeutic options", "TREATMENT", 0, 48], ["anti-IL", "TEST", 58, 65], ["SARs", "PROBLEM", 127, 131], ["CoV", "TEST", 132, 135], ["an effective treatment strategy", "TREATMENT", 146, 177], ["steroid", "TREATMENT", 181, 188], ["refractory pneumonitis", "PROBLEM", 189, 211], ["refractory", "OBSERVATION_MODIFIER", 189, 199], ["pneumonitis", "OBSERVATION", 200, 211]]], ["These preliminary recommendations are made within the context of the urgent need for evidence-based guidance and should be refined as prospective data emerge.ConclusionICI therapies have rapidly changed the landscape of cancer therapeutics and are currently used as standard of care for a broad range of refractory cancers.", [["cancer", "ANATOMY", 220, 226], ["cancers", "ANATOMY", 315, 322], ["cancer", "DISEASE", 220, 226], ["cancers", "DISEASE", 315, 322], ["cancer", "CANCER", 220, 226], ["cancers", "CANCER", 315, 322], ["prospective data", "TEST", 134, 150], ["ConclusionICI therapies", "TREATMENT", 158, 181], ["cancer therapeutics", "TREATMENT", 220, 239], ["refractory cancers", "PROBLEM", 304, 322], ["cancer", "OBSERVATION", 220, 226], ["refractory", "OBSERVATION_MODIFIER", 304, 314], ["cancers", "OBSERVATION", 315, 322]]], ["This class of drugs may trigger a spectrum of IrAEs which are generally well tolerated.", [["IrAEs", "DISEASE", 46, 51], ["drugs", "TREATMENT", 14, 19], ["IrAEs", "PROBLEM", 46, 51]]], ["Pneumonitis is less common than toxicities involving some other organ systems; however, lung injury represents a potentially lethal form of IrAEs and one of the most frequent causes of drug discontinuation.", [["organ", "ANATOMY", 64, 69], ["lung", "ANATOMY", 88, 92], ["Pneumonitis", "DISEASE", 0, 11], ["toxicities", "DISEASE", 32, 42], ["lung injury", "DISEASE", 88, 99], ["IrAEs", "DISEASE", 140, 145], ["organ", "ORGAN", 64, 69], ["lung", "ORGAN", 88, 92], ["Pneumonitis", "PROBLEM", 0, 11], ["some other organ systems", "PROBLEM", 53, 77], ["lung injury", "PROBLEM", 88, 99], ["IrAEs", "PROBLEM", 140, 145], ["drug discontinuation", "TREATMENT", 185, 205], ["less common", "OBSERVATION_MODIFIER", 15, 26], ["lung", "ANATOMY", 88, 92], ["injury", "OBSERVATION", 93, 99]]], ["Currently, the burden of lung-related events associated with this class of drugs is low.", [["lung", "ANATOMY", 25, 29], ["lung", "ORGAN", 25, 29], ["lung-related events", "PROBLEM", 25, 44], ["burden", "OBSERVATION_MODIFIER", 15, 21], ["lung", "ANATOMY", 25, 29], ["low", "OBSERVATION_MODIFIER", 84, 87]]], ["The prevalence of pneumonitis will undoubtedly continue to grow in Fig. 5 Approach to management of ICI-related interstitial lung disease Support Care Cancer parallel with better recognition of this clinical entity coupled with the expanding indication of ICI therapies to other tumor types and the addition of these agents to complex treatment strategies that carry an additional toxicity risk.", [["interstitial lung", "ANATOMY", 112, 129], ["tumor", "ANATOMY", 279, 284], ["pneumonitis", "DISEASE", 18, 29], ["ICI", "CHEMICAL", 100, 103], ["interstitial lung disease", "DISEASE", 112, 137], ["Cancer", "DISEASE", 151, 157], ["ICI", "CHEMICAL", 256, 259], ["tumor", "DISEASE", 279, 284], ["toxicity", "DISEASE", 381, 389], ["ICI", "CHEMICAL", 100, 103], ["ICI", "CHEMICAL", 256, 259], ["ICI", "SIMPLE_CHEMICAL", 100, 103], ["lung", "ORGAN", 125, 129], ["ICI", "SIMPLE_CHEMICAL", 256, 259], ["tumor", "CANCER", 279, 284], ["pneumonitis", "PROBLEM", 18, 29], ["management", "TREATMENT", 86, 96], ["ICI", "PROBLEM", 100, 103], ["interstitial lung disease", "PROBLEM", 112, 137], ["ICI therapies", "TREATMENT", 256, 269], ["other tumor types", "PROBLEM", 273, 290], ["these agents", "TREATMENT", 311, 323], ["complex treatment strategies", "TREATMENT", 327, 355], ["an additional toxicity risk", "PROBLEM", 367, 394], ["pneumonitis", "OBSERVATION", 18, 29], ["interstitial", "ANATOMY_MODIFIER", 112, 124], ["lung", "ANATOMY", 125, 129], ["disease", "OBSERVATION", 130, 137]]], ["Early recognition and vigorous diagnostic evaluations are key.", [["vigorous diagnostic evaluations", "TEST", 22, 53]]], ["Knowledge of the diverse clinical, pathologic, and radiographic presentations of IR-pneumonitis may inform patient management and lead to improved patient outcomes.", [["pneumonitis", "DISEASE", 84, 95], ["patient", "ORGANISM", 107, 114], ["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 107, 114], ["patient", "SPECIES", 147, 154], ["pneumonitis", "PROBLEM", 84, 95], ["patient management", "TREATMENT", 107, 125], ["pneumonitis", "OBSERVATION", 84, 95]]], ["Additional studies are needed to better elucidate risk factors and comorbidities that predispose to a higher risk of lung toxicity and to establish biomarkers that are predictive of lung injury.ConclusionAuthors' contributions All of the authors contributed equally to the conceptualization of the manuscript; VS drafted the manuscript, while BLR and DBJ provided clinical input and DBJ, BLR, and RA editorial oversight.", [["lung", "ANATOMY", 117, 121], ["lung", "ANATOMY", 182, 186], ["lung toxicity", "DISEASE", 117, 130], ["lung injury", "DISEASE", 182, 193], ["lung", "ORGAN", 117, 121], ["lung", "ORGAN", 182, 186], ["Additional studies", "TEST", 0, 18], ["risk factors", "PROBLEM", 50, 62], ["comorbidities", "PROBLEM", 67, 80], ["lung toxicity", "PROBLEM", 117, 130], ["biomarkers", "TEST", 148, 158], ["lung injury", "PROBLEM", 182, 193], ["BLR", "TEST", 343, 346], ["clinical input", "TEST", 364, 378], ["DBJ", "TEST", 383, 386], ["BLR", "TEST", 388, 391], ["lung", "ANATOMY", 117, 121], ["toxicity", "OBSERVATION", 122, 130], ["lung", "ANATOMY", 182, 186], ["injury", "OBSERVATION", 187, 193], ["RA", "ANATOMY", 397, 399]]], ["All of the authors provided critical appraisal of the manuscript and approval of its submission.ConclusionFunding information Professor BL Rapoport is supported by the Cancer Association of South Africa (CANSA) and the National Research Foundation (NRF) of South Africa.", [["Cancer", "DISEASE", 168, 174], ["Cancer", "OBSERVATION", 168, 174]]], ["Dr. I. Glezerman is supported by the NIH/NCI (Cancer Center Support Grant P30 CA008748).Compliance with ethical standardsConflict of interest AB, RA, JC, TC, PG, DG, RAG, and VRS have no conflict of interest to declare.", [["Cancer", "DISEASE", 46, 52], ["RA", "DISEASE", 146, 148], ["JC", "DISEASE", 150, 152], ["PG", "CHEMICAL", 158, 160], ["Cancer", "CANCER", 46, 52], ["PG", "SIMPLE_CHEMICAL", 158, 160], ["DG", "SIMPLE_CHEMICAL", 162, 164], ["RAG", "GENE_OR_GENE_PRODUCT", 166, 169], ["RAG", "PROTEIN", 166, 169], ["ethical standards", "TREATMENT", 104, 121], ["interest AB", "TEST", 133, 144], ["PG", "TEST", 158, 160], ["RA", "ANATOMY", 146, 148]]], ["MG reports consultant work with Bristol Myers Squibb (BMS), and AstraZeneca, outside the submitted work.", [["MG", "DISEASE", 0, 2], ["AstraZeneca", "CHEMICAL", 64, 75], ["AstraZeneca", "TREATMENT", 64, 75]]], ["In addition, DBJ has a patent Co-inventor on use of CTLA-4 agonist for IAEs pending.", [["DBJ", "CHEMICAL", 13, 16], ["IAEs", "DISEASE", 71, 75], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 52, 58], ["IAEs", "SIMPLE_CHEMICAL", 71, 75], ["CTLA", "TEST", 52, 56], ["IAEs", "TEST", 71, 75], ["patent", "OBSERVATION", 23, 29]]], ["BLR reports personal fees and other (advisory board) from Merck and Co, grants, personal fees, and other (advisory board) from BMS, grants, personal fees, and other (advisory board) from Roche South Africa, and personal fees and other (advisory board) from AstraZeneca, during the conduct of the study.", [["AstraZeneca", "CHEMICAL", 257, 268], ["AstraZeneca", "TREATMENT", 257, 268], ["the study", "TEST", 292, 301]]]], "PMC7314712": [["Throughout this time, the main effort in this direction of research consisted in showing how Petri nets can be thought of as presenting various flavors of free monoidal categories [2, 5, 6, 8] This idea has been very influential, successfully modeling the individual-token philosophy via process semantics.IntroductionOn the other hand, shortly after Petri\u2019s first publications about the nets that carry his name [7] researchers started investigating what happens when nets are enriched with new features.", [["main", "OBSERVATION_MODIFIER", 26, 30]]], ["One of the most successful extensions of Petri nets is guarded (or coloured) nets [3].", [["Petri nets", "TREATMENT", 41, 51], ["most", "OBSERVATION_MODIFIER", 11, 15], ["successful", "OBSERVATION_MODIFIER", 16, 26], ["Petri nets", "OBSERVATION", 41, 51]]]]}